[{"title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"3NEPvLll8SQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42153-4/abstract","googleCitationCount":1011,"googleAuthor":""},{"title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"XE-ODN-GxesJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31710-7/abstract","googleCitationCount":606,"googleAuthor":""},{"title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of …","googleId":"BTK0UF4IMiEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321817","googleCitationCount":662,"googleAuthor":"","doi":"10.1093/annonc/mdx308","elsevierAuthor":"Pelliccia C.","publicationName":"Virchows Archiv","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0"},{"title":"4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4)","googleId":"OovdHxUh4f4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34113-4/abstract","googleCitationCount":639,"googleAuthor":"F Cardoso"},{"title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GLg3ND5iWuAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42150-9/abstract","googleCitationCount":596,"googleAuthor":"PE Postmus"},{"title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"1Dai1BwvSmwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42152-2/abstract","googleCitationCount":599,"googleAuthor":"R Glynne-Jones"},{"title":"Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 …","googleId":"iH4n8WCRI_gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341055","googleCitationCount":506,"googleAuthor":"","doi":"10.1093/annonc/mdy166","elsevierAuthor":"Haenssle H.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"323"},{"title":"Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"E_R-TgfQFuQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31692-8/abstract","googleCitationCount":346,"googleAuthor":""},{"title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR …","googleId":"V6aPgr8tkZwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321350","googleCitationCount":455,"googleAuthor":"B Lueza","doi":"10.1093/annonc/mdx175","elsevierAuthor":"Mineur L.","publicationName":"PLoS ONE","elsevierCoverDate":"2021-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0"},{"title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","googleId":"whLdzWN07sUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324317","googleCitationCount":403,"googleAuthor":"P Lepage","doi":"10.1093/annonc/mdx108","elsevierAuthor":"Wang F.","publicationName":"Frontiers in Oncology","elsevierCoverDate":"2020-10-20","elsevierCoverDisplayDate":"20 October 2020","elsevierCitationCount":"0"},{"title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"oIQVuQDeP1EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31711-9/abstract","googleCitationCount":237,"googleAuthor":"A Vogel"},{"title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","googleId":"rPeA_3if0MYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348938","googleCitationCount":283,"googleAuthor":"L Derosa","doi":"10.1093/annonc/mdy103","elsevierAuthor":"Derosa L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"214"},{"title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety …","googleId":"dfrhxNec43MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322707","googleCitationCount":369,"googleAuthor":"GV Long","doi":"10.1093/annonc/mdx176","elsevierAuthor":"Granados K.","publicationName":"International Journal of Molecular Sciences","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"1 November 2020","elsevierCitationCount":"1"},{"title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"973T08Eu4qYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42145-5/abstract","googleCitationCount":518,"googleAuthor":"P Moreau"},{"title":"Comprehensive analysis of the clinical immuno-oncology landscape","googleId":"JMxuRntBcUIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350203","googleCitationCount":301,"googleAuthor":"J Tang","doi":"10.1093/annonc/mdx755","elsevierAuthor":"Tang J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"212"},{"title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","googleId":"s_s_PGmenvcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321933","googleCitationCount":468,"googleAuthor":"AM Menzies","doi":"10.1093/annonc/mdw443","elsevierAuthor":"Menzies A.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"348"},{"title":"Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma","googleId":"kSUFFxCzMCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322720","googleCitationCount":303,"googleAuthor":"","doi":"10.1093/annonc/mdx178","elsevierAuthor":"Perlstein D.","publicationName":"PLoS ONE","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"5"},{"title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"RmK6BhSdorEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42148-0/abstract","googleCitationCount":287,"googleAuthor":"S Mahner"},{"title":"Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","googleId":"lpwU8nhhn9QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349269","googleCitationCount":268,"googleAuthor":"LL Siu","doi":"10.1093/annonc/mdx286","elsevierAuthor":"Khoja L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"197"},{"title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","googleId":"Nn_pEWNVQQwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322227","googleCitationCount":286,"googleAuthor":"EH Tan","doi":"10.1093/annonc/mdw611","elsevierAuthor":"Paz-Ares L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"222"},{"title":"Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes …","googleId":"HVMLQS5nSUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454859","googleCitationCount":229,"googleAuthor":"L Horn","doi":"10.1093/annonc/mdy041","elsevierAuthor":"Vokes E.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"180"},{"title":"ESMO-magnitude of clinical benefit scale version 1.1","googleId":"jIFgK4FbpqoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349324","googleCitationCount":259,"googleAuthor":"NI Cherny","doi":"10.1093/annonc/mdx310","elsevierAuthor":"Cherny N.I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"174"},{"title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2 …","googleId":"KUsvv8xkoKIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321052","googleCitationCount":240,"googleAuthor":"SM Stemmer","doi":"10.1093/annonc/mdy155","elsevierAuthor":"Ribelles N.","publicationName":"European Journal of Cancer","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0"},{"title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro …","googleId":"xgZdBbeTMhwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341936","googleCitationCount":187,"googleAuthor":"KW Lee","doi":"10.1093/annonc/mdy264","elsevierAuthor":"Bang Y.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"138"},{"title":"Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"pNNlJJvhfpgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31691-6/abstract","googleCitationCount":220,"googleAuthor":""},{"title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by …","googleId":"n1aDxA3wLe8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350173","googleCitationCount":198,"googleAuthor":"G Pentheroudakis","doi":"10.1093/annonc/mdx738","elsevierAuthor":"Yoshino T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"154"},{"title":"Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology","googleId":"-9AxJsn5Uh0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324123","googleCitationCount":232,"googleAuthor":"EJ Limkin","doi":"10.1093/annonc/mdx034","elsevierAuthor":"Noortman W.A.","publicationName":"PLoS ONE","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"0"},{"title":"Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"VWEZuMEIBLoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31712-0/abstract","googleCitationCount":154,"googleAuthor":""},{"title":"Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines","googleId":"GCroUoe4INgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31698-9/abstract","googleCitationCount":220,"googleAuthor":"R Giusti"},{"title":"Selective RET kinase inhibition for patients with RET-altered cancers","googleId":"BK7Pn-ZJLqwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341043","googleCitationCount":153,"googleAuthor":"V Subbiah","doi":"10.1093/annonc/mdy137","elsevierAuthor":"Subbiah V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"114"},{"title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","googleId":"4OIdLzBp2PYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319593","googleCitationCount":278,"googleAuthor":"JC Osorio","doi":"10.1093/annonc/mdw640","elsevierAuthor":"Osorio J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"221"},{"title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"UEw7iOVaJsIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42147-9/abstract","googleCitationCount":192,"googleAuthor":""},{"title":"European cancer mortality predictions for the year 2017, with focus on lung cancer","googleId":"hhQuz1hvJhoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320125","googleCitationCount":201,"googleAuthor":"M Malvezzi","doi":"10.1093/annonc/mdx033","elsevierAuthor":"Zhou J.","publicationName":"Bioscience Reports","elsevierCoverDate":"2019-08-02","elsevierCoverDisplayDate":"2 August 2019","elsevierCitationCount":"12"},{"title":"High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients","googleId":"n0kEd1gUlI8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320691","googleCitationCount":212,"googleAuthor":"FA San Lucas","doi":"10.1093/annonc/mdx004","elsevierAuthor":"Pofali P.","publicationName":"Current Cancer Drug Targets","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"2"},{"title":"Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies, an update of the evidence of the WCRF-AICR …","googleId":"b9rdYFR6Z1cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321337","googleCitationCount":193,"googleAuthor":"L Abar","doi":"10.1093/annonc/mdx171","elsevierAuthor":"Nimptsch K.","publicationName":"British Journal of Cancer","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0"},{"title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","googleId":"mCTvC-S32QoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50454-9/abstract","googleCitationCount":145,"googleAuthor":""},{"title":"Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors","googleId":"BtloFdMWIG8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316692","googleCitationCount":161,"googleAuthor":"CM Lovly","doi":"10.1093/annonc/mdx703","elsevierAuthor":"Westover D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"124"},{"title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"7JMTnEptucgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31690-4/abstract","googleCitationCount":136,"googleAuthor":""},{"title":"Glioblastoma targeted therapy: updated approaches from recent biological insights","googleId":"SYyIipepKswJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322483","googleCitationCount":176,"googleAuthor":"M Touat","doi":"10.1093/annonc/mdx106","elsevierAuthor":"Mishinov S.V.","publicationName":"Sovremennye Tehnologii v Medicine","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","googleId":"CWHiydiOzTkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345326","googleCitationCount":153,"googleAuthor":"MK McConechy","doi":"10.1093/annonc/mdy058","elsevierAuthor":"Kommoss S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"103"},{"title":"ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up","googleId":"Z5_4ivDLP68J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934133X","googleCitationCount":120,"googleAuthor":"D Berney","doi":"10.1093/annonc/mdy217","elsevierAuthor":"Honecker F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"83"},{"title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","googleId":"Z2g9gYxJEgoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341468","googleCitationCount":131,"googleAuthor":"AR Hansen","doi":"10.1093/annonc/mdy232","elsevierAuthor":"Hansen A.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"92"},{"title":"European cancer mortality predictions for the year 2018 with focus on colorectal cancer","googleId":"9X7u_Z26O6QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945477X","googleCitationCount":138,"googleAuthor":"M Malvezzi","doi":"10.1093/annonc/mdy033","elsevierAuthor":"Malvezzi M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"90"},{"title":"Human papillomavirus-related oropharyngeal cancer","googleId":"4V7Cy1WI_lUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349300","googleCitationCount":165,"googleAuthor":"M Mena","doi":"10.1093/annonc/mdx304","elsevierAuthor":"Taberna M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"109"},{"title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","googleId":"rGRTXs2Y9gIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934997X","googleCitationCount":156,"googleAuthor":"A Betof","doi":"10.1093/annonc/mdx642","elsevierAuthor":"Pollack M.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"130"},{"title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","googleId":"VhPcvkOL7Q8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320058","googleCitationCount":167,"googleAuthor":"JH Lee","doi":"10.1093/annonc/mdx026","elsevierAuthor":"Strudel M.","publicationName":"Current Medicinal Chemistry","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board","googleId":"whg1ImT-CS8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350720","googleCitationCount":138,"googleAuthor":"","doi":"10.1093/annonc/mdx781","elsevierAuthor":"Somashekhar S.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"89"},{"title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage …","googleId":"CKBbpFfqB9MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345417","googleCitationCount":127,"googleAuthor":"MR Sydes","doi":"10.1093/annonc/mdy072","elsevierAuthor":"Sydes M.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"91"},{"title":"KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)","googleId":"8lloK8EpRN8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50436-7/abstract","googleCitationCount":117,"googleAuthor":"R Greil"},{"title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients","googleId":"9t2ppcGDgfsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321386","googleCitationCount":149,"googleAuthor":"JL Perez-Gracia","doi":"10.1093/annonc/mdx190","elsevierAuthor":"Yang H.j.","publicationName":"Molecular Genetics and Genomic Medicine","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"1 June 2020","elsevierCitationCount":"2"},{"title":"An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between Sarcoma Patients EuroNet (SPAEN) and …","googleId":"bz1ZHAiiHV4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934935X","googleCitationCount":146,"googleAuthor":"J Garcia","doi":"10.1093/annonc/mdx323","elsevierAuthor":"Kasper B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"102"},{"title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","googleId":"ZgSR3-cC5XQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320101","googleCitationCount":157,"googleAuthor":"AR Mato","doi":"10.1093/annonc/mdx031","elsevierAuthor":"Rogers B.B.","publicationName":"Clinical Journal of Oncology Nursing","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"0"},{"title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","googleId":"2orw7pHP3CsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320988","googleCitationCount":115,"googleAuthor":"M Bruzzone","doi":"10.1093/annonc/mdy127","elsevierAuthor":"Poggio F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"81"},{"title":"Mechanisms regulating T-cell infiltration and activity in solid tumors","googleId":"s_m2z9sXZAsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541473","googleCitationCount":138,"googleAuthor":"M Irving","doi":"10.1093/annonc/mdx238","elsevierAuthor":"Lanitis E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"105"},{"title":"BET inhibitors: a novel epigenetic approach","googleId":"5AB-EvjYCFQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321313","googleCitationCount":140,"googleAuthor":"DB Doroshow","doi":"10.1093/annonc/mdx157","elsevierAuthor":"Frame S.","publicationName":"PLoS ONE","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"2"},{"title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","googleId":"M20N-uY9ucwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345569","googleCitationCount":117,"googleAuthor":"S Gutiérrez-Enríquez","doi":"10.1093/annonc/mdy099","elsevierAuthor":"Cruz C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"84"},{"title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","googleId":"TcW2JC9xwwsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350069","googleCitationCount":137,"googleAuthor":"V Lemaire","doi":"10.1093/annonc/mdx686","elsevierAuthor":"Rotte A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"89"},{"title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi …","googleId":"W4Svblm1hmAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322550","googleCitationCount":154,"googleAuthor":"","doi":"10.1093/annonc/mdx155","elsevierAuthor":"Conteduca V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"118"},{"title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX …","googleId":"jmz885CC1e8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318848","googleCitationCount":105,"googleAuthor":"S Peters","doi":"10.1093/annonc/mdy405","elsevierAuthor":"Gadgeel S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"83"},{"title":"Surgical resection versus watchful waiting in low-grade gliomas","googleId":"rkQkqgAfhtMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321611","googleCitationCount":143,"googleAuthor":"AS Jakola","doi":"10.1093/annonc/mdx230","elsevierAuthor":"Mato D.","publicationName":"Neurosurgery","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"1 February 2021","elsevierCitationCount":"0"},{"title":"Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients","googleId":"Oew1KAYCj8oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324445","googleCitationCount":150,"googleAuthor":"J Vidal","doi":"10.1093/annonc/mdx125","elsevierAuthor":"Zou D.","publicationName":"Carcinogenesis","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"1 November 2020","elsevierCitationCount":"0"},{"title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","googleId":"UT6vsWS8DcsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322069","googleCitationCount":146,"googleAuthor":"L Spain","doi":"10.1093/annonc/mdw558","elsevierAuthor":"Spain L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"108"},{"title":"Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease …","googleId":"KopIl4fMbmUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322756","googleCitationCount":143,"googleAuthor":"","doi":"10.1093/annonc/mdx183","elsevierAuthor":"Haratani K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"118"},{"title":"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program","googleId":"y3PaGTiJQdIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350379","googleCitationCount":129,"googleAuthor":"F Cardoso","doi":"10.1093/annonc/mdx651","elsevierAuthor":"Cardoso F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"91"},{"title":"Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer","googleId":"WqKlO74zAvMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454641","googleCitationCount":123,"googleAuthor":"","doi":"10.1093/annonc/mdy014","elsevierAuthor":"Adam J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"107"},{"title":"Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer","googleId":"bME61RUdIk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354985","googleCitationCount":129,"googleAuthor":"","doi":"10.1093/annonc/mdx784","elsevierAuthor":"Condorelli R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"102"},{"title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","googleId":"nxKUezNOicQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320733","googleCitationCount":142,"googleAuthor":"NB Leighl","doi":"10.1093/annonc/mdx008","elsevierAuthor":"Song P.","publicationName":"Thoracic Cancer","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"1"},{"title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines","googleId":"Rq1p5-uN4eMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31688-6/abstract","googleCitationCount":99,"googleAuthor":"M Dicato"},{"title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"AaYqT9WkkDUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42151-0/abstract","googleCitationCount":134,"googleAuthor":"M Dreyling"},{"title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","googleId":"U9Hmo_iY_D8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352482","googleCitationCount":135,"googleAuthor":"M Dreyling","doi":"10.1093/annonc/mdx289","elsevierAuthor":"Dreyling M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"107"},{"title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR …","googleId":"DYKqcjdUTUwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349014","googleCitationCount":116,"googleAuthor":"J Mazières","doi":"10.1093/annonc/mdy121","elsevierAuthor":"Griesinger F.","publicationName":"Oncotarget","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"1 October 2018","elsevierCitationCount":"6"},{"title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic …","googleId":"NR80ytPApcMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341341","googleCitationCount":104,"googleAuthor":"TR Cottrell","doi":"10.1093/annonc/mdy218","elsevierAuthor":"Cottrell T.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"74"},{"title":"Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study","googleId":"sZmT8SYUz0sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321532","googleCitationCount":127,"googleAuthor":"L Cabel","doi":"10.1093/annonc/mdx212","elsevierAuthor":"Yang S.","publicationName":"Journal of Cellular Physiology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"1 February 2020","elsevierCitationCount":"25"},{"title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","googleId":"sOhBQzXEP1cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349439","googleCitationCount":126,"googleAuthor":"J Larkin","doi":"10.1093/annonc/mdx339","elsevierAuthor":"Chapman P.B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"85"},{"title":"CheckMate 214: efficacy and safety of nivolumab+ ipilimumab (N+ I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC) …","googleId":"YwcXZMNYlHIJ","googleLink":"https://www.researchgate.net/profile/Toni_Choueiri/publication/320350214_LBA5CheckMate_214_Efficacy_and_safety_of_nivolumab_ipilimumab_NI_v_sunitinib_S_for_treatment-naive_advanced_or_metastatic_renal_cell_carcinoma_mRCC_including_IMDC_risk_and_PD-L1_expression_subgroups/links/5a888e5caca272017e5f5d25/LBA5CheckMate-214-Efficacy-and-safety-of-nivolumab-ipilimumab-N-I-v-sunitinib-S-for-treatment-naive-advanced-or-metastatic-renal-cell-carcinoma-mRCC-including-IMDC-risk-and-PD-L1-expression-subgrou.pdf","googleCitationCount":126,"googleAuthor":""},{"title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","googleId":"MboC3oFoRkkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320083","googleCitationCount":130,"googleAuthor":"P Munster","doi":"10.1093/annonc/mdx029","elsevierAuthor":"Bucau M.","publicationName":"Oncotarget","elsevierCoverDate":"2020-09-29","elsevierCoverDisplayDate":"29 September 2020","elsevierCitationCount":"0"},{"title":"Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA","googleId":"EM1xZd7VyuMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320800","googleCitationCount":131,"googleAuthor":"J Remon","doi":"10.1093/annonc/mdx017","elsevierAuthor":"Abate R.E.","publicationName":"Cancers","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0"},{"title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","googleId":"f1jkyjFeOmsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316795","googleCitationCount":102,"googleAuthor":"","doi":"10.1093/annonc/mdx810","elsevierAuthor":"Baracos V.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"71"},{"title":"Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma","googleId":"4vLEiRxJlBAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322665","googleCitationCount":127,"googleAuthor":"MA Qazi","doi":"10.1093/annonc/mdx169","elsevierAuthor":"Qazi M.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"78"},{"title":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results …","googleId":"tPKKWUyHOLoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342462","googleCitationCount":85,"googleAuthor":"S Loibl","doi":"10.1093/annonc/mdy460","elsevierAuthor":"Loibl S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"58"},{"title":"Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy","googleId":"KqQPr9qeJKYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541461","googleCitationCount":109,"googleAuthor":"AR Sánchez-Paulete","doi":"10.1093/annonc/mdx237","elsevierAuthor":"To J.","publicationName":"Communications Biology","elsevierCoverDate":"2021-12-01","elsevierCoverDisplayDate":"December 2021","elsevierCitationCount":"0"},{"title":"Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC","googleId":"zRwJzoFqamIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32762-0/abstract","googleCitationCount":86,"googleAuthor":"NA Rizvi"},{"title":"Causes of death among cancer patients","googleId":"TmSXqBV4QdsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322161","googleCitationCount":166,"googleAuthor":"NG Zaorsky","doi":"10.1093/annonc/mdw604","elsevierAuthor":"Zaorsky N.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"121"},{"title":"BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives","googleId":"ZK3QRnJ9VaYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345867","googleCitationCount":113,"googleAuthor":"","doi":"10.1093/annonc/mdx401","elsevierAuthor":"Sanz-Garcia E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"77"},{"title":"Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line …","googleId":"I4W3gQF9OwEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932126X","googleCitationCount":121,"googleAuthor":"C Rolfo","doi":"10.1093/annonc/mdx119","elsevierAuthor":"Xie Y.H.","publicationName":"Signal Transduction and Targeted Therapy","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"1 December 2020","elsevierCitationCount":"46"},{"title":"Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer","googleId":"kZCcStisSwAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318861","googleCitationCount":80,"googleAuthor":"GV Long","doi":"10.1093/annonc/mdy408","elsevierAuthor":"Long G.V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"58"},{"title":"Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors","googleId":"JM3oYibCnAIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934966X","googleCitationCount":113,"googleAuthor":"I Sloma","doi":"10.1093/annonc/mdx416","elsevierAuthor":"Izumchenko E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"87"},{"title":"Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"roYk1TxvdXIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31689-8/abstract","googleCitationCount":81,"googleAuthor":"I Ray-Coquard"},{"title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","googleId":"KZvArhuaafoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342413","googleCitationCount":89,"googleAuthor":"TG Kwon","doi":"10.1093/annonc/mdy454","elsevierAuthor":"Gross-Goupil M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"58"},{"title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","googleId":"5eX2SfV5OHkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341791","googleCitationCount":110,"googleAuthor":"J Mateo","doi":"10.1093/annonc/mdy263","elsevierAuthor":"Mateo J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"75"},{"title":"Intratumoral immunotherapy: using the tumor as the remedy","googleId":"fjXgSwnZdxUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541515","googleCitationCount":100,"googleAuthor":"L Tselikas","doi":"10.1093/annonc/mdx683","elsevierAuthor":"Marabelle A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"73"},{"title":"Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples","googleId":"-JfQrlb8rssJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319076","googleCitationCount":148,"googleAuthor":"LA Renfro","doi":"10.1093/annonc/mdw413","elsevierAuthor":"Renfro L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"103"},{"title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","googleId":"ZLv0BPO-6RcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342073","googleCitationCount":84,"googleAuthor":"","doi":"10.1093/annonc/mdy334","elsevierAuthor":"Sabari J.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"60"},{"title":"First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma …","googleId":"QAaz4pRUNj4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349579","googleCitationCount":105,"googleAuthor":"CM Ding","doi":"10.1093/annonc/mdx359","elsevierAuthor":"Shi Y.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"91"},{"title":"Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","googleId":"5HT_3DNQlooJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50455-0/abstract","googleCitationCount":84,"googleAuthor":""},{"title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care","googleId":"ZRjJkyqwv_8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350215","googleCitationCount":99,"googleAuthor":"F Scotté","doi":"10.1093/annonc/mdx757","elsevierAuthor":"Jordan K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"68"},{"title":"Improved survival using specialized multidisciplinary board in sarcoma patients","googleId":"EeWwvLBbDmYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346046","googleCitationCount":98,"googleAuthor":"JY Blay","doi":"10.1093/annonc/mdx484","elsevierAuthor":"Blay J.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"86"},{"title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","googleId":"xG-NnAYhDXAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454707","googleCitationCount":102,"googleAuthor":"Y Bareche","doi":"10.1093/annonc/mdy024","elsevierAuthor":"Bareche Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"63"},{"title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","googleId":"eu1SFmu76QYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35043-4/abstract","googleCitationCount":96,"googleAuthor":"AG Marcelin"},{"title":"Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331","googleId":"U2QG0fxaBlAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32761-9/abstract","googleCitationCount":75,"googleAuthor":""},{"title":"Immunotherapy in ovarian cancer","googleId":"W2LDurrEmjkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342034655X","googleCitationCount":93,"googleAuthor":"K Odunsi","doi":"10.1093/annonc/mdx444","elsevierAuthor":"Odunsi K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"68"},{"title":"Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund","googleId":"1zDO6V11IKcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321258","googleCitationCount":100,"googleAuthor":"","doi":"10.1093/annonc/mdx110","elsevierAuthor":"Ushkalova E.A.","publicationName":"Farmakoekonomika","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Alpelisib (ALP)+ fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial","googleId":"9zOYoaMAvCwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50401-X/abstract","googleCitationCount":79,"googleAuthor":"F André"},{"title":"Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma","googleId":"znmBens0W60J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321490","googleCitationCount":102,"googleAuthor":"A Strati","doi":"10.1093/annonc/mdx206","elsevierAuthor":"Hofman P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-09-01","elsevierCoverDisplayDate":"1 September 2019","elsevierCitationCount":"34"},{"title":"Updated safety and clinical activity results from a phase Ib study of atezolizumab+ bevacizumab in hepatocellular carcinoma (HCC)","googleId":"vBdmkqm1QqQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50419-7/abstract","googleCitationCount":78,"googleAuthor":""},{"title":"Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)","googleId":"uSBIuWlxEokJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38546-X/abstract","googleCitationCount":97,"googleAuthor":""},{"title":"Real-world evidence in the treatment of ovarian cancer","googleId":"bkc_3fnAHb4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346548","googleCitationCount":90,"googleAuthor":"","doi":"10.1093/annonc/mdx443","elsevierAuthor":"Eisenhauer E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"70"},{"title":"Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma","googleId":"xnFuV0ZuYnkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354900","googleCitationCount":94,"googleAuthor":"","doi":"10.1093/annonc/mdx765","elsevierAuthor":"Krug A.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"67"},{"title":"Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced …","googleId":"pO5kBYhk4FkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348926","googleCitationCount":83,"googleAuthor":"","doi":"10.1093/annonc/mdy101","elsevierAuthor":"Abou-Alfa G.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"64"},{"title":"Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study","googleId":"2T6KSY8r_ooJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319684","googleCitationCount":101,"googleAuthor":"","doi":"10.1093/annonc/mdw651","elsevierAuthor":"Kelley R.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"68"},{"title":"Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors","googleId":"_HM1ZnpeLuQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321660","googleCitationCount":100,"googleAuthor":"","doi":"10.1093/annonc/mdx235","elsevierAuthor":"Navani V.","publicationName":"British Journal of Clinical Pharmacology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"1"},{"title":"Concordance of blood-and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer","googleId":"6P1_W9eWCZEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324342","googleCitationCount":103,"googleAuthor":"","doi":"10.1093/annonc/mdx112","elsevierAuthor":"Vera R.","publicationName":"Clinical and Translational Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer","googleId":"nNtHp7zSw7oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349919","googleCitationCount":94,"googleAuthor":"M Ilié","doi":"10.1093/annonc/mdx636","elsevierAuthor":"Ilié M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"65"},{"title":"CCAT1 and CCAT2 long noncoding RNAs, located within the 8q. 24.21 'gene desert', serve as important prognostic biomarkers in colorectal cancer","googleId":"H_O6jWyUlE8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321696","googleCitationCount":94,"googleAuthor":"","doi":"10.1093/annonc/mdx248","elsevierAuthor":"Gong T.","publicationName":"Aging","elsevierCoverDate":"2020-06-30","elsevierCoverDisplayDate":"30 June 2020","elsevierCitationCount":"0"},{"title":"First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid …","googleId":"KEeidmV8NrwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320678","googleCitationCount":100,"googleAuthor":"","doi":"10.1093/annonc/mdx002","elsevierAuthor":"Derakhshani A.","publicationName":"Journal of Cellular Physiology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"1 April 2020","elsevierCitationCount":"9"},{"title":"Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study","googleId":"liXDPg06Gw8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320241","googleCitationCount":94,"googleAuthor":"AI Phipps","doi":"10.1093/annonc/mdx052","elsevierAuthor":"Nkune N.W.","publicationName":"Anti-Cancer Agents in Medicinal Chemistry","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"1"},{"title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study","googleId":"xnbz4U15er0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931960X","googleCitationCount":120,"googleAuthor":"GA McArthur","doi":"10.1093/annonc/mdw641","elsevierAuthor":"McArthur G.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"85"},{"title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of …","googleId":"hjfkNGjS19sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454604","googleCitationCount":85,"googleAuthor":"JJ Yang","doi":"10.1093/annonc/mdy009","elsevierAuthor":"Li Y.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"65"},{"title":"Immunological differences between primary and metastatic breast cancer","googleId":"YMCvlmhyiV8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318782","googleCitationCount":73,"googleAuthor":"X Li","doi":"10.1093/annonc/mdy399","elsevierAuthor":"Szekely B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"51"},{"title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GNA4kIAX048J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31693-X/abstract","googleCitationCount":63,"googleAuthor":"PL Zinzani"},{"title":"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium …","googleId":"KsHU8XswW04J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320186","googleCitationCount":91,"googleAuthor":"O Sartor","doi":"10.1093/annonc/mdx044","elsevierAuthor":"Sartor O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"May 2017","elsevierCitationCount":"69"},{"title":"Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines","googleId":"n-RV3PkMrBYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31697-7/abstract","googleCitationCount":63,"googleAuthor":"NI Cherny"},{"title":"Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results …","googleId":"W2CN8WOhwPUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39105-5/abstract","googleCitationCount":89,"googleAuthor":"S Loi"},{"title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","googleId":"Ac6sX81ICFkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932246X","googleCitationCount":128,"googleAuthor":"P Hilden","doi":"10.1093/annonc/mdx097","elsevierAuthor":"Berzaczy D.","publicationName":"PLoS ONE","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"March 2019","elsevierCitationCount":"1"},{"title":"Treatment of recurrent ovarian cancer","googleId":"irGrI6z5oVkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346524","googleCitationCount":76,"googleAuthor":"S Pignata","doi":"10.1093/annonc/mdx441","elsevierAuthor":"Pignata S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"55"},{"title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","googleId":"y5Dmny7hSl0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322070","googleCitationCount":116,"googleAuthor":"SH Lee","doi":"10.1093/annonc/mdw559","elsevierAuthor":"Lee S.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"87"},{"title":"Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease","googleId":"gikE_afqJsEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320459","googleCitationCount":112,"googleAuthor":"MR Mirza","doi":"10.1093/annonc/mdw663","elsevierAuthor":"Wilson M.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"93"},{"title":"Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy","googleId":"Gc26OX2gqiQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352366","googleCitationCount":85,"googleAuthor":"","doi":"10.1093/annonc/mdx271","elsevierAuthor":"Bozzetti F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"65"},{"title":"Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients","googleId":"hUIjPQsLEXAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934983X","googleCitationCount":82,"googleAuthor":"V Bernard","doi":"10.1093/annonc/mdx542","elsevierAuthor":"Castillo J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"66"},{"title":"IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin+ nab-paclitaxel (CnP) with or without atezolizumab …","googleId":"dpDeks1nvgEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50456-2/abstract","googleCitationCount":69,"googleAuthor":"F Cappuzzo"},{"title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","googleId":"TMTicSZFpmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355115","googleCitationCount":112,"googleAuthor":"G Goss","doi":"10.1093/annonc/mdx820","elsevierAuthor":"Goss G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"86"},{"title":"Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast …","googleId":"j9n3rYkfiOUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349798","googleCitationCount":84,"googleAuthor":"M Robson","doi":"10.1093/annonc/mdx505","elsevierAuthor":"Han H.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"74"},{"title":"Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer","googleId":"EAJljg9-vMgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345570","googleCitationCount":66,"googleAuthor":"S Siena","doi":"10.1093/annonc/mdy100","elsevierAuthor":"Siena S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"51"},{"title":"Long-term toxicity of cisplatin in germ-cell tumor survivors","googleId":"iDfg2GfwZHYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345855","googleCitationCount":81,"googleAuthor":"M Chovanec","doi":"10.1093/annonc/mdx360","elsevierAuthor":"Chovanec M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"59"},{"title":"RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study","googleId":"z2Eb6009_PUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934534X","googleCitationCount":77,"googleAuthor":"JB Bachet","doi":"10.1093/annonc/mdy061","elsevierAuthor":"Bachet J.B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"56"},{"title":"EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","googleId":"9evIP-N-k5UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)42149-2/abstract","googleCitationCount":112,"googleAuthor":""},{"title":"Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the …","googleId":"Y_hyrbStDjMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319829","googleCitationCount":110,"googleAuthor":"GM Wulf","doi":"10.1093/annonc/mdw672","elsevierAuthor":"Matulonis U.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"86"},{"title":"Differential protein stability and clinical responses ofEML4-ALK fusion variants to various ALK inhibitors in advancedALK-rearranged non-small cell lung …","googleId":"Wpw1kl--lYYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320630","googleCitationCount":108,"googleAuthor":"","doi":"10.1093/annonc/mdw693","elsevierAuthor":"Elsayed M.","publicationName":"Pharmaceuticals","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0"},{"title":"Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H …","googleId":"9MWA4VyBm4kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50410-0/abstract","googleCitationCount":64,"googleAuthor":"HJJ Lenz"},{"title":"Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer","googleId":"oWfOuyjvNCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349774","googleCitationCount":81,"googleAuthor":"IG Murillas","doi":"10.1093/annonc/mdx483","elsevierAuthor":"Fribbens C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"53"},{"title":"Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial","googleId":"cBIkLJ3XgVwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352512","googleCitationCount":84,"googleAuthor":"D Alterio","doi":"10.1093/annonc/mdx299","elsevierAuthor":"Ghi M.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"66"},{"title":"FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma","googleId":"HOtsu9gEikcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342036","googleCitationCount":54,"googleAuthor":"L Emmett","doi":"10.1093/annonc/mdy330","elsevierAuthor":"Tan A.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"50"},{"title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","googleId":"K-gyFUrJvL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322082","googleCitationCount":104,"googleAuthor":"P Hammel","doi":"10.1093/annonc/mdw561","elsevierAuthor":"Faivre S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"70"},{"title":"Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a …","googleId":"-CbF1tPfjc0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320745","googleCitationCount":87,"googleAuthor":"","doi":"10.1093/annonc/mdx009","elsevierAuthor":"Jiang D.M.","publicationName":"Oncology (Switzerland)","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0"},{"title":"Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized …","googleId":"7U4PJZR1zDwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319830","googleCitationCount":104,"googleAuthor":"F Khosrow-Khavar","doi":"10.1093/annonc/mdw673","elsevierAuthor":"Khosrow-Khavar F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"62"},{"title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206","googleId":"4XrLOEF45I4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350033","googleCitationCount":75,"googleAuthor":"N Adra","doi":"10.1093/annonc/mdx680","elsevierAuthor":"Adra N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"66"},{"title":"Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015","googleId":"Gr_-4cpYDBsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320253","googleCitationCount":83,"googleAuthor":"","doi":"10.1093/annonc/mdx053","elsevierAuthor":"Hilal T.","publicationName":"JAMA Internal Medicine","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"3"},{"title":"Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer","googleId":"9j0uvrbDQh4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50438-0/abstract","googleCitationCount":59,"googleAuthor":""},{"title":"A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma …","googleId":"vX0hz0VkgKoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324305","googleCitationCount":78,"googleAuthor":"RD Petty","doi":"10.1093/annonc/mdx107","elsevierAuthor":"Ishii T.","publicationName":"International Journal of Clinical Oncology","elsevierCoverDate":"2019-07-12","elsevierCoverDisplayDate":"12 July 2019","elsevierCitationCount":"5"},{"title":"Latest clinical evidence and further development of PARP inhibitors in ovarian cancer","googleId":"P6jyX2doe-4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349178","googleCitationCount":59,"googleAuthor":"MR Mirza","doi":"10.1093/annonc/mdy174","elsevierAuthor":"Mirza M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"46"},{"title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","googleId":"VH2wnWYIDlAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318964","googleCitationCount":52,"googleAuthor":"","doi":"10.1093/annonc/mdy423","elsevierAuthor":"Marabelle A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"43"},{"title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","googleId":"2jn2ehTMEpUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50408-2/abstract","googleCitationCount":61,"googleAuthor":""},{"title":"Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer","googleId":"f9GG1JvXz9wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454586","googleCitationCount":72,"googleAuthor":"N Feeney","doi":"10.1093/annonc/mdy005","elsevierAuthor":"Guibert N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"55"},{"title":"Safety and dose modification for patients receiving niraparib","googleId":"iqtQSV85LXkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341092","googleCitationCount":64,"googleAuthor":"","doi":"10.1093/annonc/mdy181","elsevierAuthor":"Banerjee S.","publicationName":"ESMO Open","elsevierCoverDate":"2020-12-11","elsevierCoverDisplayDate":"11 December 2020","elsevierCitationCount":"1"},{"title":"A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma …","googleId":"LqvwrgRiaU0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354936","googleCitationCount":74,"googleAuthor":"","doi":"10.1093/annonc/mdx770","elsevierAuthor":"Frikha M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"51"},{"title":"Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial","googleId":"dHFBcK4DYAMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39140-7/abstract","googleCitationCount":76,"googleAuthor":"EE Cohen"},{"title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","googleId":"WVQ8RRu2S3gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346010","googleCitationCount":74,"googleAuthor":"","doi":"10.1093/annonc/mdx479","elsevierAuthor":"Schlumberger M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"54"},{"title":"Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions","googleId":"EgUSBwBNP0MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322513","googleCitationCount":77,"googleAuthor":"MB Atkins","doi":"10.1093/annonc/mdx151","elsevierAuthor":"Ghiringhelli F.","publicationName":"Bulletin du Cancer","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"0"},{"title":"Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions","googleId":"f7sVN9C17pUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352470","googleCitationCount":73,"googleAuthor":"","doi":"10.1093/annonc/mdx288","elsevierAuthor":"Mayo-de-las-Casas C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"61"},{"title":"Delirium in adult cancer patients: ESMO Clinical Practice Guidelines","googleId":"g7JkhZhsFgMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31696-5/abstract","googleCitationCount":53,"googleAuthor":"SH Bush"},{"title":"Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo (radio) therapy: current …","googleId":"vmXWzOuDY_EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345661","googleCitationCount":56,"googleAuthor":"A Laviano","doi":"10.1093/annonc/mdy114","elsevierAuthor":"de van der Schueren M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"49"},{"title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","googleId":"zR9Z-sTCGYoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324299","googleCitationCount":79,"googleAuthor":"A Molassiotis","doi":"10.1093/annonc/mdx100","elsevierAuthor":"Aapro M.","publicationName":"Cancer Reports","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"9"},{"title":"Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional …","googleId":"YkOYFko8N-EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345338","googleCitationCount":66,"googleAuthor":"","doi":"10.1093/annonc/mdy060","elsevierAuthor":"Nauta I.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"60"},{"title":"Molecular correlates differentiate response to atezolizumab (atezo)+ bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated …","googleId":"z6r8M_03wBAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50428-8/abstract","googleCitationCount":59,"googleAuthor":"BI Rini"},{"title":"Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group","googleId":"ADqejP7k9eIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324147","googleCitationCount":78,"googleAuthor":"A Gronchi","doi":"10.1093/annonc/mdx054","elsevierAuthor":"Traylor J.I.","publicationName":"Neurosurgery","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"1 February 2021","elsevierCitationCount":"1"},{"title":"Blood-based biomarkers for cancer immunotherapy: tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ …","googleId":"ZIZg79FE5DAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38544-6/abstract","googleCitationCount":72,"googleAuthor":""},{"title":"Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer","googleId":"n3ncIXWoiqsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934904X","googleCitationCount":57,"googleAuthor":"","doi":"10.1093/annonc/mdy126","elsevierAuthor":"Wang H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"43"},{"title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma","googleId":"7HpsXiZd5nEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350501","googleCitationCount":67,"googleAuthor":"RJ Lee","doi":"10.1093/annonc/mdx717","elsevierAuthor":"Lee R.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"52"},{"title":"GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial","googleId":"hKoB9Dhlh0cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321374","googleCitationCount":75,"googleAuthor":"","doi":"10.1093/annonc/mdx184","elsevierAuthor":"Leonard R.C.F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"56"},{"title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","googleId":"c4_Mxz0sCQ8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342061","googleCitationCount":57,"googleAuthor":"M Scheffler","doi":"10.1093/annonc/mdy333","elsevierAuthor":"Kron A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"44"},{"title":"PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non …","googleId":"pwsxNfKR6bIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932068X","googleCitationCount":76,"googleAuthor":"MS Tsao","doi":"10.1093/annonc/mdx003","elsevierAuthor":"Yotsukura M.","publicationName":"Japanese Journal of Clinical Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"1 January 2021","elsevierCitationCount":"0"},{"title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study","googleId":"aH6AkxVOh1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342310","googleCitationCount":69,"googleAuthor":"AA Brandes","doi":"10.1093/annonc/mdy414","elsevierAuthor":"Conte P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"49"},{"title":"ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia","googleId":"7l4AWkNT6SAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321398","googleCitationCount":70,"googleAuthor":"D Currow","doi":"10.1093/annonc/mdx192","elsevierAuthor":"Wakabayashi H.","publicationName":"Journal of Cachexia, Sarcopenia and Muscle","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1"},{"title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","googleId":"G38FIF-DPwAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345879","googleCitationCount":65,"googleAuthor":"M Collins","doi":"10.1093/annonc/mdx403","elsevierAuthor":"Collins M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"46"},{"title":"Practical guidance for mismatch repair-deficiency testing in endometrial cancer","googleId":"8z34RnYa-VsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319325","googleCitationCount":93,"googleAuthor":"AML Jansen","doi":"10.1093/annonc/mdw542","elsevierAuthor":"Stelloo E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"68"},{"title":"A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2–advanced breast cancer …","googleId":"_Ir6wXQwHMAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322094","googleCitationCount":89,"googleAuthor":"L Dirix","doi":"10.1093/annonc/mdw562","elsevierAuthor":"Martín M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"67"},{"title":"First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer","googleId":"VFnIN_ezYA0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341651","googleCitationCount":52,"googleAuthor":"C Massard","doi":"10.1093/annonc/mdy244","elsevierAuthor":"Massard C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"40"},{"title":"Preclinical and clinical development of neoantigen vaccines","googleId":"joryDcGfW_sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541497","googleCitationCount":64,"googleAuthor":"","doi":"10.1093/annonc/mdx681","elsevierAuthor":"Li L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"49"},{"title":"Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in PTS with melanoma who …","googleId":"YcTlNYnQpMgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39111-0/abstract","googleCitationCount":69,"googleAuthor":"PA Ascierto"},{"title":"Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient …","googleId":"8UMUDp2Gh8IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341766","googleCitationCount":56,"googleAuthor":"","doi":"10.1093/annonc/mdy257","elsevierAuthor":"Ettl J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"32"},{"title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody …","googleId":"bSDvFNFrInAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353840","googleCitationCount":64,"googleAuthor":"","doi":"10.1093/annonc/mdx514","elsevierAuthor":"Arnold D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"44"},{"title":"Pembrolizumab for advanced biliary adenocarcinoma: results from the multicohort, phase II KEYNOTE-158 study","googleId":"-BvgtB7RN94J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49087-X/abstract","googleCitationCount":52,"googleAuthor":"A Nagrial"},{"title":"Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution","googleId":"hFVONvIPuWwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355152","googleCitationCount":60,"googleAuthor":"S Venkatesan","doi":"10.1093/annonc/mdy003","elsevierAuthor":"Venkatesan S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"41"},{"title":"Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer","googleId":"FSY7ZBOy77oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353979","googleCitationCount":64,"googleAuthor":"G D'Souza","doi":"10.1093/annonc/mdx535","elsevierAuthor":"D'Souza G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"47"},{"title":"Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trial","googleId":"_7KmT2NiuQkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319118","googleCitationCount":88,"googleAuthor":"C Lo","doi":"10.1093/annonc/mdw438","elsevierAuthor":"McDonald J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"55"},{"title":"Pertuzumab, trastuzumab, and standard anthracycline-and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive …","googleId":"ySGaJ99_7m0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935495X","googleCitationCount":63,"googleAuthor":"SM Swain","doi":"10.1093/annonc/mdx773","elsevierAuthor":"Swain S.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"49"},{"title":"Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial","googleId":"V0mTyQeYmDsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454513","googleCitationCount":64,"googleAuthor":"B Allard","doi":"10.1093/annonc/mdx730","elsevierAuthor":"Buisseret L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"50"},{"title":"LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors","googleId":"IssF7hstf1cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354754","googleCitationCount":63,"googleAuthor":"SK Chia","doi":"10.1093/annonc/mdx557","elsevierAuthor":"Burugu S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"48"},{"title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary …","googleId":"UmMY_-3_bgYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454525","googleCitationCount":61,"googleAuthor":"H Takahashi","doi":"10.1093/annonc/mdx771","elsevierAuthor":"Fushimi C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"49"},{"title":"Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment","googleId":"BytWdQvYgigJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352652","googleCitationCount":67,"googleAuthor":"AR Thierry","doi":"10.1093/annonc/mdx330","elsevierAuthor":"Thierry A.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"51"},{"title":"Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: first-line interventions","googleId":"FfE-jHZ106gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320769","googleCitationCount":68,"googleAuthor":"JA Ledermann","doi":"10.1093/annonc/mdx011","elsevierAuthor":"Karam A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"April 2017","elsevierCitationCount":"61"},{"title":"International cancer seminars: a focus on esophageal squamous cell carcinoma","googleId":"a-VgWBvwgMcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935241X","googleCitationCount":61,"googleAuthor":"G Murphy","doi":"10.1093/annonc/mdx279","elsevierAuthor":"Murphy G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"49"},{"title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","googleId":"XDSDHP500vwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324238","googleCitationCount":69,"googleAuthor":"RD Carvajal","doi":"10.1093/annonc/mdx079","elsevierAuthor":"Khachigian L.M.","publicationName":"Current Medicinal Chemistry","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1"},{"title":"Overview of current systemic management of EGFR-mutant NSCLC","googleId":"vFBC2Khe6MkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316680","googleCitationCount":58,"googleAuthor":"HH Loong","doi":"10.1093/annonc/mdx702","elsevierAuthor":"Hsu W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"44"},{"title":"Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer","googleId":"rzSFX2XnlxIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353876","googleCitationCount":61,"googleAuthor":"E Pleasance","doi":"10.1093/annonc/mdx523","elsevierAuthor":"Jones M.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"45"},{"title":"Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up","googleId":"BVO2fy8qa4EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931909X","googleCitationCount":81,"googleAuthor":"H Kadara","doi":"10.1093/annonc/mdw436","elsevierAuthor":"Wang F.","publicationName":"Frontiers in Oncology","elsevierCoverDate":"2020-10-20","elsevierCoverDisplayDate":"20 October 2020","elsevierCitationCount":"0"},{"title":"ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal …","googleId":"bChMFevPuykJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39139-0/abstract","googleCitationCount":64,"googleAuthor":"I McNeish"},{"title":"Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma …","googleId":"WgrkaTwq-SUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934952X","googleCitationCount":64,"googleAuthor":"HM Prince","doi":"10.1093/annonc/mdx352","elsevierAuthor":"Alhusayen R.","publicationName":"Dermatology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0"},{"title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study","googleId":"S5lXFX-HE2cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353864","googleCitationCount":66,"googleAuthor":"RW Joseph","doi":"10.1093/annonc/mdx518","elsevierAuthor":"Necchi A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"53"},{"title":"The European society for medical oncology (ESMO) precision medicine glossary","googleId":"16uKHIZmFr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350112","googleCitationCount":61,"googleAuthor":"LL Siu","doi":"10.1093/annonc/mdx707","elsevierAuthor":"Yates L.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"35"},{"title":"Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013","googleId":"UBKIYXH_QgQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349464","googleCitationCount":60,"googleAuthor":"F Islami","doi":"10.1093/annonc/mdx342","elsevierAuthor":"Islami F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"43"},{"title":"The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular …","googleId":"x5G1gAdb-PgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318885","googleCitationCount":54,"googleAuthor":"CK Lee","doi":"10.1093/annonc/mdy410","elsevierAuthor":"Mooi J.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"37"},{"title":"Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind …","googleId":"iVoGQe7utRMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354912","googleCitationCount":57,"googleAuthor":"","doi":"10.1093/annonc/mdx767","elsevierAuthor":"Tabernero J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"41"},{"title":"Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with …","googleId":"nd2kB4tfcM4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50406-9/abstract","googleCitationCount":53,"googleAuthor":"J Brody"},{"title":"Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) young oncologists committee burnout …","googleId":"59EQj5YOZIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322811","googleCitationCount":63,"googleAuthor":"R Califano","doi":"10.1093/annonc/mdx196","elsevierAuthor":"Phillips C.S.","publicationName":"Journal of Advanced Nursing","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"5"},{"title":"ClonEvol: clonal ordering and visualization in cancer sequencing","googleId":"Nk1etyO1BTcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353852","googleCitationCount":59,"googleAuthor":"HX Dang","doi":"10.1093/annonc/mdx517","elsevierAuthor":"Dang H.X.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"41"},{"title":"Development of an integrated electronic platform for patient self-report and management of adverse events during cancer treatment","googleId":"fDV3rOx_GwIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352597","googleCitationCount":59,"googleAuthor":"P Holch","doi":"10.1093/annonc/mdx317","elsevierAuthor":"Holch P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"35"},{"title":"JAVELIN renal 101: a randomized, Phase III study of avelumab+ axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)","googleId":"7ycuXzG_e7YJ","googleLink":"https://researchers.mq.edu.au/files/117842959/Publisher_version_open_access_.pdf","googleCitationCount":48,"googleAuthor":"K Penkov"},{"title":"Pertuzumab (P)+ trastuzumab (H)+ chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): final analysis of a …","googleId":"EiiSpPr7zd4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37890-X/abstract","googleCitationCount":59,"googleAuthor":"PM Hoff"},{"title":"Corrections to “Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"ya4axIpRsIQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31702-8/abstract","googleCitationCount":55,"googleAuthor":"S Mahner"},{"title":"Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information","googleId":"BxJyYr852YUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454689","googleCitationCount":55,"googleAuthor":"S Kim","doi":"10.1093/annonc/mdy022","elsevierAuthor":"Kim S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"44"},{"title":"Molecular tumor boards: current practice and future needs","googleId":"5Mz-lPEyZO8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353918","googleCitationCount":55,"googleAuthor":"","doi":"10.1093/annonc/mdx528","elsevierAuthor":"van der Velden D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"38"},{"title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial","googleId":"V7m10H-CD6EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454628","googleCitationCount":59,"googleAuthor":"","doi":"10.1093/annonc/mdy012","elsevierAuthor":"Rugo H.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"44"},{"title":"Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East …","googleId":"-cL_0UV2Vn8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345958","googleCitationCount":54,"googleAuthor":"S Lu","doi":"10.1093/annonc/mdx419","elsevierAuthor":"Nokihara H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"42"},{"title":"Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)","googleId":"X-TX3qZNWXkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319556","googleCitationCount":78,"googleAuthor":"","doi":"10.1093/annonc/mdw625","elsevierAuthor":"Mesnage S.J.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"65"},{"title":"Primary PFS and safety analyses of a randomized phase III study of carboplatin+ paclitaxel+/− bevacizumab, with or without atezolizumab in 1L non-squamous …","googleId":"tW_SKT_2ZGIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32868-6/abstract","googleCitationCount":55,"googleAuthor":"F Cappuzzo"},{"title":"Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA","googleId":"Xn_fzJLlcP0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39150-X/abstract","googleCitationCount":57,"googleAuthor":""},{"title":"Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials","googleId":"8i5eZ_PLMVMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319623","googleCitationCount":73,"googleAuthor":"CG Smith","doi":"10.1093/annonc/mdw645","elsevierAuthor":"Fanelli G.N.","publicationName":"Cancer Cell International","elsevierCoverDate":"2020-01-29","elsevierCoverDisplayDate":"29 January 2020","elsevierCitationCount":"7"},{"title":"Subjective and objective taste and smell changes in cancer","googleId":"FYPektw0N9wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320009","googleCitationCount":56,"googleAuthor":"CA Corish","doi":"10.1093/annonc/mdx018","elsevierAuthor":"Azzam P.","publicationName":"ecancermedicalscience","elsevierCoverDate":"2020-05-16","elsevierCoverDisplayDate":"16 May 2020","elsevierCitationCount":"0"},{"title":"Fluoropyrimidine (FP)+ bevacizumab (BEV)+ atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL–a …","googleId":"CnozItgixTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50411-2/abstract","googleCitationCount":44,"googleAuthor":"A Grothey"},{"title":"Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic …","googleId":"_TruGkshOrMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342334","googleCitationCount":44,"googleAuthor":"F Diehl","doi":"10.1093/annonc/mdy417","elsevierAuthor":"Kruger S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"27"},{"title":"The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC","googleId":"Q0RqKI0np2oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935255X","googleCitationCount":57,"googleAuthor":"PN Aguiar Jr","doi":"10.1093/annonc/mdx305","elsevierAuthor":"Bravaccini S.","publicationName":"Lung Cancer","elsevierCoverDate":"2019-06-01","elsevierCoverDisplayDate":"June 2019","elsevierCitationCount":"3"},{"title":"Pattern recognition receptors: immune targets to enhance cancer immunotherapy","googleId":"g4dxCRjrbT8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321362","googleCitationCount":57,"googleAuthor":"J Brody","doi":"10.1093/annonc/mdx179","elsevierAuthor":"Bai L.","publicationName":"Pharmacological Research","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"1"},{"title":"Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach","googleId":"08Pe7nwlSfEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48876-5/abstract","googleCitationCount":43,"googleAuthor":"UN Lassen"},{"title":"Infection-related complications during treatment for childhood acute lymphoblastic leukemia","googleId":"qsJjY-GcvoEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322057","googleCitationCount":62,"googleAuthor":"SC Howard","doi":"10.1093/annonc/mdw557","elsevierAuthor":"Inaba H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"29"},{"title":"Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the …","googleId":"O3snlcxwf78J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349506","googleCitationCount":54,"googleAuthor":"A Molassiotis","doi":"10.1093/annonc/mdx350","elsevierAuthor":"Molassiotis A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"0"},{"title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","googleId":"1Gdv-h0Gr3gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341407","googleCitationCount":50,"googleAuthor":"","doi":"10.1093/annonc/mdy226","elsevierAuthor":"Tetzlaff M.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"39"},{"title":"Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers","googleId":"7YMm8uDyEfEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37805-4/abstract","googleCitationCount":54,"googleAuthor":"TW Kim"},{"title":"Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone …","googleId":"q-aW8DuuEI0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341705","googleCitationCount":47,"googleAuthor":"","doi":"10.1093/annonc/mdy249","elsevierAuthor":"Hong R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"35"},{"title":"Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis","googleId":"leiMMexwTX8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320010","googleCitationCount":61,"googleAuthor":"P Maisonneuve","doi":"10.1093/annonc/mdx019","elsevierAuthor":"Chen Y.","publicationName":"Journal of Clinical Periodontology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"0"},{"title":"A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive …","googleId":"zU4jRRRngCAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324226","googleCitationCount":56,"googleAuthor":"MH Kulke","doi":"10.1093/annonc/mdx078","elsevierAuthor":"Kulke M.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"0"},{"title":"Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer","googleId":"_JHsuXugQlAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346095","googleCitationCount":52,"googleAuthor":"AB Schrock","doi":"10.1093/annonc/mdx490","elsevierAuthor":"Chung J.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"40"},{"title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","googleId":"I4f4osDJABEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322185","googleCitationCount":69,"googleAuthor":"","doi":"10.1093/annonc/mdw606","elsevierAuthor":"Zhao Y.","publicationName":"Cell Biology and Toxicology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0"},{"title":"Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for …","googleId":"5s9MQ2NMZO4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50458-6/abstract","googleCitationCount":42,"googleAuthor":"V Velcheti"},{"title":"Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic …","googleId":"trGJOyDGiK0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349476","googleCitationCount":56,"googleAuthor":"J Siveke","doi":"10.1093/annonc/mdx343","elsevierAuthor":"Schultheis B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"39"},{"title":"Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer","googleId":"cJDlrTiTRyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454719","googleCitationCount":51,"googleAuthor":"N Priedigkeit","doi":"10.1093/annonc/mdy025","elsevierAuthor":"Hartmaier R.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"37"},{"title":"Acquired chemotherapy resistance in ovarian cancer","googleId":"kRQ7nHL9jb8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346573","googleCitationCount":50,"googleAuthor":"EL Christie","doi":"10.1093/annonc/mdx446","elsevierAuthor":"Christie E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"35"},{"title":"Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative …","googleId":"y_Hwm3sXs-kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320460","googleCitationCount":67,"googleAuthor":"J Brown","doi":"10.1093/annonc/mdw665","elsevierAuthor":"Tufano A.M.","publicationName":"Clinical Breast Cancer","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0"},{"title":"Nivolumab induced radiation recall pneumonitis after two years of radiotherapy","googleId":"LwcPSS7YNk0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32437-8/abstract","googleCitationCount":57,"googleAuthor":""},{"title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA …","googleId":"yhogiUBXn4kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354997","googleCitationCount":48,"googleAuthor":"","doi":"10.1093/annonc/mdx787","elsevierAuthor":"Fossard G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"36"},{"title":"Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study","googleId":"uc12gvuaon4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320162","googleCitationCount":54,"googleAuthor":"A Ribas","doi":"10.1093/annonc/mdx040","elsevierAuthor":"Cohen-Aubart F.","publicationName":"Annals of the Rheumatic Diseases","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the …","googleId":"0MebEzG64wIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321015","googleCitationCount":47,"googleAuthor":"C Cremolini","doi":"10.1093/annonc/mdy140","elsevierAuthor":"Cremolini C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"40"},{"title":"Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients","googleId":"3GpLyzqtnMoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345521","googleCitationCount":42,"googleAuthor":"JL Perez-Gracia","doi":"10.1093/annonc/mdy089","elsevierAuthor":"Rodríguez-Ruiz M.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"34"},{"title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","googleId":"gFl3-e4UZEYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341754","googleCitationCount":41,"googleAuthor":"","doi":"10.1093/annonc/mdy256","elsevierAuthor":"De Vos S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"33"},{"title":"Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative …","googleId":"Tmzq_-ul8E0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341328","googleCitationCount":43,"googleAuthor":"L Malorni","doi":"10.1093/annonc/mdy214","elsevierAuthor":"Malorni L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"37"},{"title":"Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity","googleId":"QKpKRxgqzG8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66216-2/abstract","googleCitationCount":54,"googleAuthor":""},{"title":"Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2 …","googleId":"hNWw21fKSlEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352561","googleCitationCount":53,"googleAuthor":"AS Hamy","doi":"10.1093/annonc/mdx309","elsevierAuthor":"Hamy A.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"34"},{"title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","googleId":"cArXuAfWad4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342358","googleCitationCount":38,"googleAuthor":"P Cottu","doi":"10.1093/annonc/mdy448","elsevierAuthor":"Cottu P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"30"},{"title":"Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer","googleId":"wjQPzV-QDo0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316710","googleCitationCount":49,"googleAuthor":"L Friboulet","doi":"10.1093/annonc/mdx705","elsevierAuthor":"Favazza L.A.","publicationName":"Modern Pathology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"0"},{"title":"The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast","googleId":"M2YUfbqT4RgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932229X","googleCitationCount":53,"googleAuthor":"M Lazzeroni","doi":"10.1093/annonc/mdw623","elsevierAuthor":"Pruneri G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"41"},{"title":"nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast …","googleId":"39qHxHyYTlMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341225","googleCitationCount":43,"googleAuthor":"R Coleman","doi":"10.1093/annonc/mdy201","elsevierAuthor":"Yardley D.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"37"},{"title":"Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients","googleId":"Saws194IJzUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349944","googleCitationCount":49,"googleAuthor":"M Lambertini","doi":"10.1093/annonc/mdx639","elsevierAuthor":"Lambertini M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"37"},{"title":"Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?","googleId":"p0LeEFdraUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353839","googleCitationCount":47,"googleAuthor":"IH Sahin","doi":"10.1093/annonc/mdx503","elsevierAuthor":"Sahin I.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"30"},{"title":"What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis","googleId":"2o93TR0d-F4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345405","googleCitationCount":45,"googleAuthor":"IR White","doi":"10.1093/annonc/mdy071","elsevierAuthor":"Vale C.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"34"},{"title":"Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: exploratory analysis of the phase ii checkmate 275 study","googleId":"4bFbq6yoz74J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38122-9/abstract","googleCitationCount":49,"googleAuthor":""},{"title":"Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma","googleId":"zpHVKPgqZhEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350070","googleCitationCount":48,"googleAuthor":"E Ghorani","doi":"10.1093/annonc/mdx687","elsevierAuthor":"Ghorani E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"37"},{"title":"Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions","googleId":"GJWU25bDTYkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345582","googleCitationCount":41,"googleAuthor":"EEW Cohen","doi":"10.1093/annonc/mdy102","elsevierAuthor":"Haddad R.I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"30"},{"title":"Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide","googleId":"w99YVEXzsH0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341420","googleCitationCount":38,"googleAuthor":"F Scotté","doi":"10.1093/annonc/mdy228","elsevierAuthor":"Scotté F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"30"},{"title":"CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer","googleId":"BRzdf1031OUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345491","googleCitationCount":41,"googleAuthor":"","doi":"10.1093/annonc/mdy085","elsevierAuthor":"Smeby J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"31"},{"title":"Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm","googleId":"KdzBP6cnKjAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31971-4/abstract","googleCitationCount":62,"googleAuthor":"N Shenoy"},{"title":"Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients","googleId":"_nzkQ6SAG-0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454781","googleCitationCount":43,"googleAuthor":"E Pectasides","doi":"10.1093/annonc/mdy034","elsevierAuthor":"Kim S.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"35"},{"title":"Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic","googleId":"hXWDpA0TieUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32420-2/abstract","googleCitationCount":48,"googleAuthor":""},{"title":"Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit?","googleId":"h12xVhUjB-sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319301","googleCitationCount":63,"googleAuthor":"R Sullivan","doi":"10.1093/annonc/mdw538","elsevierAuthor":"Del Paggio J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"38"},{"title":"Waldenström's macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","googleId":"iUFI1cMahvEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31695-3/abstract","googleCitationCount":35,"googleAuthor":"E Kastritis"},{"title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","googleId":"_TamHOAeuMwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345302","googleCitationCount":43,"googleAuthor":"W Jurczak","doi":"10.1093/annonc/mdy056","elsevierAuthor":"Jurczak W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"32"},{"title":"Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE …","googleId":"Rfgoqy9ugfkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349002","googleCitationCount":42,"googleAuthor":"HG Wirsching","doi":"10.1093/annonc/mdy120","elsevierAuthor":"Wirsching H.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"34"},{"title":"Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors","googleId":"OcT33W3-ynMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350525","googleCitationCount":47,"googleAuthor":"C Albany","doi":"10.1093/annonc/mdx731","elsevierAuthor":"Albany C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"44"},{"title":"Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","googleId":"0m4C53yZBWQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342371","googleCitationCount":35,"googleAuthor":"MC Vegliante","doi":"10.1093/annonc/mdy450","elsevierAuthor":"Wei T.","publicationName":"Journal of Cancer Research and Clinical Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"0"},{"title":"A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)","googleId":"kWE4dmgWkqwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346150","googleCitationCount":49,"googleAuthor":"","doi":"10.1093/annonc/mdx496","elsevierAuthor":"Martin P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"39"},{"title":"Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) …","googleId":"exQLpop4URMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49923-7/abstract","googleCitationCount":43,"googleAuthor":""},{"title":"Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the …","googleId":"UappUNCpm50J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932280X","googleCitationCount":52,"googleAuthor":"","doi":"10.1093/annonc/mdx193","elsevierAuthor":"Jin C.","publicationName":"Cardiology (Switzerland)","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0"},{"title":"Epacadostat plus pembrolizumab in patients with advanced melanoma: phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037","googleId":"qRmyrEsZRyEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38477-5/abstract","googleCitationCount":48,"googleAuthor":"TF Gajewski"},{"title":"Use of chemotherapy near the end of life: what factors matter?","googleId":"rcVUW7N3zWUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320435","googleCitationCount":58,"googleAuthor":"P Rochigneux","doi":"10.1093/annonc/mdw654","elsevierAuthor":"Kaasa S.","publicationName":"The Lancet Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"130"},{"title":"Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy","googleId":"Wl0K-q-jCVMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320095","googleCitationCount":48,"googleAuthor":"R Douard","doi":"10.1093/annonc/mdx030","elsevierAuthor":"Yang Y.","publicationName":"Aging","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0"},{"title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)","googleId":"2YoX13n8AQIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49078-9/abstract","googleCitationCount":39,"googleAuthor":""},{"title":"Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of …","googleId":"l7Z2984aA-EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349646","googleCitationCount":50,"googleAuthor":"PC Barata","doi":"10.1093/annonc/mdx405","elsevierAuthor":"Barata P.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"39"},{"title":"OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant …","googleId":"0tsNO6QGSpkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350641","googleCitationCount":43,"googleAuthor":"DM Provencher","doi":"10.1093/annonc/mdx754","elsevierAuthor":"Provencher D.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"26"},{"title":"Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged …","googleId":"pghwK1aDCbEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38550-1/abstract","googleCitationCount":46,"googleAuthor":""},{"title":"Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study of the EAU-Young …","googleId":"XzgWREbE7kQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38138-2/abstract","googleCitationCount":44,"googleAuthor":"L Mariani"},{"title":"A polymorphic MYC response element in KBTBD11 influences colorectal cancer risk, especially in interaction with an MYC-regulated SNP rs6983267","googleId":"lgJq764m2EkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355012","googleCitationCount":42,"googleAuthor":"J Gong","doi":"10.1093/annonc/mdx789","elsevierAuthor":"Gong J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"39"},{"title":"IMpower132: efficacy of atezolizumab (atezo)+ carboplatin (carbo)/cisplatin (cis)+ pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous …","googleId":"sXw_bfOpDGsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50457-4/abstract","googleCitationCount":37,"googleAuthor":""},{"title":"Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+ cobimetinib and atezolizumab monotherapy vs regorafenib in …","googleId":"g6KV-0HjOu8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34066-9/abstract","googleCitationCount":44,"googleAuthor":"F Ciardiello"},{"title":"Alcohol and cigarette consumption predict mortality in patients with head and neck cancer: a pooled analysis within the International Head and Neck Cancer …","googleId":"KEeyRXUZMAEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346058","googleCitationCount":45,"googleAuthor":"V Wünsch-Filho","doi":"10.1093/annonc/mdx486","elsevierAuthor":"Giraldi L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"34"},{"title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001","googleId":"EM4ODdMcr88J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43453-4/abstract","googleCitationCount":34,"googleAuthor":""},{"title":"ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe","googleId":"-6G_-cztLikJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346204","googleCitationCount":44,"googleAuthor":"NI Cherny","doi":"10.1093/annonc/mdx521","elsevierAuthor":"Cherny N.I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"27"},{"title":"Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in …","googleId":"KA396dkhjk4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324196","googleCitationCount":50,"googleAuthor":"JJ Knox","doi":"10.1093/annonc/mdx075","elsevierAuthor":"Zhou F.","publicationName":"Drug Design, Development and Therapy","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"9"},{"title":"Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms","googleId":"thQg4b1NgbUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350756","googleCitationCount":39,"googleAuthor":"F Blackhall","doi":"10.1093/annonc/mdx790","elsevierAuthor":"Kordbacheh T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"35"},{"title":"RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI …","googleId":"hg-h3xCw_0EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349762","googleCitationCount":48,"googleAuthor":"N Normanno","doi":"10.1093/annonc/mdx417","elsevierAuthor":"Normanno N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"40"},{"title":"Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and …","googleId":"nGtxw5h62GgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350549","googleCitationCount":39,"googleAuthor":"AM Udager","doi":"10.1093/annonc/mdx736","elsevierAuthor":"Udager A.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"32"},{"title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","googleId":"tJRXb-T0tc0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349592","googleCitationCount":42,"googleAuthor":"AA Sahin","doi":"10.1093/annonc/mdx397","elsevierAuthor":"Fujii T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"31"},{"title":"KEYNOTE-059 update: efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G …","googleId":"Pliwvuq75hEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39120-1/abstract","googleCitationCount":45,"googleAuthor":""},{"title":"Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC …","googleId":"JlSB7lImorUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321106","googleCitationCount":35,"googleAuthor":"J Mateo","doi":"10.1093/annonc/mdy172","elsevierAuthor":"Lorente D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"30"},{"title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were …","googleId":"7VJCiuB1Y_UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33687-7/abstract","googleCitationCount":37,"googleAuthor":"F Meric-Bernstam"},{"title":"Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trial","googleId":"omcSF3epBc8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321489","googleCitationCount":44,"googleAuthor":"HM Dhillon","doi":"10.1093/annonc/mdx205","elsevierAuthor":"Ma R.C.","publicationName":"Oncology Nursing Forum","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"0"},{"title":"Front-line therapy of advanced epithelial ovarian cancer: standard treatment","googleId":"HAj8cjAzVcAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346615","googleCitationCount":40,"googleAuthor":"","doi":"10.1093/annonc/mdx450","elsevierAuthor":"Marth C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"32"},{"title":"Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines","googleId":"u-98sAqANuAJ","googleLink":"https://www.researchgate.net/profile/Fabio_Trippa/publication/325949870_Diarrhoea_in_adult_cancer_patients_ESMO_Clinical_Practice_Guidelines/links/5c9a73c545851506d72d9cff/Diarrhoea-in-adult-cancer-patients-ESMO-Clinical-Practice-Guidelines.pdf","googleCitationCount":37,"googleAuthor":"NI Cherny"},{"title":"Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck …","googleId":"1q63F7Ca7cAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349488","googleCitationCount":45,"googleAuthor":"EEW Cohen","doi":"10.1093/annonc/mdx344","elsevierAuthor":"Brisson R.J.","publicationName":"Head and Neck","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"1 November 2019","elsevierCitationCount":"3"},{"title":"Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy","googleId":"HTHb-EUC7EEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353761","googleCitationCount":42,"googleAuthor":"F Dhermain","doi":"10.1093/annonc/mdx408","elsevierAuthor":"Tallet A.V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"32"},{"title":"RET fusions in a small subset of advanced colorectal cancers at risk of being neglected","googleId":"d9nlJM-GtpkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348902","googleCitationCount":40,"googleAuthor":"F Pietrantonio","doi":"10.1093/annonc/mdy090","elsevierAuthor":"Pietrantonio F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"35"},{"title":"Epigenetic modifiers as new immunomodulatory therapies in solid tumours","googleId":"nO4muLjCS34J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454884","googleCitationCount":33,"googleAuthor":"S Aspeslagh","doi":"10.1093/annonc/mdy050","elsevierAuthor":"Aspeslagh S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"27"},{"title":"The evolution of chemotherapy for the treatment of prostate cancer","googleId":"EAjfhsqX_GQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345831","googleCitationCount":40,"googleAuthor":"HM Sandler","doi":"10.1093/annonc/mdx348","elsevierAuthor":"Quinn D.I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"30"},{"title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant …","googleId":"H9PCtq6DUYgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350446","googleCitationCount":44,"googleAuthor":"","doi":"10.1093/annonc/mdx698","elsevierAuthor":"Zhang L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"23"},{"title":"Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study","googleId":"BXaC7ic5pTcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354729","googleCitationCount":42,"googleAuthor":"C Cremolini","doi":"10.1093/annonc/mdx546","elsevierAuthor":"Cremolini C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"33"},{"title":"Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI)–analysis of somatic alterations (SAs)","googleId":"5MkdF4a3rg4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38408-8/abstract","googleCitationCount":46,"googleAuthor":"S Menon"},{"title":"DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update","googleId":"kOVhdOZ_aJgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353773","googleCitationCount":45,"googleAuthor":"LM Henricks","doi":"10.1093/annonc/mdx411","elsevierAuthor":"Henricks L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"28"},{"title":"ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with …","googleId":"NcEKQkK9BeMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354821","googleCitationCount":39,"googleAuthor":"M Hutchings","doi":"10.1093/annonc/mdx413","elsevierAuthor":"Buske C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"29"},{"title":"Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients","googleId":"vi7JoLHDtUMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35399-2/abstract","googleCitationCount":42,"googleAuthor":"TK Eigentler"},{"title":"CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair","googleId":"p71vDR8bcIAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322628","googleCitationCount":54,"googleAuthor":"W Guo","doi":"10.1093/annonc/mdx165","elsevierAuthor":"Shenoy T.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"44"},{"title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","googleId":"je1M02-5dCEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324160","googleCitationCount":45,"googleAuthor":"","doi":"10.1093/annonc/mdx072","elsevierAuthor":"von Tresckow B.","publicationName":"Hematologic Malignancies","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a …","googleId":"g2A1yxVoo3MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341298","googleCitationCount":33,"googleAuthor":"M Ignatiadis","doi":"10.1093/annonc/mdy211","elsevierAuthor":"Ignatiadis M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"28"},{"title":"Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?","googleId":"sSPFbNDwv74J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350689","googleCitationCount":38,"googleAuthor":"PC Chou","doi":"10.1093/annonc/mdx766","elsevierAuthor":"Yang M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"32"},{"title":"A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups","googleId":"km6xLrSaOFgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322562","googleCitationCount":44,"googleAuthor":"S Michiels","doi":"10.1093/annonc/mdx156","elsevierAuthor":"Lindsay C.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"40"},{"title":"A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable …","googleId":"83ZYG67gc8oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50420-3/abstract","googleCitationCount":37,"googleAuthor":""},{"title":"Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma","googleId":"MtliDix5DsMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346149","googleCitationCount":42,"googleAuthor":"M Reni","doi":"10.1093/annonc/mdx495","elsevierAuthor":"Reni M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"34"},{"title":"Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy …","googleId":"yQ1PPO77ELEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345934","googleCitationCount":43,"googleAuthor":"","doi":"10.1093/annonc/mdx414","elsevierAuthor":"McCoach C.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"1"},{"title":"Are liquid biopsies a surrogate for tissue EGFR testing?","googleId":"dZ0zv7H09PoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316722","googleCitationCount":35,"googleAuthor":"J Remon","doi":"10.1093/annonc/mdx706","elsevierAuthor":"Goldman J.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"29"},{"title":"Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification","googleId":"rF_cAGb2yhYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348999","googleCitationCount":36,"googleAuthor":"","doi":"10.1093/annonc/mdy119","elsevierAuthor":"Liu L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"27"},{"title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular …","googleId":"yvbIEGOb5ysJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320575","googleCitationCount":49,"googleAuthor":"TM Kim","doi":"10.1093/annonc/mdw685","elsevierAuthor":"Johnson M.L.","publicationName":"JAMA Oncology","elsevierCoverDate":"2019-07-01","elsevierCoverDisplayDate":"July 2019","elsevierCitationCount":"13"},{"title":"Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study","googleId":"1ssg-TvfRGMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37844-3/abstract","googleCitationCount":39,"googleAuthor":"JM Mehnert"},{"title":"An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell …","googleId":"46IO_PuxTQUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39141-9/abstract","googleCitationCount":38,"googleAuthor":"RL Ferris"},{"title":"Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized …","googleId":"h-KmQLwSnKUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348951","googleCitationCount":37,"googleAuthor":"S Hayoz","doi":"10.1093/annonc/mdy105","elsevierAuthor":"Ruhstaller T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"31"},{"title":"Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of …","googleId":"1idKyaNWjBsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353906","googleCitationCount":40,"googleAuthor":"","doi":"10.1093/annonc/mdx527","elsevierAuthor":"Pu X.","publicationName":"Pathology Research and Practice","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"0"},{"title":"Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience","googleId":"tSZAFQ5nggoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349452","googleCitationCount":40,"googleAuthor":"S Paydaş","doi":"10.1093/annonc/mdx341","elsevierAuthor":"Beköz H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"31"},{"title":"Observation as the initial management strategy in patients with mantle cell lymphoma","googleId":"WFSZjObmnsQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349415","googleCitationCount":40,"googleAuthor":"C Steidl","doi":"10.1093/annonc/mdx333","elsevierAuthor":"Abrisqueta P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"32"},{"title":"Updated results from KEYNOTE-021 cohort G: a randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line …","googleId":"h8zY8M_XCR8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39152-3/abstract","googleCitationCount":40,"googleAuthor":""},{"title":"Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: a systematic review and meta-analyses","googleId":"EO2boc02XogJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454938","googleCitationCount":32,"googleAuthor":"PR Carr","doi":"10.1093/annonc/mdy059","elsevierAuthor":"Carr P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"23"},{"title":"Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review","googleId":"s4cp_xMB0UQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353815","googleCitationCount":37,"googleAuthor":"E Díaz-Rubio","doi":"10.1093/annonc/mdx501","elsevierAuthor":"Garciá-Foncillas J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"30"},{"title":"Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide","googleId":"8JlsI3G0ZmUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352433","googleCitationCount":46,"googleAuthor":"","doi":"10.1093/annonc/mdx283","elsevierAuthor":"Rathkopf D.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"35"},{"title":"Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as …","googleId":"koPW_5KxlBkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931912X","googleCitationCount":49,"googleAuthor":"M Yamasaki","doi":"10.1093/annonc/mdw439","elsevierAuthor":"Yamasaki M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"42"},{"title":"Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and …","googleId":"Aze7hvTc_BQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32760-7/abstract","googleCitationCount":29,"googleAuthor":"RS Herbst"},{"title":"Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases","googleId":"zgADMXTMMgQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355085","googleCitationCount":38,"googleAuthor":"","doi":"10.1093/annonc/mdx797","elsevierAuthor":"Turner N.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"31"},{"title":"Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function","googleId":"ctPU4Fz7_GcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319106","googleCitationCount":49,"googleAuthor":"M Choi","doi":"10.1093/annonc/mdw437","elsevierAuthor":"Choi M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"40"},{"title":"Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in …","googleId":"ZX63eOfznqoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352408","googleCitationCount":39,"googleAuthor":"Q Wei","doi":"10.1093/annonc/mdx278","elsevierAuthor":"Wei Q.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"36"},{"title":"De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and …","googleId":"uwXf1v2qix4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346137","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx494","elsevierAuthor":"Nitz U.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"34"},{"title":"Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO","googleId":"Y28UjvI_tF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454574","googleCitationCount":39,"googleAuthor":"C Cremolini","doi":"10.1093/annonc/mdy004","elsevierAuthor":"Dell'Aquila E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"30"},{"title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","googleId":"oX-EbV8o7XwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350495","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx716","elsevierAuthor":"Ek L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"30"},{"title":"Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study","googleId":"4-jXpDH9DOEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350586","googleCitationCount":38,"googleAuthor":"","doi":"10.1093/annonc/mdx742","elsevierAuthor":"Pettersson A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"30"},{"title":"CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced …","googleId":"LVeXIPO3xTgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)56553-X/abstract","googleCitationCount":39,"googleAuthor":""},{"title":"Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study","googleId":"GkKbfCLYZvkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349567","googleCitationCount":39,"googleAuthor":"E Calvo","doi":"10.1093/annonc/mdx357","elsevierAuthor":"Calvo E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"33"},{"title":"Clinical and molecular characterization of patients with cancer of unknown primary in the modern era","googleId":"eXD5xaipjaAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354717","googleCitationCount":40,"googleAuthor":"A Arora","doi":"10.1093/annonc/mdx545","elsevierAuthor":"Varghese A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"34"},{"title":"Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 …","googleId":"V69ZH4S1hYsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39130-4/abstract","googleCitationCount":41,"googleAuthor":"A Bex"},{"title":"Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury","googleId":"j5-5f6DMHNUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31966-0/abstract","googleCitationCount":46,"googleAuthor":"A D'Errico"},{"title":"Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 …","googleId":"eLDZdL4LwFsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934236X","googleCitationCount":29,"googleAuthor":"L Marandino","doi":"10.1093/annonc/mdy449","elsevierAuthor":"Marandino L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"24"},{"title":"Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)","googleId":"ZtJkQMEl428J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38535-5/abstract","googleCitationCount":39,"googleAuthor":""},{"title":"A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic …","googleId":"0KzyXGxgWQcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934596X","googleCitationCount":36,"googleAuthor":"","doi":"10.1093/annonc/mdx439","elsevierAuthor":"Bossi P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"28"},{"title":"InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly …","googleId":"22-PQuHEO-8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50413-6/abstract","googleCitationCount":30,"googleAuthor":"S Rao"},{"title":"Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the …","googleId":"eZA3ClSM_PYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341997","googleCitationCount":28,"googleAuthor":"","doi":"10.1093/annonc/mdy326","elsevierAuthor":"Thomas M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"21"},{"title":"Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study","googleId":"Sl_YwOfw4wsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934548X","googleCitationCount":34,"googleAuthor":"CKY Ng","doi":"10.1093/annonc/mdy083","elsevierAuthor":"Ng C.K.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"28"},{"title":"The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients","googleId":"Jda9ZZYFvBoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320642","googleCitationCount":46,"googleAuthor":"","doi":"10.1093/annonc/mdw694","elsevierAuthor":"Lian B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"27"},{"title":"Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?","googleId":"PS_v6m2GZ6kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346627","googleCitationCount":35,"googleAuthor":"","doi":"10.1093/annonc/mdx451","elsevierAuthor":"Monk B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"28"},{"title":"Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group …","googleId":"90vZAZD8tU4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321702","googleCitationCount":37,"googleAuthor":"JY Blay","doi":"10.1093/annonc/mdx250","elsevierAuthor":"Salas S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"30"},{"title":"Insulin resistance and body composition in cancer patients","googleId":"NSShSoL3hKMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316801","googleCitationCount":35,"googleAuthor":"","doi":"10.1093/annonc/mdx815","elsevierAuthor":"Dev R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"23"},{"title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted …","googleId":"mioz49VZr5UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349610","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx399","elsevierAuthor":"Ross J.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"32"},{"title":"Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform …","googleId":"f-zpVhV9gsoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35514-0/abstract","googleCitationCount":32,"googleAuthor":"R Herold"},{"title":"Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study","googleId":"-q2ZBmdIUsQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348963","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdy106","elsevierAuthor":"Gramatzki D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"20"},{"title":"Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of …","googleId":"nKloUUhDlH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348975","googleCitationCount":28,"googleAuthor":"","doi":"10.1093/annonc/mdy117","elsevierAuthor":"Rieger C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"20"},{"title":"Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial","googleId":"8P5jNf2i44cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318897","googleCitationCount":34,"googleAuthor":"AD Colevas","doi":"10.1093/annonc/mdy411","elsevierAuthor":"Colevas A.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"30"},{"title":"Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters","googleId":"2vU0-sR64q8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349555","googleCitationCount":38,"googleAuthor":"G Goh","doi":"10.1093/annonc/mdx355","elsevierAuthor":"Linch M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"30"},{"title":"Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast …","googleId":"bjzJO7dvF_sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352457","googleCitationCount":37,"googleAuthor":"MM Regan","doi":"10.1093/annonc/mdx285","elsevierAuthor":"Regan M.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"29"},{"title":"Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer","googleId":"oT5RrFs8UbYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349786","googleCitationCount":37,"googleAuthor":"S Siena","doi":"10.1093/annonc/mdx504","elsevierAuthor":"Siena S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"27"},{"title":"Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine","googleId":"vEDBX5kP0tQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319532","googleCitationCount":44,"googleAuthor":"A Mitra","doi":"10.1093/annonc/mdw619","elsevierAuthor":"Fantappiè G.","publicationName":"Anti-Cancer Drugs","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer","googleId":"Au9RDXHm_cMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341729","googleCitationCount":32,"googleAuthor":"","doi":"10.1093/annonc/mdy251","elsevierAuthor":"Hanna G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"26"},{"title":"Research needs in breast cancer","googleId":"bfGg9tfaLWMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322148","googleCitationCount":44,"googleAuthor":"F Cardoso","doi":"10.1093/annonc/mdw571","elsevierAuthor":"Cardoso F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"35"},{"title":"Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma","googleId":"b10x_crRrCIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320071","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx028","elsevierAuthor":"Sadasivan C.","publicationName":"Clinical Science","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"0"},{"title":"Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients","googleId":"vxP9MCH8BvEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316709","googleCitationCount":37,"googleAuthor":"J Remon","doi":"10.1093/annonc/mdx704","elsevierAuthor":"Remon J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"21"},{"title":"Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro)","googleId":"2loUKQP38moJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50466-5/abstract","googleCitationCount":29,"googleAuthor":"RS Herbst"},{"title":"Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial","googleId":"RtZCCORwjCwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49797-4/abstract","googleCitationCount":30,"googleAuthor":"K Brock"},{"title":"Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer","googleId":"9FTG-ZVFNYEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342450","googleCitationCount":23,"googleAuthor":"Y Wan","doi":"10.1093/annonc/mdy458","elsevierAuthor":"Wan Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"17"},{"title":"Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung …","googleId":"e56AvpARhZYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319234","googleCitationCount":44,"googleAuthor":"","doi":"10.1093/annonc/mdw531","elsevierAuthor":"Iwama E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"40"},{"title":"DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)","googleId":"otBre9AvaqYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349580","googleCitationCount":34,"googleAuthor":"A Martinez-Marti","doi":"10.1093/annonc/mdx396","elsevierAuthor":"Martinez-Marti A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"32"},{"title":"A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma","googleId":"l3k7W4_bGXIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38121-7/abstract","googleCitationCount":37,"googleAuthor":"V Makker"},{"title":"Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of …","googleId":"TfuAuQSE-FUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354961","googleCitationCount":35,"googleAuthor":"","doi":"10.1093/annonc/mdx774","elsevierAuthor":"Schöffski P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"23"},{"title":"Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group","googleId":"_4X3FR_x6HcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320563","googleCitationCount":43,"googleAuthor":"P Coppo","doi":"10.1093/annonc/mdw684","elsevierAuthor":"Tchernonog E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"25"},{"title":"New agents on the horizon in gastric cancer","googleId":"t_Ekt80dJTYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321234","googleCitationCount":39,"googleAuthor":"F Lordick","doi":"10.1093/annonc/mdx051","elsevierAuthor":"Yang Z.","publicationName":"Aging","elsevierCoverDate":"2020-12-31","elsevierCoverDisplayDate":"31 December 2020","elsevierCitationCount":"0"},{"title":"Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification","googleId":"btks4kwFrWQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352263","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx180","elsevierAuthor":"Gilbert J.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"29"},{"title":"Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and …","googleId":"c1H9oTITIU8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355127","googleCitationCount":32,"googleAuthor":"AK Godwin","doi":"10.1093/annonc/mdx821","elsevierAuthor":"Sharma P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"25"},{"title":"Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup …","googleId":"kL0IoWRrwCsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352639","googleCitationCount":37,"googleAuthor":"H van Tinteren","doi":"10.1093/annonc/mdx322","elsevierAuthor":"Goey K.K.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"28"},{"title":"Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review","googleId":"3JFW5E76ihgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454823","googleCitationCount":29,"googleAuthor":"A Quintela","doi":"10.1093/annonc/mdy038","elsevierAuthor":"Arnold D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"24"},{"title":"Front-line therapy of advanced ovarian cancer: new approaches","googleId":"2tVKzhhRo4UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346639","googleCitationCount":31,"googleAuthor":"JA Ledermann","doi":"10.1093/annonc/mdx452","elsevierAuthor":"Ledermann J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"27"},{"title":"Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach","googleId":"Gxcr7M-j_jsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342395","googleCitationCount":26,"googleAuthor":"J Guigay","doi":"10.1093/annonc/mdy452","elsevierAuthor":"Galot R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"22"},{"title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized …","googleId":"59XRyXBbRwcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341249","googleCitationCount":28,"googleAuthor":"MJ Maurer","doi":"10.1093/annonc/mdy203","elsevierAuthor":"Maurer M.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"23"},{"title":"Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III …","googleId":"xFcYQPgPLGMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319507","googleCitationCount":41,"googleAuthor":"S Loibl","doi":"10.1093/annonc/mdw610","elsevierAuthor":"Loibl S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"39"},{"title":"A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with …","googleId":"U-CCvi3pCCsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350380","googleCitationCount":34,"googleAuthor":"L Wang","doi":"10.1093/annonc/mdx689","elsevierAuthor":"Wang L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"31"},{"title":"The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical …","googleId":"uIgZ33ZMljQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321519","googleCitationCount":36,"googleAuthor":"","doi":"10.1093/annonc/mdx210","elsevierAuthor":"Lenouvel D.","publicationName":"Oral Diseases","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"1"},{"title":"From hepatitis C virus infection to B-cell lymphoma","googleId":"Rlx4XBGYNr0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349907","googleCitationCount":32,"googleAuthor":"E Bachy","doi":"10.1093/annonc/mdx635","elsevierAuthor":"Couronné L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"24"},{"title":"Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma","googleId":"S2k0Z1pUAEAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320976","googleCitationCount":28,"googleAuthor":"J Lewin","doi":"10.1093/annonc/mdy124","elsevierAuthor":"Lewin J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"19"},{"title":"Epstein–Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations","googleId":"5MAT3tTumroJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320204","googleCitationCount":34,"googleAuthor":"","doi":"10.1093/annonc/mdx047","elsevierAuthor":"Schoop I.","publicationName":"Human Pathology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0"},{"title":"Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study","googleId":"ddH5awlIvk8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319489","googleCitationCount":40,"googleAuthor":"SR Markar","doi":"10.1093/annonc/mdw560","elsevierAuthor":"Markar S.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"27"},{"title":"Early evolutionary divergence between papillary and anaplastic thyroid cancers","googleId":"bZoPXsZwPtMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349026","googleCitationCount":26,"googleAuthor":"FM Mancuso","doi":"10.1093/annonc/mdy123","elsevierAuthor":"Capdevila J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"0"},{"title":"Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma","googleId":"75IlyciclcEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32271-9/abstract","googleCitationCount":37,"googleAuthor":"J Larkin"},{"title":"An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients","googleId":"GVf8_uJnZRoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345971","googleCitationCount":33,"googleAuthor":"KA Tomaszewski","doi":"10.1093/annonc/mdx453","elsevierAuthor":"Koller M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"21"},{"title":"Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer","googleId":"nHN3cfhjJGYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50424-0/abstract","googleCitationCount":28,"googleAuthor":"ND James"},{"title":"Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell …","googleId":"l182jcdz9uMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349440","googleCitationCount":33,"googleAuthor":"M Moorhead","doi":"10.1093/annonc/mdx340","elsevierAuthor":"Takamatsu H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"22"},{"title":"Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection","googleId":"B_BuGIWqMwkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34190-0/abstract","googleCitationCount":27,"googleAuthor":"EP Scully"},{"title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor …","googleId":"G97EY5ClyK8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345508","googleCitationCount":32,"googleAuthor":"F Lunardi","doi":"10.1093/annonc/mdy086","elsevierAuthor":"Pasello G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"24"},{"title":"Bevacizumab+ chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial …","googleId":"r8X0HbEgJzEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419351312","googleCitationCount":31,"googleAuthor":"J Taieb","doi":"10.1093/annonc/mdx529","elsevierAuthor":"Gilabert M.","publicationName":"Journal of Geriatric Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0"},{"title":"Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial","googleId":"cJUUvTTpos0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341432","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdy229","elsevierAuthor":"Corrie P.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"0"},{"title":"Progestin-associated shift of meningioma mutational landscape","googleId":"V90YADzxXlkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354882","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdx763","elsevierAuthor":"Peyre M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"20"},{"title":"Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial","googleId":"toe2baYlDKkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419343042","googleCitationCount":39,"googleAuthor":"T Jiang","doi":"10.1093/annonc/mdw434","elsevierAuthor":"Oshi M.","publicationName":"Cancers","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"0"},{"title":"Artificial intelligence for melanoma diagnosis: how can we deliver on the promise?","googleId":"e8u8DQgTCh0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34114-6/abstract","googleCitationCount":29,"googleAuthor":"VJ Mar"},{"title":"Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma","googleId":"8LRIf0ULqEYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324275","googleCitationCount":31,"googleAuthor":"HR Kim","doi":"10.1093/annonc/mdx098","elsevierAuthor":"Kim H.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"26"},{"title":"Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies","googleId":"g106dAwUM6gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320551","googleCitationCount":36,"googleAuthor":"H Tang","doi":"10.1093/annonc/mdw683","elsevierAuthor":"Richard M.","publicationName":"PLoS Computational Biology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"1 May 2020","elsevierCitationCount":"0"},{"title":"Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer","googleId":"GXc84oeMHbEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321441","googleCitationCount":31,"googleAuthor":"H Mamiya","doi":"10.1093/annonc/mdx201","elsevierAuthor":"Cersosimo R.J.","publicationName":"American Journal of Health-System Pharmacy","elsevierCoverDate":"2019-08-15","elsevierCoverDisplayDate":"15 August 2019","elsevierCitationCount":"2"},{"title":"Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma","googleId":"M50iwsWEVSoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352469","googleCitationCount":32,"googleAuthor":"BS Hoppe","doi":"10.1093/annonc/mdx287","elsevierAuthor":"Hoppe B.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"24"},{"title":"Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the …","googleId":"rDvJA9goAgYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350513","googleCitationCount":30,"googleAuthor":"MGE Verdam","doi":"10.1093/annonc/mdx726","elsevierAuthor":"Noordman B.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"18"},{"title":"IMpower131: progression-free survival (PFS) and overall survival (OS) analysis of a randomised Phase III study of atezolizumab+ carboplatin+ paclitaxel or nab …","googleId":"qtda6Fnh9u8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50468-9/abstract","googleCitationCount":25,"googleAuthor":""},{"title":"Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for …","googleId":"yHTKOTGcRe4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349518","googleCitationCount":31,"googleAuthor":"J Doyen","doi":"10.1093/annonc/mdx351","elsevierAuthor":"Azria D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"26"},{"title":"Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials","googleId":"IOb38PUvRtMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34240-1/abstract","googleCitationCount":25,"googleAuthor":"K Hess"},{"title":"Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 …","googleId":"GVLn-T6xUn4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38315-0/abstract","googleCitationCount":34,"googleAuthor":""},{"title":"Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium","googleId":"MWkCKOn1BfYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341547","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdy210","elsevierAuthor":"Kenis C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"21"},{"title":"Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes","googleId":"uPUgWMKvfD8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319696","googleCitationCount":38,"googleAuthor":"M Parasramka","doi":"10.1093/annonc/mdw652","elsevierAuthor":"Ho T.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"32"},{"title":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","googleId":"6Z2UXopOlXYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349981","googleCitationCount":31,"googleAuthor":"M Riester","doi":"10.1093/annonc/mdx645","elsevierAuthor":"Riester M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"19"},{"title":"Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer …","googleId":"IMjY1NOb16MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324421","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdx122","elsevierAuthor":"Aparicio T.","publicationName":"Digestive and Liver Disease","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"2"},{"title":"Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism","googleId":"SdRMXIw4JvUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322008","googleCitationCount":39,"googleAuthor":"JC Soria","doi":"10.1093/annonc/mdw552","elsevierAuthor":"Morel D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"29"},{"title":"CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification","googleId":"jW8SE8n0BekJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320277","googleCitationCount":33,"googleAuthor":"C Pilati","doi":"10.1093/annonc/mdx066","elsevierAuthor":"Hirano D.","publicationName":"PLoS ONE","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"February 2019","elsevierCitationCount":"2"},{"title":"MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial","googleId":"MgUtRlll7l4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322252","googleCitationCount":34,"googleAuthor":"G Brown","doi":"10.1093/annonc/mdw616","elsevierAuthor":"Patel U.B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"24"},{"title":"Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force","googleId":"d4OQfN9_EnQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321969","googleCitationCount":38,"googleAuthor":"","doi":"10.1093/annonc/mdw547","elsevierAuthor":"Stauder R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"27"},{"title":"Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 …","googleId":"1ZYJ4cMtTF0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320216","googleCitationCount":33,"googleAuthor":"R Lesurf","doi":"10.1093/annonc/mdx048","elsevierAuthor":"Buzdar A.","publicationName":"JAMA Oncology","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"January 2019","elsevierCitationCount":"6"},{"title":"Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant …","googleId":"3r3mww53iX8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454690","googleCitationCount":26,"googleAuthor":"MJ Birrer","doi":"10.1093/annonc/mdy023","elsevierAuthor":"Banerjee S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"20"},{"title":"Muscle protein anabolism in advanced cancer patients: response to protein and amino acids support, and to physical activity","googleId":"CGr03QMpcLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316783","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdx809","elsevierAuthor":"Antoun S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"16"},{"title":"mFOLFOXIRI+ panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m (CRC): a randomized phase II …","googleId":"qBi0mbbSJAwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38962-6/abstract","googleCitationCount":31,"googleAuthor":""},{"title":"Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel …","googleId":"8Qn_gJzMCMsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321672","googleCitationCount":30,"googleAuthor":"K Nishikawa","doi":"10.1093/annonc/mdx236","elsevierAuthor":"Ke J.","publicationName":"Gastroenterology Report","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"1 June 2020","elsevierCitationCount":"2"},{"title":"First-onset mental disorders after cancer diagnosis and cancer-specific mortality: a nationwide cohort study","googleId":"Mn7OnArOv-sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321738","googleCitationCount":31,"googleAuthor":"F Fang","doi":"10.1093/annonc/mdx265","elsevierAuthor":"Binnal A.","publicationName":"Oral Diseases","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0"},{"title":"Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory …","googleId":"irZnmOPv8HgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319787","googleCitationCount":39,"googleAuthor":"","doi":"10.1093/annonc/mdw666","elsevierAuthor":"Belin L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"30"},{"title":"Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma","googleId":"9CuomzqcLNAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320046","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdx025","elsevierAuthor":"Teckie S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"May 2017","elsevierCitationCount":"19"},{"title":"Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial","googleId":"pvXM_NAmOz8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321040","googleCitationCount":28,"googleAuthor":"E Fokas","doi":"10.1093/annonc/mdy143","elsevierAuthor":"Fokas E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"20"},{"title":"Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC …","googleId":"E4XkErDxfX8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49289-2/abstract","googleCitationCount":24,"googleAuthor":""},{"title":"The antibody–drug conjugate target landscape across a broad range of tumour types","googleId":"hnt3cInNXa0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354705","googleCitationCount":30,"googleAuthor":"DJA de Groot","doi":"10.1093/annonc/mdx541","elsevierAuthor":"Moek K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"23"},{"title":"The use of antidepressants in oncology: a review and practical tips for oncologists","googleId":"qU1Vmn_j-c4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349804","googleCitationCount":29,"googleAuthor":"L Grassi","doi":"10.1093/annonc/mdx526","elsevierAuthor":"Grassi L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"15"},{"title":"Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types","googleId":"crLgaWCIdLwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342085","googleCitationCount":23,"googleAuthor":"T Pascual","doi":"10.1093/annonc/mdy335","elsevierAuthor":"Paré L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"19"},{"title":"Cancer mortality predictions for 2017 in Latin America","googleId":"0YBUv7yyAwkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352536","googleCitationCount":31,"googleAuthor":"C La Vecchia","doi":"10.1093/annonc/mdx301","elsevierAuthor":"Carioli G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"25"},{"title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","googleId":"GMpLz0ZU4yQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349270","googleCitationCount":31,"googleAuthor":"K Hartmann","doi":"10.1093/annonc/mdx290","elsevierAuthor":"Valent P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"27"},{"title":"Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated …","googleId":"IuOrI65imtcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319799","googleCitationCount":36,"googleAuthor":"SJ Klempner","doi":"10.1093/annonc/mdw669","elsevierAuthor":"Kim S.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"26"},{"title":"Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers","googleId":"_dRf8jrRj6UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322045","googleCitationCount":36,"googleAuthor":"HA Yu","doi":"10.1093/annonc/mdw556","elsevierAuthor":"Yu H.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"27"},{"title":"Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer","googleId":"_VYZDZroF5kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354973","googleCitationCount":29,"googleAuthor":"BS Sørensen","doi":"10.1093/annonc/mdx778","elsevierAuthor":"Schou J.V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"24"},{"title":"A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with …","googleId":"eXb0Pb9DxDEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350008","googleCitationCount":33,"googleAuthor":"P Nuciforo","doi":"10.1093/annonc/mdx647","elsevierAuthor":"Nuciforo P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"22"},{"title":"A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma","googleId":"b-Q4gNG1tvAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346125","googleCitationCount":28,"googleAuthor":"B Keam","doi":"10.1093/annonc/mdx493","elsevierAuthor":"Voss M.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"24"},{"title":"The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study","googleId":"NYZW8hEGzo8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322100","googleCitationCount":37,"googleAuthor":"","doi":"10.1093/annonc/mdw563","elsevierAuthor":"Mangili G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"23"},{"title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","googleId":"JoRsCB8XTA8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932109X","googleCitationCount":25,"googleAuthor":"","doi":"10.1093/annonc/mdy171","elsevierAuthor":"Ferrarotto R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"21"},{"title":"Body mass index and 20 specific cancers: re-analyses of dose–response meta-analyses of observational studies","googleId":"fJG7prhy-BoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355103","googleCitationCount":29,"googleAuthor":"EK Choi","doi":"10.1093/annonc/mdx819","elsevierAuthor":"Choi E.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"19"},{"title":"Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies","googleId":"9TpQ6Fb66VsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931926X","googleCitationCount":37,"googleAuthor":"SJ Moschos","doi":"10.1093/annonc/mdw534","elsevierAuthor":"Salama A.K.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"31"},{"title":"Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial","googleId":"Tdh15v7VFQcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321751","googleCitationCount":30,"googleAuthor":"","doi":"10.1093/annonc/mdx268","elsevierAuthor":"Dong S.","publicationName":"Molecular Genetics and Genomic Medicine","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"1 March 2020","elsevierCitationCount":"1"},{"title":"Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non …","googleId":"doO7r7oysoQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50481-1/abstract","googleCitationCount":23,"googleAuthor":"N Reguart"},{"title":"Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support","googleId":"TxgNThEKQucJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934181X","googleCitationCount":24,"googleAuthor":"GH Lyman","doi":"10.1093/annonc/mdy311","elsevierAuthor":"Lyman G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"14"},{"title":"Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial","googleId":"4NQc1m_sS90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354894","googleCitationCount":26,"googleAuthor":"TE Witzig","doi":"10.1093/annonc/mdx764","elsevierAuthor":"Witzig T.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"19"},{"title":"Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint …","googleId":"mkCY1Q_9AlUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34579-X/abstract","googleCitationCount":30,"googleAuthor":"D Sueta"},{"title":"Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States","googleId":"3XHxrVI-rawJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320174","googleCitationCount":31,"googleAuthor":"BA Mahal","doi":"10.1093/annonc/mdx041","elsevierAuthor":"Mahal B.A.","publicationName":"Annals of oncology : official journal of the European Society for Medical Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"1 May 2017","elsevierCitationCount":"18"},{"title":"Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma","googleId":"rbSkmHINoksJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350045","googleCitationCount":31,"googleAuthor":"SJ Kim","doi":"10.1093/annonc/mdx684","elsevierAuthor":"Kwong Y.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"22"},{"title":"Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A …","googleId":"G_kf_BTjScMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49394-0/abstract","googleCitationCount":26,"googleAuthor":""},{"title":"Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study","googleId":"EJZsifuAIV4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38314-9/abstract","googleCitationCount":32,"googleAuthor":"A Algazi"},{"title":"Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid …","googleId":"okyGDd6cp2EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322549","googleCitationCount":32,"googleAuthor":"G Leone","doi":"10.1093/annonc/mdx154","elsevierAuthor":"Leone G.","publicationName":"Mediterranean Journal of Hematology and Infectious Diseases","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"2018","elsevierCitationCount":"1"},{"title":"Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma …","googleId":"-gH0bvWgbwEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50421-5/abstract","googleCitationCount":23,"googleAuthor":"S Roychowdhury"},{"title":"T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression","googleId":"Sep5QdX7cBoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321003","googleCitationCount":27,"googleAuthor":"A Draghi","doi":"10.1093/annonc/mdy139","elsevierAuthor":"Andersen R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"19"},{"title":"Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically …","googleId":"B4fBIsU9Q1oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49217-X/abstract","googleCitationCount":22,"googleAuthor":"A Hollebecque"},{"title":"A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma","googleId":"pTJeizM-EmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454616","googleCitationCount":24,"googleAuthor":"MY Wang","doi":"10.1093/annonc/mdy011","elsevierAuthor":"Li X.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"22"},{"title":"A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)","googleId":"Sg0McIKl18MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49397-6/abstract","googleCitationCount":24,"googleAuthor":"CM Annunziata"},{"title":"PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?","googleId":"jQUHhjHLuOEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45455-0/abstract","googleCitationCount":27,"googleAuthor":"O Lambotte"},{"title":"S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer …","googleId":"t7rM46hJoHcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355097","googleCitationCount":28,"googleAuthor":"","doi":"10.1093/annonc/mdx816","elsevierAuthor":"Yamada Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"21"},{"title":"Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of …","googleId":"0NM7X_V7ugsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353980","googleCitationCount":29,"googleAuthor":"J Martin-Broto","doi":"10.1093/annonc/mdx536","elsevierAuthor":"Martin-Broto J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"22"},{"title":"Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only …","googleId":"PSMJHz_g9HYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934205X","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdy332","elsevierAuthor":"Yang B.","publicationName":"Acta Biochimica Polonica","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0"},{"title":"Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions","googleId":"gyxyVqAau4YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342097","googleCitationCount":24,"googleAuthor":"DB Costa","doi":"10.1093/annonc/mdy336","elsevierAuthor":"Piotrowska Z.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"20"},{"title":"A phase 2, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin …","googleId":"_al17P_WNw4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320228","googleCitationCount":32,"googleAuthor":"C Aghajanian","doi":"10.1093/annonc/mdx049","elsevierAuthor":"Monk B.J.","publicationName":"Annals of oncology : official journal of the European Society for Medical Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"1 May 2017","elsevierCitationCount":"26"},{"title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International …","googleId":"xQbj7CEj29kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350392","googleCitationCount":26,"googleAuthor":"A Bamias","doi":"10.1093/annonc/mdx692","elsevierAuthor":"Bamias A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"0"},{"title":"A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting …","googleId":"SKOljdoOUJkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349348","googleCitationCount":29,"googleAuthor":"","doi":"10.1093/annonc/mdx315","elsevierAuthor":"Bossi P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"12"},{"title":"Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two …","googleId":"a6fkvMnSQ3wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319271","googleCitationCount":33,"googleAuthor":"FC Bidard","doi":"10.1093/annonc/mdw535","elsevierAuthor":"Pierga J.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"26"},{"title":"Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours","googleId":"otCL_yHIrecJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322173","googleCitationCount":33,"googleAuthor":"","doi":"10.1093/annonc/mdw605","elsevierAuthor":"Heidenreich A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"26"},{"title":"Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead","googleId":"1ClRTULh6LIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353785","googleCitationCount":24,"googleAuthor":"C Faivre-Finn","doi":"10.1093/annonc/mdx481","elsevierAuthor":"Ulahannan D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"18"},{"title":"Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial","googleId":"XkJC-HzspRsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342024","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdy329","elsevierAuthor":"Staehler M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"16"},{"title":"A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer","googleId":"xFuVGlEqvyYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350100","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdx691","elsevierAuthor":"Criscitiello C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"19"},{"title":"Advances in the systemic treatment of melanoma brain metastases","googleId":"8Eis8SZnbawJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321143","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy185","elsevierAuthor":"Glitza Oliva I.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"16"},{"title":"Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative …","googleId":"Xs-QNUTCpUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345880","googleCitationCount":29,"googleAuthor":"JP Merlio","doi":"10.1093/annonc/mdx404","elsevierAuthor":"Leduc C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"28"},{"title":"KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma","googleId":"77JmKaZARXEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38479-9/abstract","googleCitationCount":29,"googleAuthor":"A Ribas"},{"title":"Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)","googleId":"fHDXumLgQIMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39158-4/abstract","googleCitationCount":28,"googleAuthor":"J Mazieres"},{"title":"HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer?","googleId":"AYg7pe0SmcUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34119-5/abstract","googleCitationCount":26,"googleAuthor":"S Mahner"},{"title":"Results of COLUMBUS part 2: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma","googleId":"sRRZKnmxh-MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38478-7/abstract","googleCitationCount":27,"googleAuthor":"PA Ascierto"},{"title":"Clinical and genetic predictors of paclitaxel neurotoxicity based on patient-versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial","googleId":"Xrj_W2ZIPnEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346101","googleCitationCount":28,"googleAuthor":"SB Park","doi":"10.1093/annonc/mdx491","elsevierAuthor":"Park S.B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"21"},{"title":"Impact of prediagnostic smoking and smoking cessation on colorectal cancer prognosis: a meta-analysis of individual patient data from cohorts within the …","googleId":"hohreMbynu8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350665","googleCitationCount":26,"googleAuthor":"JM Ordóñez-Mena","doi":"10.1093/annonc/mdx761","elsevierAuthor":"Ordóñez-Mena J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"19"},{"title":"Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)","googleId":"UzMapHEWsLUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38553-7/abstract","googleCitationCount":28,"googleAuthor":"R Ferrara"},{"title":"Adjuvant FOLFOX+/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients","googleId":"D7yq5-gMH7MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320599","googleCitationCount":37,"googleAuthor":"J Taieb","doi":"10.1093/annonc/mdw687","elsevierAuthor":"Taieb J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"20"},{"title":"A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)","googleId":"7opP6sVHBi8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50430-6/abstract","googleCitationCount":22,"googleAuthor":"C Albany"},{"title":"Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools","googleId":"XT4SqkBsB4gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346162","googleCitationCount":27,"googleAuthor":"E Giovannetti","doi":"10.1093/annonc/mdx499","elsevierAuthor":"Giovannetti E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"21"},{"title":"Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer","googleId":"hB-3gVRFOsgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322197","googleCitationCount":33,"googleAuthor":"TRJ Evans","doi":"10.1093/annonc/mdw607","elsevierAuthor":"Evans J.T.R.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"29"},{"title":"What treatment in 2017 for inoperable pancreatic cancers?","googleId":"P8FHuyPv_9MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322690","googleCitationCount":27,"googleAuthor":"J Taieb","doi":"10.1093/annonc/mdx174","elsevierAuthor":"Taieb J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"18"},{"title":"Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer","googleId":"BbjhiPIAHV0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931885X","googleCitationCount":22,"googleAuthor":"AJ Armstrong","doi":"10.1093/annonc/mdy406","elsevierAuthor":"Armstrong A.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"12"},{"title":"Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a …","googleId":"NlNpiQoGMuUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349403","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdx332","elsevierAuthor":"Churilla T.","publicationName":"Current Oncology Reports","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"6"},{"title":"Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysis","googleId":"jIjfB10CDSEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345429","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy073","elsevierAuthor":"Benke I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"14"},{"title":"Novel tools to assist neoepitope targeting in personalized cancer immunotherapy","googleId":"PAN7PWIsxDcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541485","googleCitationCount":24,"googleAuthor":"SK Saini","doi":"10.1093/annonc/mdx544","elsevierAuthor":"Saini S.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"21"},{"title":"PD-1 blockade with nivolumab in endemic Kaposi sarcoma","googleId":"reD3H_rI-_sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45459-8/abstract","googleCitationCount":25,"googleAuthor":""},{"title":"Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 …","googleId":"p08HsWEwvcEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321726","googleCitationCount":27,"googleAuthor":"JRB Dyck","doi":"10.1093/annonc/mdx264","elsevierAuthor":"Li C.","publicationName":"Bioscience Reports","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"0"},{"title":"Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results …","googleId":"YaFal-HnnPYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935389X","googleCitationCount":24,"googleAuthor":"A Oseledchyk","doi":"10.1093/annonc/mdx525","elsevierAuthor":"Oseledchyk A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"23"},{"title":"JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma","googleId":"IFHXCUTanNEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37893-5/abstract","googleCitationCount":26,"googleAuthor":""},{"title":"Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial","googleId":"bKa4yZJDllgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349531","googleCitationCount":28,"googleAuthor":"D Cunningham","doi":"10.1093/annonc/mdx353","elsevierAuthor":"Gleeson M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"20"},{"title":"Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer","googleId":"2-7H6KWmKREJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345442","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy075","elsevierAuthor":"Liang F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"16"},{"title":"Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors","googleId":"0iSGPa6fywQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320757","googleCitationCount":29,"googleAuthor":"I McNeish","doi":"10.1093/annonc/mdx010","elsevierAuthor":"Tran K.B.","publicationName":"Current Pharmaceutical Design","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"3"},{"title":"The 'critical mass' survey of palliative care programme at ESMO designated centres of integrated oncology and palliative care","googleId":"gwFICm3vJvsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352421","googleCitationCount":25,"googleAuthor":"D Hui","doi":"10.1093/annonc/mdx280","elsevierAuthor":"Hui D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"14"},{"title":"Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: updated results from multicenter, randomized Phase 3 FLOT4-AIO …","googleId":"6eZXkXQ5s9oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39119-5/abstract","googleCitationCount":26,"googleAuthor":"SE Al-Batran"},{"title":"Stevens–Johnson syndrome during nivolumab treatment of NSCLC","googleId":"uAc3wAiT0LgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34995-6/abstract","googleCitationCount":26,"googleAuthor":"F Bertolini"},{"title":"MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer","googleId":"0UmrZUDGfqIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39108-0/abstract","googleCitationCount":28,"googleAuthor":"A Di Leo"},{"title":"Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations","googleId":"vlUUT8WS6uYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49503-3/abstract","googleCitationCount":22,"googleAuthor":"AL Ho"},{"title":"Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line …","googleId":"ez8qmwSqUAkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341286","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdy209","elsevierAuthor":"Zhang J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"16"},{"title":"A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma","googleId":"oKawZ9q_OwUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32642-0/abstract","googleCitationCount":25,"googleAuthor":"J Abramson"},{"title":"An unknown reaction to pembrolizumab: giant cell arteritis","googleId":"k7FA-cv9YocJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34931-2/abstract","googleCitationCount":28,"googleAuthor":""},{"title":"Pembrolizumab for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial","googleId":"7VrYy7MOOYEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49253-3/abstract","googleCitationCount":20,"googleAuthor":""},{"title":"A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer","googleId":"YjsZe06k-poJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49398-8/abstract","googleCitationCount":21,"googleAuthor":""},{"title":"Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled …","googleId":"5MK2c0hYhzkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341626","googleCitationCount":19,"googleAuthor":"HJ Lenz","doi":"10.1093/annonc/mdy241","elsevierAuthor":"Van Cutsem E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"12"},{"title":"Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study","googleId":"6-m33z3H0nkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50050-3/abstract","googleCitationCount":18,"googleAuthor":"I Bondarenko"},{"title":"Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial","googleId":"EhDdfqjpsBcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320307","googleCitationCount":27,"googleAuthor":"W Eberhardt","doi":"10.1093/annonc/mdx069","elsevierAuthor":"Atkins K.M.","publicationName":"JAMA Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"1"},{"title":"Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final …","googleId":"3pBPcxo6FFwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350094","googleCitationCount":25,"googleAuthor":"A du Bois","doi":"10.1093/annonc/mdx690","elsevierAuthor":"Möbus V.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"16"},{"title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for …","googleId":"MkjwHflhoEEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352585","googleCitationCount":25,"googleAuthor":"JY Hong","doi":"10.1093/annonc/mdx316","elsevierAuthor":"Lim S.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"16"},{"title":"Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer","googleId":"RusJqw5o9F4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419348987","googleCitationCount":19,"googleAuthor":"T Murata","doi":"10.1093/annonc/mdy118","elsevierAuthor":"Katakami N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"9"},{"title":"A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the …","googleId":"nI_nTyI351kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342309","googleCitationCount":17,"googleAuthor":"EC Smyth","doi":"10.1093/annonc/mdy407","elsevierAuthor":"Smyth E.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"15"},{"title":"Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their …","googleId":"6EwgpzkqDNsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341559","googleCitationCount":23,"googleAuthor":"Z Sztupinszki","doi":"10.1093/annonc/mdy216","elsevierAuthor":"Diossy M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"0"},{"title":"Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial","googleId":"R7Zbo3ROuJwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341237","googleCitationCount":20,"googleAuthor":"V Scott","doi":"10.1093/annonc/mdy202","elsevierAuthor":"Arnedos M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"16"},{"title":"Oncologist use and perception of large panel next-generation tumor sequencing","googleId":"sZQggFA455MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352500","googleCitationCount":25,"googleAuthor":"","doi":"10.1093/annonc/mdx294","elsevierAuthor":"Schram A.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"20"},{"title":"Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)","googleId":"hIOAYowlqdcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322604","googleCitationCount":28,"googleAuthor":"P Jain","doi":"10.1093/annonc/mdx163","elsevierAuthor":"Jain P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"15"},{"title":"Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers","googleId":"3CGS3IsilM4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318836","googleCitationCount":17,"googleAuthor":"D Głodzik","doi":"10.1093/annonc/mdy404","elsevierAuthor":"Głodzik D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"10"},{"title":"Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequentBAP1, PIK3CA, and other actionable genomic alterations","googleId":"BR0zAAUdFA8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320617","googleCitationCount":27,"googleAuthor":"AB Schrock","doi":"10.1093/annonc/mdw689","elsevierAuthor":"Wang K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"16"},{"title":"Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC","googleId":"dnFv8ZEF0TcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32757-7/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"ARCTIC: Durvalumab+ tremelimumab and durvalumab monotherapy vs SoC in≥ 3L advanced NSCLC treatment","googleId":"kdfctA5xk9MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49791-3/abstract","googleCitationCount":18,"googleAuthor":"SV Orlov"},{"title":"Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation","googleId":"k7UyrTgk3mUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341183","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdy197","elsevierAuthor":"Morano F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"16"},{"title":"Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab","googleId":"NJdRB17ZVmwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320654","googleCitationCount":28,"googleAuthor":"SM Swain","doi":"10.1093/annonc/mdw695","elsevierAuthor":"Swain S.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"0"},{"title":"Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer","googleId":"2vLiOdJhwxUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320502","googleCitationCount":26,"googleAuthor":"","doi":"10.1093/annonc/mdw678","elsevierAuthor":"M-Rabet M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"21"},{"title":"Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer","googleId":"QRoFFWkU-ZMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932112X","googleCitationCount":17,"googleAuthor":"L Horn","doi":"10.1093/annonc/mdy177","elsevierAuthor":"Gerber D.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"13"},{"title":"MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase …","googleId":"uCKj8i0ndMwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319805","googleCitationCount":26,"googleAuthor":"HJ Huang","doi":"10.1093/annonc/mdw670","elsevierAuthor":"Janku F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"23"},{"title":"Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7","googleId":"b7HRtUOqqZ8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38595-1/abstract","googleCitationCount":22,"googleAuthor":"T Kato"},{"title":"HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma","googleId":"z4JXtcybchQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35382-7/abstract","googleCitationCount":24,"googleAuthor":"B Toka"},{"title":"The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?","googleId":"g8tUvyl-4UYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345375","googleCitationCount":22,"googleAuthor":"A Grothey","doi":"10.1093/annonc/mdy064","elsevierAuthor":"Sobrero A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"18"},{"title":"Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the …","googleId":"lRNtKpufmv0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349889","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdx630","elsevierAuthor":"Nabieva N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"18"},{"title":"Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone …","googleId":"n1U8-4NkyvEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349397","googleCitationCount":25,"googleAuthor":"O Sartor","doi":"10.1093/annonc/mdx331","elsevierAuthor":"Sartor O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"18"},{"title":"High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy","googleId":"rmoEHL7KA_UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31964-7/abstract","googleCitationCount":28,"googleAuthor":""},{"title":"Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer","googleId":"71ltQAxZVHgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935063X","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdx753","elsevierAuthor":"de Boer S.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"18"},{"title":"Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy","googleId":"aQLpEN6nrDgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32267-7/abstract","googleCitationCount":24,"googleAuthor":""},{"title":"Translational insights into gastrointestinal stromal tumor and current clinical advances","googleId":"zuZ7BhGK_6oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341961","googleCitationCount":14,"googleAuthor":"MC Heinrich","doi":"10.1093/annonc/mdy309","elsevierAuthor":"Hemming M.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"9"},{"title":"New treatments in ovarian cancer","googleId":"e8IkU5VoO7cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346536","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdx442","elsevierAuthor":"Pujade-Lauraine E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"18"},{"title":"Unmet needs in the first-line treatment of follicular lymphoma","googleId":"8ufkvoo-DhsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352275","googleCitationCount":22,"googleAuthor":"","doi":"10.1093/annonc/mdx189","elsevierAuthor":"Casulo C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"16"},{"title":"Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients","googleId":"2ZkMv8lgAx8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934164X","googleCitationCount":17,"googleAuthor":"J Fredsøe","doi":"10.1093/annonc/mdy243","elsevierAuthor":"Schmidt L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"13"},{"title":"A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study","googleId":"wXszS5LgJm4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346034","googleCitationCount":20,"googleAuthor":"P Ferrari","doi":"10.1093/annonc/mdx482","elsevierAuthor":"Chajès V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"16"},{"title":"KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric …","googleId":"ViMW45bBJhQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66220-4/abstract","googleCitationCount":23,"googleAuthor":"VC Daniel"},{"title":"Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and …","googleId":"0B_6P--tdXkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341717","googleCitationCount":16,"googleAuthor":"CA Voltin","doi":"10.1093/annonc/mdy250","elsevierAuthor":"Voltin C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"12"},{"title":"Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of …","googleId":"ytP6KFeYlawJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66219-8/abstract","googleCitationCount":23,"googleAuthor":"SE Al-Batran"},{"title":"Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain …","googleId":"Ew02-3G-JAQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350562","googleCitationCount":19,"googleAuthor":"","doi":"10.1093/annonc/mdx740","elsevierAuthor":"McTyre E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"11"},{"title":"Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative …","googleId":"ZvUL6KRwalYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319635","googleCitationCount":24,"googleAuthor":"M Shiota","doi":"10.1093/annonc/mdw646","elsevierAuthor":"Shiota M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"19"},{"title":"Human endogenous retroviruses and their implication for immunotherapeutics of cancer","googleId":"ReeXC9-NowMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318915","googleCitationCount":21,"googleAuthor":"AM Bjerregaard","doi":"10.1093/annonc/mdy413","elsevierAuthor":"Attermann A.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"15"},{"title":"Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance)","googleId":"54KbiUmb4h8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324329","googleCitationCount":23,"googleAuthor":"","doi":"10.1093/annonc/mdx109","elsevierAuthor":"Fuchs M.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"19"},{"title":"Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for …","googleId":"c0k2nZ9PlW0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321349","googleCitationCount":24,"googleAuthor":"JA Dunn","doi":"10.1093/annonc/mdx173","elsevierAuthor":"Earl H.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"15"},{"title":"A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal …","googleId":"t-dRoNljyh0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931974X","googleCitationCount":38,"googleAuthor":"H Gelderblom","doi":"10.1093/annonc/mdw659","elsevierAuthor":"Wagner A.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"28"},{"title":"Can we trust burnout research?","googleId":"r-Ets0GsUJQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35235-4/abstract","googleCitationCount":23,"googleAuthor":"R Bianchi"},{"title":"Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas","googleId":"sPCILO20Tw8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341158","googleCitationCount":17,"googleAuthor":"T Lesluyes","doi":"10.1093/annonc/mdy194","elsevierAuthor":"Le Guellec S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"12"},{"title":"Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or …","googleId":"6y7OCylAkyQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341742","googleCitationCount":16,"googleAuthor":"RL Jones","doi":"10.1093/annonc/mdy253","elsevierAuthor":"Jones R.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"14"},{"title":"KEYNOTE-427 cohort A: pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)","googleId":"6w9xRMIoNboJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49260-0/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Acute liver graft rejection after ipilimumab therapy","googleId":"1TchYA_Nsk0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34924-5/abstract","googleCitationCount":20,"googleAuthor":""},{"title":"Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial","googleId":"Eaow9uIViF8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321593","googleCitationCount":19,"googleAuthor":"A Bamias","doi":"10.1093/annonc/mdx228","elsevierAuthor":"Bamias A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"11"},{"title":"A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma","googleId":"Hx9MNzhjukEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320496","googleCitationCount":24,"googleAuthor":"E Jonasch","doi":"10.1093/annonc/mdw676","elsevierAuthor":"Vlachostergios P.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"May 2017","elsevierCitationCount":"3"},{"title":"Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?","googleId":"HSL2uEL21x4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350598","googleCitationCount":18,"googleAuthor":"GD Stewart","doi":"10.1093/annonc/mdx743","elsevierAuthor":"Figlin R.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"12"},{"title":"Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results","googleId":"im12lI4fvdsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38131-X/abstract","googleCitationCount":22,"googleAuthor":"B Faltas"},{"title":"Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial","googleId":"kjY_Ybq9LqwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39106-7/abstract","googleCitationCount":22,"googleAuthor":"HM Horlings"},{"title":"Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram","googleId":"W0PksKQk3V8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319568","googleCitationCount":27,"googleAuthor":"F Pietrantonio","doi":"10.1093/annonc/mdw627","elsevierAuthor":"Pietrantonio F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"20"},{"title":"A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT# …","googleId":"yzJrJBlWUgEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341931957X","googleCitationCount":26,"googleAuthor":"R Salani","doi":"10.1093/annonc/mdw635","elsevierAuthor":"Thaker P.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"23"},{"title":"Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 …","googleId":"W42m9bsjJEkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50429-X/abstract","googleCitationCount":16,"googleAuthor":"P Sharma"},{"title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours","googleId":"x70p9EJt0EQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320447","googleCitationCount":27,"googleAuthor":"","doi":"10.1093/annonc/mdw662","elsevierAuthor":"Leary A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"17"},{"title":"A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder","googleId":"KoDrspbUCDAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320484","googleCitationCount":24,"googleAuthor":"","doi":"10.1093/annonc/mdw675","elsevierAuthor":"Obara W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"24"},{"title":"Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives","googleId":"bjzEFYI2CpkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319246","googleCitationCount":23,"googleAuthor":"BA Carneiro","doi":"10.1093/annonc/mdw532","elsevierAuthor":"Costa R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"16"},{"title":"Cyclin D mediates tolerance of genome-doubling in cancers with functional p53","googleId":"fypj4BDBu30J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319350","googleCitationCount":25,"googleAuthor":"LP Zalmas","doi":"10.1093/annonc/mdw612","elsevierAuthor":"Crockford A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"18"},{"title":"Introducing whole-genome sequencing into routine cancer care: the Genomics England 100 000 Genomes Project","googleId":"5wKE82e5TP4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45492-6/abstract","googleCitationCount":21,"googleAuthor":"C Turnbull"},{"title":"Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) …","googleId":"Zoq1NlqiFYEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48485-8/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma","googleId":"cpOIgVS2IMAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66171-5/abstract","googleCitationCount":20,"googleAuthor":"JC Soria"},{"title":"Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/US National Cancer Institute phase II collaborative …","googleId":"SBxqqFC1CaQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50473-2/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?","googleId":"tqhWTdlN128J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31986-6/abstract","googleCitationCount":23,"googleAuthor":""},{"title":"Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene …","googleId":"3lcq344HU4oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352494","googleCitationCount":19,"googleAuthor":"R Sanz-Pamplona","doi":"10.1093/annonc/mdx293","elsevierAuthor":"Gonçalves-Ribeiro S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"15"},{"title":"Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient","googleId":"Vhjkc2v_oAEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35230-5/abstract","googleCitationCount":20,"googleAuthor":""},{"title":"Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the …","googleId":"aYqOwqacxX4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318770","googleCitationCount":13,"googleAuthor":"E Calvo","doi":"10.1093/annonc/mdy398","elsevierAuthor":"Smoragiewicz M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-11-01","elsevierCoverDisplayDate":"November 2018","elsevierCitationCount":"9"},{"title":"Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)","googleId":"t0F-wBRJfW8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38548-3/abstract","googleCitationCount":25,"googleAuthor":""},{"title":"Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)","googleId":"T_ZkwSFNi9YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50450-1/abstract","googleCitationCount":16,"googleAuthor":"T Cascone"},{"title":"Drug-induced liver injury in Oncology","googleId":"EWaSsAb4qsgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32132-5/abstract","googleCitationCount":18,"googleAuthor":""},{"title":"Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164","googleId":"fum4WBDNkx4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33707-X/abstract","googleCitationCount":16,"googleAuthor":"D Le"},{"title":"Phase II study evaluating trifluridine/tipiracil+ bevacizumab and capecitabine+ bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients …","googleId":"JV5gyM7CEboJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33708-1/abstract","googleCitationCount":17,"googleAuthor":""},{"title":"Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration","googleId":"XLGTvyyhFqEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34591-0/abstract","googleCitationCount":18,"googleAuthor":"CK Wu"},{"title":"An update of the WCRF/AICR systematic literature review and meta-analysis on dietary and anthropometric factors and esophageal cancer risk","googleId":"Oht1iDOv0MUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349427","googleCitationCount":20,"googleAuthor":"","doi":"10.1093/annonc/mdx338","elsevierAuthor":"Vingeliene S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"15"},{"title":"Different menopausal hormone regimens and risk of breast cancer","googleId":"KoDhSU0EaOQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341304","googleCitationCount":13,"googleAuthor":"N Brusselaers","doi":"10.1093/annonc/mdy212","elsevierAuthor":"Brusselaers N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"10"},{"title":"Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and …","googleId":"JwXhwsY5A7IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345922","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdx412","elsevierAuthor":"Berger M.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"16"},{"title":"Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy","googleId":"ZF82SFTckCYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349920","googleCitationCount":19,"googleAuthor":"S Jain","doi":"10.1093/annonc/mdx637","elsevierAuthor":"Jain S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"12"},{"title":"Looking beyond drivers and passengers in cancer genome sequencing data","googleId":"eB24NYtlQMQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319982","googleCitationCount":24,"googleAuthor":"S De","doi":"10.1093/annonc/mdw677","elsevierAuthor":"De S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"May 2017","elsevierCitationCount":"13"},{"title":"Preliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma …","googleId":"RNuAT5d9ahwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49086-8/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?","googleId":"lkNJ-ZDJGYUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324251","googleCitationCount":21,"googleAuthor":"M Sánchez","doi":"10.1093/annonc/mdx081","elsevierAuthor":"Hierro C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"0"},{"title":"Clinic-pathological pattern of hepatocellular carcinoma (HCC) in Egypt","googleId":"J0z1b6T62TcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33755-X/abstract","googleCitationCount":15,"googleAuthor":"H Elghazaly"},{"title":"Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics","googleId":"PfzOf6mXy14J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419318903","googleCitationCount":19,"googleAuthor":"","doi":"10.1093/annonc/mdy412","elsevierAuthor":"Ligtenberg K.G.","publicationName":"JAAD Case Reports","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"0"},{"title":"Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC","googleId":"-TYPnW4rfi0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49776-7/abstract","googleCitationCount":14,"googleAuthor":"C Faivre-Finn"},{"title":"A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head …","googleId":"nKmlcJ_x_tUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49501-X/abstract","googleCitationCount":16,"googleAuthor":"EEW Cohen"},{"title":"Initial results of Phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior …","googleId":"sSIojlFg_bQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50068-0/abstract","googleCitationCount":14,"googleAuthor":"M Heinrich"},{"title":"Long-term safety and clinical outcomes of atezolizumab in head and neck cancer: phase Ia trial results","googleId":"SWjnIPv6N6cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38316-2/abstract","googleCitationCount":22,"googleAuthor":""},{"title":"Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial","googleId":"3rIlapCVssEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324433","googleCitationCount":22,"googleAuthor":"","doi":"10.1093/annonc/mdx124","elsevierAuthor":"Kollmannsberger C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"3"},{"title":"Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor","googleId":"1CsBUKqy9PAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324263","googleCitationCount":20,"googleAuthor":"G Siravegna","doi":"10.1093/annonc/mdx095","elsevierAuthor":"Siravegna G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"40"},{"title":"Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer","googleId":"8uYTfnNPqJcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320137","googleCitationCount":25,"googleAuthor":"M Schirripa","doi":"10.1093/annonc/mdx035","elsevierAuthor":"Suenaga M.","publicationName":"Annals of oncology : official journal of the European Society for Medical Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"1 May 2017","elsevierCitationCount":"21"},{"title":"Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer","googleId":"o4QbMjcrAO8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324330","googleCitationCount":20,"googleAuthor":"I Ray-Coquard","doi":"10.1093/annonc/mdx111","elsevierAuthor":"Pujade-Lauraine E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"18"},{"title":"Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2","googleId":"URsX6_3tfgEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342103","googleCitationCount":12,"googleAuthor":"K Chang","doi":"10.1093/annonc/mdy337","elsevierAuthor":"Chang K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"11"},{"title":"Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: updated results from PROFILE 1014","googleId":"ycDOB8VYG54J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39153-5/abstract","googleCitationCount":22,"googleAuthor":"DW Kim"},{"title":"Phase II study of tepotinib+ gefitinib (TEP+ GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)","googleId":"-IR_F2bHA5MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49790-1/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors","googleId":"lwi5Pm4ueKMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32724-3/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Struggling with nutrition in patients with advanced cancer: Nutrition and nourishment—focusing on metabolism and supportive care","googleId":"4JlfDG4yCFcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419316813","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy093","elsevierAuthor":"Arends J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"February 2018","elsevierCitationCount":"9"},{"title":"Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC)","googleId":"SBJR5OdhPfkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37786-3/abstract","googleCitationCount":18,"googleAuthor":"R Kim"},{"title":"Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab","googleId":"Q1Ym5W1uRhcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32164-7/abstract","googleCitationCount":18,"googleAuthor":""},{"title":"Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers","googleId":"DTxfE1-adboJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454872","googleCitationCount":15,"googleAuthor":"NJ Birkbak","doi":"10.1093/annonc/mdy049","elsevierAuthor":"Birkbak N.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"12"},{"title":"Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018","googleId":"rpvmicisVyMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342152","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy343","elsevierAuthor":"Stiefel F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"9"},{"title":"Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma","googleId":"KnN6t6zpLQcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320587","googleCitationCount":20,"googleAuthor":"JK Lee","doi":"10.1093/annonc/mdw686","elsevierAuthor":"Chau N.G.","publicationName":"JNCI Cancer Spectrum","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"11"},{"title":"Prognostic markers for colorectal cancer: estimating ploidy and stroma","googleId":"AEp90PAaGGkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935505X","googleCitationCount":28,"googleAuthor":"HE Danielsen","doi":"10.1093/annonc/mdx794","elsevierAuthor":"Tijhuis A.E.","publicationName":"Molecular Cytogenetics","elsevierCoverDate":"2019-05-14","elsevierCoverDisplayDate":"14 May 2019","elsevierCitationCount":"10"},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort","googleId":"hfyI4X625RsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49505-7/abstract","googleCitationCount":14,"googleAuthor":"A Ravaud"},{"title":"Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)","googleId":"R7Q2jxfXe6sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454902","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy052","elsevierAuthor":"MacNeill A.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"22"},{"title":"A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results …","googleId":"6i5UummQzPYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50049-7/abstract","googleCitationCount":15,"googleAuthor":"JL Pujol"},{"title":"Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of …","googleId":"r7hTrrq6v5cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322495","googleCitationCount":20,"googleAuthor":"D Cunningham","doi":"10.1093/annonc/mdx128","elsevierAuthor":"Pedersen M.Ø.","publicationName":"PLoS ONE","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"5"},{"title":"Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and …","googleId":"utVCoNNqn0cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319143","googleCitationCount":21,"googleAuthor":"C Massard","doi":"10.1093/annonc/mdw441","elsevierAuthor":"Massard C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"17"},{"title":"A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck …","googleId":"3rDkwF3nxFMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934949X","googleCitationCount":17,"googleAuthor":"SS Baxi","doi":"10.1093/annonc/mdx346","elsevierAuthor":"Zhang Z.","publicationName":"Toxicology in Vitro","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"2"},{"title":"Corrections to “Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”","googleId":"W2kW2oceqAcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31701-6/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients …","googleId":"m1FpWm1P458J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66215-0/abstract","googleCitationCount":19,"googleAuthor":"NH Segal"},{"title":"Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding","googleId":"PMmSXqJi_LQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355061","googleCitationCount":16,"googleAuthor":"PF Thall","doi":"10.1093/annonc/mdx795","elsevierAuthor":"Yan F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"9"},{"title":"Statistical controversies in clinical research: publication bias evaluations are not routinely conducted in clinical oncology systematic reviews","googleId":"KvYSVQlYeTcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319994","googleCitationCount":19,"googleAuthor":"S Khan","doi":"10.1093/annonc/mdw691","elsevierAuthor":"Ayorinde A.A.","publicationName":"PLoS ONE","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"1 January 2020","elsevierCitationCount":"1"},{"title":"Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic …","googleId":"KzjZjdRKzpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321088","googleCitationCount":15,"googleAuthor":"L Schwartzberg","doi":"10.1093/annonc/mdy169","elsevierAuthor":"Schwartzberg L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"12"},{"title":"Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis","googleId":"CzWG6Xi1xe0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319817","googleCitationCount":20,"googleAuthor":"H Abdel-Qadir","doi":"10.1093/annonc/mdw671","elsevierAuthor":"Abdel-Qadir H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"15"},{"title":"Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer","googleId":"Rw-_3Hq-l-UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341663","googleCitationCount":12,"googleAuthor":"B Basu","doi":"10.1093/annonc/mdy245","elsevierAuthor":"Basu B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"8"},{"title":"A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD …","googleId":"enJNriCwrKMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37891-1/abstract","googleCitationCount":21,"googleAuthor":"YK Kang"},{"title":"Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","googleId":"Gs_18euEWSYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355024","googleCitationCount":15,"googleAuthor":"AF Herrera","doi":"10.1093/annonc/mdx791","elsevierAuthor":"Herrera A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"9"},{"title":"Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote …","googleId":"vTTAnrfAo-UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49733-0/abstract","googleCitationCount":15,"googleAuthor":"CU Blank"},{"title":"Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 …","googleId":"oPZk42tSSQoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350653","googleCitationCount":15,"googleAuthor":"D Cella","doi":"10.1093/annonc/mdx759","elsevierAuthor":"Cella D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"15"},{"title":"Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in …","googleId":"AePZEsAGOwIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39101-8/abstract","googleCitationCount":21,"googleAuthor":""},{"title":"A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer","googleId":"rRy55OyBl5IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322203","googleCitationCount":21,"googleAuthor":"","doi":"10.1093/annonc/mdw608","elsevierAuthor":"Belani C.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"14"},{"title":"Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities","googleId":"Au2SyprlXq4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322598","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdx162","elsevierAuthor":"Pécuchet N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"16"},{"title":"Clinical efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: results from the randomized OAK study","googleId":"_EFusNevjhIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38545-8/abstract","googleCitationCount":19,"googleAuthor":"W Zou"},{"title":"Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)","googleId":"1o27HQJgVNUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49268-5/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Therapeutic advantage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatment","googleId":"6C2RUZpSm1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341614","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdy240","elsevierAuthor":"Yoon W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"8"},{"title":"BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib+ MEK inhibitor binimetinib+ anti–epidermal growth factor receptor antibody …","googleId":"i78V2ZpoX7AJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33713-5/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference","googleId":"YtMetVxVAq4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346603","googleCitationCount":17,"googleAuthor":"G Stuart","doi":"10.1093/annonc/mdx449","elsevierAuthor":"Bookman M.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"10"},{"title":"Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)","googleId":"2goHhcDf9kIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945463X","googleCitationCount":16,"googleAuthor":"JP Machiels","doi":"10.1093/annonc/mdy013","elsevierAuthor":"Machiels J.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"13"},{"title":"Drug-sensitiveFGFR3 mutations in lung adenocarcinoma","googleId":"3FyZ7o0RSUAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319581","googleCitationCount":20,"googleAuthor":"P Chandrani","doi":"10.1093/annonc/mdw636","elsevierAuthor":"Chandrani P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"14"},{"title":"The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications","googleId":"U4GIn-0DLfAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346561","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdx445","elsevierAuthor":"Duska L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"13"},{"title":"Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC","googleId":"uYSpjXssdI8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50453-7/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection","googleId":"hosGS95gfBoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37898-4/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in …","googleId":"ZcMyUm9_bLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349932","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdx638","elsevierAuthor":"Blackwell K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"10"},{"title":"Changes in the use of end points in clinical trials for elderly cancer patients over time","googleId":"27eCLQmryaIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349543","googleCitationCount":16,"googleAuthor":"C Falandry","doi":"10.1093/annonc/mdx354","elsevierAuthor":"Saux O.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"12"},{"title":"Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative forFLT3-ITD, NPM1-or biallelicCEBPA mutations","googleId":"MIMezPCxcgUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346174","googleCitationCount":18,"googleAuthor":"C Thiede","doi":"10.1093/annonc/mdx500","elsevierAuthor":"Heidrich K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"9"},{"title":"An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages","googleId":"sb7WeCx4H6AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352573","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdx314","elsevierAuthor":"Huber-Ruano I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"11"},{"title":"CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications","googleId":"EbEPj3dhQLIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454835","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdy039","elsevierAuthor":"Holmes P.M.","publicationName":"Transactions of the Royal Society of South Africa","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"3"},{"title":"A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for …","googleId":"ca6bZigFCvYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37662-6/abstract","googleCitationCount":19,"googleAuthor":""},{"title":"Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy","googleId":"AuDPBGBLzzUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932160X","googleCitationCount":18,"googleAuthor":"FT Roncolato","doi":"10.1093/annonc/mdx229","elsevierAuthor":"Frantellizzi V.","publicationName":"Hellenic Journal of Nuclear Medicine","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"1"},{"title":"Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402 …","googleId":"fXs_21pmSw8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49702-0/abstract","googleCitationCount":12,"googleAuthor":"JMP Rodriguez"},{"title":"Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus …","googleId":"ueSqddO-8H0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39132-8/abstract","googleCitationCount":19,"googleAuthor":"TK Choueiri"},{"title":"Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2 …","googleId":"p20aovgfKecJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37526-8/abstract","googleCitationCount":18,"googleAuthor":""},{"title":"HPV16 DNA and integration in normal and malignant epithelium: implications for the etiology of laryngeal squamous cell carcinoma","googleId":"cyTFpp9Iq9YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932006X","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdx027","elsevierAuthor":"Chen X.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"May 2017","elsevierCitationCount":"14"},{"title":"Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study","googleId":"BndPiJYhfyMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39157-2/abstract","googleCitationCount":18,"googleAuthor":"S Peters"},{"title":"Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population","googleId":"YScanx5D-J8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346113","googleCitationCount":16,"googleAuthor":"S Buti","doi":"10.1093/annonc/mdx492","elsevierAuthor":"Buti S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-07-01","elsevierCoverDisplayDate":"1 July 2018","elsevierCitationCount":"0"},{"title":"Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature","googleId":"05yUc7PNmAsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32154-4/abstract","googleCitationCount":19,"googleAuthor":"A Chauhan"},{"title":"Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice","googleId":"wYOPlx1Qcz0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349890","googleCitationCount":15,"googleAuthor":"D Cunningham","doi":"10.1093/annonc/mdx631","elsevierAuthor":"Moorcraft S.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"11"},{"title":"BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in …","googleId":"pPBA7Z-rPYQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320022","googleCitationCount":19,"googleAuthor":"","doi":"10.1093/annonc/mdx022","elsevierAuthor":"Petrella T.","publicationName":"Annals of oncology : official journal of the European Society for Medical Oncology","elsevierCoverDate":"2017-05-01","elsevierCoverDisplayDate":"1 May 2017","elsevierCitationCount":"10"},{"title":"A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer","googleId":"JhoQkzbrjx8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352391","googleCitationCount":19,"googleAuthor":"I Bondarenko","doi":"10.1093/annonc/mdx275","elsevierAuthor":"Ajani J.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"14"},{"title":"Blinatumomab (Blincyto): Lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL)","googleId":"N0yRvgEPp2cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32130-1/abstract","googleCitationCount":18,"googleAuthor":"G Friberg"},{"title":"Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment","googleId":"jg3ju11PfBMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319155","googleCitationCount":20,"googleAuthor":"CY Ock","doi":"10.1093/annonc/mdw442","elsevierAuthor":"An E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"14"},{"title":"Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials","googleId":"lodahXmYDscJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32047-2/abstract","googleCitationCount":20,"googleAuthor":"B Gyawali"},{"title":"CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and …","googleId":"1F2oty21kPEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38409-X/abstract","googleCitationCount":16,"googleAuthor":"J Brody"},{"title":"Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic …","googleId":"6tYypZ2h6ZsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454847","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdy040","elsevierAuthor":"Tahara M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"15"},{"title":"Atezolizumab+ bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study","googleId":"64oxgXJJl6IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43117-7/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation …","googleId":"-Qcpwlf8lsgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39124-9/abstract","googleCitationCount":18,"googleAuthor":"MR Sydes"},{"title":"ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma","googleId":"KJKMJztDuwEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320708","googleCitationCount":16,"googleAuthor":"KJ Savage","doi":"10.1093/annonc/mdx005","elsevierAuthor":"Marr K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"7"},{"title":"Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid","googleId":"8NfagFu1fi8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319751","googleCitationCount":18,"googleAuthor":"E Garattini","doi":"10.1093/annonc/mdw660","elsevierAuthor":"Bolis M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"15"},{"title":"irRECIST and iRECIST: the devil is in the details","googleId":"erFp6c_ZU_gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32265-3/abstract","googleCitationCount":19,"googleAuthor":""},{"title":"Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib+ trametinib (D+ T) in patients (pts) with resected BRAF V600 …","googleId":"JsQPi7YFWAQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50444-6/abstract","googleCitationCount":13,"googleAuthor":"GV Long"},{"title":"Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK","googleId":"-wnepDaLzEkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38561-6/abstract","googleCitationCount":16,"googleAuthor":"K Syrigos"},{"title":"Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary …","googleId":"mbjEjFym6tIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932174X","googleCitationCount":17,"googleAuthor":"HR Ali","doi":"10.1093/annonc/mdx266","elsevierAuthor":"Liang H.","publicationName":"Thoracic Cancer","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"1 October 2020","elsevierCitationCount":"0"},{"title":"Intratumoral (it) injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (IPI) triggers durable responses in PD-1 inhibitor refractory …","googleId":"cO0sU3L7qqUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49700-7/abstract","googleCitationCount":11,"googleAuthor":"C Bernatchez"},{"title":"Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial","googleId":"Oy7HXk1zuqQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454768","googleCitationCount":14,"googleAuthor":"E Itti","doi":"10.1093/annonc/mdy031","elsevierAuthor":"Sobhani I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"10"},{"title":"YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus …","googleId":"rGuGA_jEggQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37894-7/abstract","googleCitationCount":16,"googleAuthor":"M Hidalgo"},{"title":"Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer","googleId":"9NlQ6H8tKXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350604","googleCitationCount":15,"googleAuthor":"DD Yang","doi":"10.1093/annonc/mdx744","elsevierAuthor":"Yang D.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"10"},{"title":"Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: results from two phase II …","googleId":"aT9x-aFNUtAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38594-X/abstract","googleCitationCount":18,"googleAuthor":"T Mitsudomi"},{"title":"Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for …","googleId":"IlOTJ2iRjfQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38628-2/abstract","googleCitationCount":15,"googleAuthor":"ES Kim"},{"title":"Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor","googleId":"aYF3EntCHi0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34107-9/abstract","googleCitationCount":15,"googleAuthor":"V Subbiah"},{"title":"Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors","googleId":"PjjArsRkw-QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49609-9/abstract","googleCitationCount":10,"googleAuthor":"R Leidner"},{"title":"CCTG IND. 231: a phase 1 trial evaluating CX-5461 in patients with advanced solid tumors","googleId":"4uKDHuV3B-QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32636-5/abstract","googleCitationCount":15,"googleAuthor":"DW Cescon"},{"title":"Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials","googleId":"XYWW_J6KU24J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322525","googleCitationCount":15,"googleAuthor":"","doi":"10.1093/annonc/mdx152","elsevierAuthor":"Yerushalmi R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"10"},{"title":"A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas","googleId":"40Oc9WgQXiIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32634-1/abstract","googleCitationCount":15,"googleAuthor":"J Abramson"},{"title":"Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus iv paclitaxel in patients with advanced gastric cancer after failure …","googleId":"Hsrby8tNKUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345296","googleCitationCount":12,"googleAuthor":"YK Kang","doi":"10.1093/annonc/mdy055","elsevierAuthor":"Kang Y.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"9"},{"title":"MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk","googleId":"lilW3MDj8q8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320198","googleCitationCount":18,"googleAuthor":"L Zhang","doi":"10.1093/annonc/mdx046","elsevierAuthor":"Yang Y.","publicationName":"Ferroptosis in Health and Disease","elsevierCoverDate":"2019-10-10","elsevierCoverDisplayDate":"10 October 2019","elsevierCitationCount":"0"},{"title":"Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors","googleId":"OIehBdTihvwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345454","googleCitationCount":14,"googleAuthor":"JR Infante","doi":"10.1093/annonc/mdy076","elsevierAuthor":"Italiano A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"9"},{"title":"Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced …","googleId":"WLbR1J3w_A0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49163-1/abstract","googleCitationCount":11,"googleAuthor":"T Meyer"},{"title":"Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1 …","googleId":"QtTaE6_4btYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341945480X","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdy036","elsevierAuthor":"Kodaira T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"14"},{"title":"(Neo-) adjuvant ipilimumab+ nivolumab (IPI+ NIVO) in palpable stage 3 melanoma–updated relapse free survival (RFS) data from the OpACIN trial and first biomarker …","googleId":"E71XlXHsvx8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38484-2/abstract","googleCitationCount":17,"googleAuthor":""},{"title":"Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent …","googleId":"FrVzjq4RKsYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37596-7/abstract","googleCitationCount":16,"googleAuthor":"D Lieber"},{"title":"EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity","googleId":"boqZl4EOZzoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454653","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdy015","elsevierAuthor":"Hofheinz R.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"14"},{"title":"Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the …","googleId":"b6E2Ur4zWawJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355073","googleCitationCount":14,"googleAuthor":"CK Lee","doi":"10.1093/annonc/mdx796","elsevierAuthor":"Friedlander M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"11"},{"title":"ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly …","googleId":"lbsUPJQO2zYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50426-4/abstract","googleCitationCount":12,"googleAuthor":"F Saad"},{"title":"Prevention of chemotherapy toxicity by agents that neutralize or degrade cell-free chromatin","googleId":"u4obYjMDdwQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352603","googleCitationCount":20,"googleAuthor":"I Mittra","doi":"10.1093/annonc/mdx318","elsevierAuthor":"Mittra I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"13"},{"title":"Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?","googleId":"s8cL_m4puMIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35013-6/abstract","googleCitationCount":12,"googleAuthor":"M Fiorentino"},{"title":"Expression III: patients' expectations and preferences regarding physician–patient relationship and clinical management—results of the international NOGGO …","googleId":"KOASZnTMoL0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454811","googleCitationCount":12,"googleAuthor":"S Alavi","doi":"10.1093/annonc/mdy037","elsevierAuthor":"Oskay-Özcelik G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"9"},{"title":"Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular …","googleId":"yN4Gc7CnZL8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345909","googleCitationCount":14,"googleAuthor":"L Magnano","doi":"10.1093/annonc/mdx407","elsevierAuthor":"Magnano L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"13"},{"title":"Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously …","googleId":"MSJ5QK4RFF8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43122-0/abstract","googleCitationCount":10,"googleAuthor":"F Meric-Bernstam"},{"title":"Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it","googleId":"YoEFZIdJIZoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35074-4/abstract","googleCitationCount":14,"googleAuthor":"V Prasad"},{"title":"No association between circulating concentrations of vitamin D and risk of lung cancer: an analysis in 20 prospective studies in the Lung Cancer Cohort …","googleId":"I3HqJpuqZmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934894X","googleCitationCount":12,"googleAuthor":"DC Muller","doi":"10.1093/annonc/mdy104","elsevierAuthor":"Muller D.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-06-01","elsevierCoverDisplayDate":"1 June 2018","elsevierCitationCount":"7"},{"title":"Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer","googleId":"rXGjs_y8pU4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32638-9/abstract","googleCitationCount":15,"googleAuthor":""},{"title":"Immunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer","googleId":"hWi9eiaerd8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38462-3/abstract","googleCitationCount":16,"googleAuthor":""},{"title":"Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study","googleId":"9Rbe3njT4QkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342449","googleCitationCount":8,"googleAuthor":"BP Hobbs","doi":"10.1093/annonc/mdy457","elsevierAuthor":"Hobbs B.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"5"},{"title":"Nivolumab in non-small-cell lung cancer with EGFR mutation","googleId":"CgfPpTQire8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35486-9/abstract","googleCitationCount":13,"googleAuthor":"YH Kim"},{"title":"Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers","googleId":"FQcv3-eYVm8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342115","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdy338","elsevierAuthor":"Chen X.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-10-01","elsevierCoverDisplayDate":"October 2018","elsevierCitationCount":"6"},{"title":"Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up","googleId":"5BzUywwZaEgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49321-6/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer","googleId":"EEZh81WWgJ0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324184","googleCitationCount":16,"googleAuthor":"L Ermini","doi":"10.1093/annonc/mdx074","elsevierAuthor":"Alves J.M.","publicationName":"Nature Communications","elsevierCoverDate":"2019-12-01","elsevierCoverDisplayDate":"1 December 2019","elsevierCitationCount":"12"},{"title":"Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer","googleId":"7JP9nIFlCLUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341171","googleCitationCount":9,"googleAuthor":"FR Hirsch","doi":"10.1093/annonc/mdy196","elsevierAuthor":"Bonomi P.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"6"},{"title":"A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two …","googleId":"qlQElXhg-9YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321453","googleCitationCount":16,"googleAuthor":"","doi":"10.1093/annonc/mdx202","elsevierAuthor":"Inhestern J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"11"},{"title":"Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or …","googleId":"xMKTts7-O1sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49123-0/abstract","googleCitationCount":11,"googleAuthor":"S Kondo"},{"title":"Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer","googleId":"BJMq0Cpl0u0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341638","googleCitationCount":11,"googleAuthor":"JC Soria","doi":"10.1093/annonc/mdy242","elsevierAuthor":"Soria J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-09-01","elsevierCoverDisplayDate":"1 September 2018","elsevierCitationCount":"10"},{"title":"Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular …","googleId":"xrgY8xtpdQ4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39122-5/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"A comparison of matched interim analysis publications and final analysis publications in oncology clinical trials","googleId":"GWZ3oyaCQh4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419342346","googleCitationCount":8,"googleAuthor":"C Wayant","doi":"10.1093/annonc/mdy447","elsevierAuthor":"Wayant C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-12-01","elsevierCoverDisplayDate":"December 2018","elsevierCitationCount":"5"},{"title":"Early-drug development in the era of immuno-oncology: are we ready to face the challenges?","googleId":"W-YwwoO5kkoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341390","googleCitationCount":9,"googleAuthor":"M Oliva","doi":"10.1093/annonc/mdy225","elsevierAuthor":"De Olza M.O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-10-01","elsevierCoverDisplayDate":"1 October 2019","elsevierCitationCount":"0"},{"title":"Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primaryEGFR mutation plus secondaryMET amplification and a novel acquired …","googleId":"Pv-ZPe7r9eQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34936-1/abstract","googleCitationCount":17,"googleAuthor":""},{"title":"Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine","googleId":"jxXQeWPfPMgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319131","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdw440","elsevierAuthor":"Husseini F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"15"},{"title":"Intratumoral heterogeneity in gastric cancer: a new challenge to face","googleId":"aaotkedc5CYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32038-1/abstract","googleCitationCount":16,"googleAuthor":"F Carneiro"},{"title":"Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic …","googleId":"j2ZwKY4AmmwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31925-8/abstract","googleCitationCount":18,"googleAuthor":""},{"title":"Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced …","googleId":"k_l-SUFn5-oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38403-9/abstract","googleCitationCount":14,"googleAuthor":"EE Cohen"},{"title":"Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a …","googleId":"mDKlvjyCsmgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934565X","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdy113","elsevierAuthor":"Iacoboni G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"4"},{"title":"JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results","googleId":"-Jcm_XzhbzsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49908-0/abstract","googleCitationCount":9,"googleAuthor":"JS Lee"},{"title":"Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases","googleId":"ekhxv8malSoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33575-6/abstract","googleCitationCount":16,"googleAuthor":"RV Lukas"},{"title":"Nivolumab (nivo) in combination with radiotherapy (RT)±temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated …","googleId":"HNjdgIA-iB4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37748-6/abstract","googleCitationCount":14,"googleAuthor":""},{"title":"Data resources for the identification and interpretation of actionable mutations by clinicians","googleId":"D2jCzpx_UDgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320034","googleCitationCount":15,"googleAuthor":"A Prawira","doi":"10.1093/annonc/mdx023","elsevierAuthor":"Roos A.","publicationName":"Cancer Treatment and Research","elsevierCoverDate":"2019-01-01","elsevierCoverDisplayDate":"2019","elsevierCitationCount":"1"},{"title":"Phase III study of gefitinib (G) versus gefitinib+ carboplatin+ pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer …","googleId":"bU4S9l_diEsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49795-0/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"OpACIN-neo: a multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)","googleId":"FbykJDO-4GwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50443-4/abstract","googleCitationCount":11,"googleAuthor":"CU Blank"},{"title":"The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma","googleId":"fOS_3nB9Y8sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350458","googleCitationCount":12,"googleAuthor":"F Bertucci","doi":"10.1093/annonc/mdx699","elsevierAuthor":"Bertucci F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"11"},{"title":"Durvalumab in≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: results from the phase 2 ATLANTIC study","googleId":"Pp0NtP49oTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33576-8/abstract","googleCitationCount":19,"googleAuthor":"MC Garassino"},{"title":"Networking for ovarian rare tumors: a significant breakthrough improving disease management","googleId":"3eKdtuax7AAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324287","googleCitationCount":14,"googleAuthor":"P Pautier","doi":"10.1093/annonc/mdx099","elsevierAuthor":"Chiannilkulchai N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"13"},{"title":"Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) …","googleId":"YQKTst0WitMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50400-8/abstract","googleCitationCount":10,"googleAuthor":"M Cristofanilli"},{"title":"Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer","googleId":"12cCb0AAurYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350082","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdx688","elsevierAuthor":"Overman M.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-03-01","elsevierCoverDisplayDate":"1 March 2019","elsevierCitationCount":"0"},{"title":"Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study","googleId":"0nx7Eh0CSvQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322689","googleCitationCount":14,"googleAuthor":"","doi":"10.1093/annonc/mdx172","elsevierAuthor":"Bourgeois H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"14"},{"title":"SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of …","googleId":"DPGsVv6IkmEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354766","googleCitationCount":13,"googleAuthor":"JC Soria","doi":"10.1093/annonc/mdx628","elsevierAuthor":"Soria J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"10"},{"title":"Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial","googleId":"ojVym39t45wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345892","googleCitationCount":14,"googleAuthor":"","doi":"10.1093/annonc/mdx406","elsevierAuthor":"Miles D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"7"},{"title":"CheckMate 227: a randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in …","googleId":"4RRO1dMAZIcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33638-5/abstract","googleCitationCount":15,"googleAuthor":"MD Hellmann"},{"title":"Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib+ fulvestrant: results from MONALEESA-3","googleId":"47mR_Vw6Yl4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48711-5/abstract","googleCitationCount":11,"googleAuthor":"FJ Esteva"},{"title":"Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer—a prospective evaluation of circulating tumor cells, 18F …","googleId":"a_rXeNt41CcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322501","googleCitationCount":15,"googleAuthor":"B Ma","doi":"10.1093/annonc/mdx149","elsevierAuthor":"Ma B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-30","elsevierCoverDisplayDate":"30 March 2017","elsevierCitationCount":"12"},{"title":"A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial","googleId":"6gCl_Xz0WiEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321635","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdx232","elsevierAuthor":"Prado C.M.","publicationName":"Journal of Cachexia, Sarcopenia and Muscle","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"1 April 2020","elsevierCitationCount":"27"},{"title":"A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)","googleId":"QumaJ_MlYZkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932277X","googleCitationCount":17,"googleAuthor":"J Bellmunt","doi":"10.1093/annonc/mdx186","elsevierAuthor":"Bellmunt J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"13"},{"title":"First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma","googleId":"y8LzN8HfCPcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35522-X/abstract","googleCitationCount":11,"googleAuthor":"S Turajlic"},{"title":"Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with …","googleId":"gai3XoXpTL8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50407-0/abstract","googleCitationCount":11,"googleAuthor":"E Calvo"},{"title":"Phase 2 study of neoadjuvant dabrafenib+ trametinib (D+ T) for resectable stage IIIB/C BRAF V600 mutant melanoma","googleId":"zlCUWsnz8HUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38483-0/abstract","googleCitationCount":14,"googleAuthor":"AM Menzies"},{"title":"Second or 3rd line nivolumab (Nivo) versus Nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 …","googleId":"Ix9hnXD8lB8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39174-2/abstract","googleCitationCount":14,"googleAuthor":"G Zalcman"},{"title":"Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the …","googleId":"wrGX6_M83lEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49922-5/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data","googleId":"d7EHdWetjYsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49080-7/abstract","googleCitationCount":9,"googleAuthor":"YK Kang"},{"title":"Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes","googleId":"cl3P3p3lzecJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32273-2/abstract","googleCitationCount":16,"googleAuthor":"I Beh"},{"title":"How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials","googleId":"IQsfHRSLt8gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352287","googleCitationCount":14,"googleAuthor":"C Borg","doi":"10.1093/annonc/mdx191","elsevierAuthor":"Bonnetain F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"9"},{"title":"Next-generation immunotherapies for lymphoma: one foot in the future","googleId":"9dkmkb6RV1AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355243","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdy032","elsevierAuthor":"Manson G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"10"},{"title":"Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer","googleId":"uOuufzkM6ToJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349622","googleCitationCount":12,"googleAuthor":"J Bellmunt","doi":"10.1093/annonc/mdx400","elsevierAuthor":"Bellmunt J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"9"},{"title":"Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with≥ 6 months of follow-up in all …","googleId":"0Fj2u2HE-GoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38129-1/abstract","googleCitationCount":14,"googleAuthor":"AB Apolo"},{"title":"Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed","googleId":"8VIe_zPSaEUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34204-8/abstract","googleCitationCount":9,"googleAuthor":"EC Smyth"},{"title":"Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head …","googleId":"qXp2ni0-4BcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49506-9/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced …","googleId":"DG3nr_4XfrsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49261-2/abstract","googleCitationCount":10,"googleAuthor":"N Agarwal"},{"title":"Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)","googleId":"41POqI8UiBsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352664","googleCitationCount":18,"googleAuthor":"","doi":"10.1093/annonc/mdx334","elsevierAuthor":"Dabaja B.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"11"},{"title":"Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas","googleId":"yLfzu97XHLAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350690","googleCitationCount":11,"googleAuthor":"LI Gordon","doi":"10.1093/annonc/mdx768","elsevierAuthor":"Karmali R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"7"},{"title":"Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study","googleId":"aC4gGUBb4_cJ","googleLink":"https://vbn.aau.dk/ws/files/306929894/Six_cycles_of_R_CHOP_21_are_not_inferior_to_eight_cycles_for_treatment_of_diffuse_large_B_cell_lymphoma_A_Nordic_Lymphoma_Group_population_based_study.pdf","googleCitationCount":9,"googleAuthor":"JL Biccler","doi":"10.1093/annonc/mdy184","elsevierAuthor":"Wästerlid T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"4"},{"title":"Open access to journal articles in oncology: current situation and citation impact","googleId":"TFbriuhi3hsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349609","googleCitationCount":14,"googleAuthor":"F Hua","doi":"10.1093/annonc/mdx398","elsevierAuthor":"Hua F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-10-01","elsevierCoverDisplayDate":"October 2017","elsevierCitationCount":"12"},{"title":"A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder …","googleId":"2PulFdXf-o0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49584-7/abstract","googleCitationCount":10,"googleAuthor":"A Naing"},{"title":"MEDIOLA: a phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours–new ovarian cancer …","googleId":"YLPWSpAo1kwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48914-X/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"A phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)","googleId":"4OicpOP0gsAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37895-9/abstract","googleCitationCount":12,"googleAuthor":"P Hammel"},{"title":"Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials","googleId":"Z7lSCNBIwzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50283-6/abstract","googleCitationCount":8,"googleAuthor":"M Mau-Sorensen"},{"title":"Nivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer","googleId":"L1-lRbB_dFoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38404-0/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib …","googleId":"v-Niy_nMe2UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49084-4/abstract","googleCitationCount":12,"googleAuthor":"PR Galle"},{"title":"Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment","googleId":"dm8nOicMgHMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35393-1/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)","googleId":"3UH3BEffnpMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49083-2/abstract","googleCitationCount":8,"googleAuthor":"TY Kim"},{"title":"Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: updated OS data from the phase IIb trial LUX-Lung 7 (LL7)","googleId":"sr3txyXte_kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33587-2/abstract","googleCitationCount":16,"googleAuthor":"JCH Yang"},{"title":"A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good …","googleId":"fsVN8TFCXfYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324159","googleCitationCount":14,"googleAuthor":"SJ Sarker","doi":"10.1093/annonc/mdx071","elsevierAuthor":"Shamash J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"8"},{"title":"Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients","googleId":"dxWeF3qG5rUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32758-9/abstract","googleCitationCount":9,"googleAuthor":"K Homicsko"},{"title":"Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: results …","googleId":"GW-Lz2YKnqcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50434-3/abstract","googleCitationCount":8,"googleAuthor":"JA Ledermann"},{"title":"Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer","googleId":"fZM3KUUnHG0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49027-3/abstract","googleCitationCount":9,"googleAuthor":"S Takahashi"},{"title":"Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma","googleId":"PQhBzeopOYcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319180","googleCitationCount":15,"googleAuthor":"A Agaimy","doi":"10.1093/annonc/mdw446","elsevierAuthor":"Dieter S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"12"},{"title":"CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and …","googleId":"7awphYJB_DUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50422-7/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Adult weight gain and colorectal adenomas—a systematic review and meta-analysis","googleId":"WwO3viqyf7YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932424X","googleCitationCount":13,"googleAuthor":"L Abar","doi":"10.1093/annonc/mdx080","elsevierAuthor":"Schlesinger S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"8"},{"title":"Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease","googleId":"Cd8LHiDHBBkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341389","googleCitationCount":10,"googleAuthor":"A Kamoun","doi":"10.1093/annonc/mdy224","elsevierAuthor":"Kamoun A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"10"},{"title":"Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L) 1","googleId":"Iv32EbsCZC8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49598-7/abstract","googleCitationCount":8,"googleAuthor":"S Champiat"},{"title":"Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials","googleId":"lncf11Y8bjIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321982","googleCitationCount":14,"googleAuthor":"B Gyawali","doi":"10.1093/annonc/mdw549","elsevierAuthor":"Gyawali B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"13"},{"title":"Genetic landscape of ultra-stable chronic lymphocytic leukemia patients","googleId":"LiLrQuW9ZC4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454677","googleCitationCount":10,"googleAuthor":"J Wang","doi":"10.1093/annonc/mdy021","elsevierAuthor":"Raponi S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"10"},{"title":"A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC","googleId":"yxdJD4z9aScJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39112-2/abstract","googleCitationCount":13,"googleAuthor":"AE Drilon"},{"title":"Metastasis of cancer: when and how?","googleId":"4kYscleVzb0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35264-0/abstract","googleCitationCount":12,"googleAuthor":"WC Lee"},{"title":"A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors","googleId":"_HQWIYeHDY8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49611-7/abstract","googleCitationCount":8,"googleAuthor":"CS Denlinger"},{"title":"Analyzing biomarkers of cancer immunotherapy (CIT) response using a real-world clinico-genomic database","googleId":"_u2r8vSuugMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38407-6/abstract","googleCitationCount":11,"googleAuthor":"G Singal"},{"title":"Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?","googleId":"MPfqAgcRSIwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932071X","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdx006","elsevierAuthor":"Font R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"10"},{"title":"Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy","googleId":"1cOysXW6k6IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50437-9/abstract","googleCitationCount":10,"googleAuthor":"H Mehanna"},{"title":"Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab","googleId":"NaKcqMY10I0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35379-7/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"Preliminary results from subsets of patients (pts) with advanced gastric cancer (GC) and esophageal carcinoma (EC) in a dose-escalation/expansion study of BGB …","googleId":"NyEAuyJsQVIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37806-6/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo)+ nab-paclitaxel (nab-P) vs placebo+ nab-P in treatment-naive …","googleId":"4GqWk8juhtMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50399-4/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"MSR1 repeats modulate gene expression and affect risk of breast and prostate cancer","googleId":"Qn5RhGQtpkcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345478","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdy082","elsevierAuthor":"Rose A.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"6"},{"title":"Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO …","googleId":"RQ3aeaGkY-wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354730","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdx547","elsevierAuthor":"de Hosson L.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"6"},{"title":"German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early …","googleId":"yO3vXot4r8AJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321465","googleCitationCount":12,"googleAuthor":"","doi":"10.1093/annonc/mdx203","elsevierAuthor":"Möbus V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"10"},{"title":"Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review","googleId":"1BVATlv7RFIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319520","googleCitationCount":15,"googleAuthor":"","doi":"10.1093/annonc/mdw617","elsevierAuthor":"Schuurhuizen C.S.E.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"11"},{"title":"Interim safety and clinical activity of nivolumab (nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable …","googleId":"MB_Vhe6ump0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37945-X/abstract","googleCitationCount":12,"googleAuthor":"YK Kang"},{"title":"PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P)+ trastuzumab (T) with or without chemotherapy both followed by T-DM1 in …","googleId":"CqDBCIlOHewJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48709-7/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO …","googleId":"UV1SvNxckN4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341262","googleCitationCount":8,"googleAuthor":"E Fokas","doi":"10.1093/annonc/mdy205","elsevierAuthor":"Hofheinz R.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"5"},{"title":"Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an …","googleId":"5bgptQfyjK8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345363","googleCitationCount":9,"googleAuthor":"I Bondarenko","doi":"10.1093/annonc/mdy063","elsevierAuthor":"Martin M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"5"},{"title":"Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer","googleId":"Ghu8q0D2eMMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37810-8/abstract","googleCitationCount":11,"googleAuthor":"S Westin"},{"title":"Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset","googleId":"r-Lug83gR3MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321520","googleCitationCount":13,"googleAuthor":"J IntHout","doi":"10.1093/annonc/mdx211","elsevierAuthor":"Eysbouts Y.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"6"},{"title":"Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia","googleId":"fhEJJB4kmLMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355218","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdy019","elsevierAuthor":"Khoury H.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"8"},{"title":"Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance","googleId":"P8XvexqBV7kJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319519","googleCitationCount":17,"googleAuthor":"","doi":"10.1093/annonc/mdw615","elsevierAuthor":"Bonavida B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"9"},{"title":"Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib","googleId":"Z7FK_hRE6tAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43119-0/abstract","googleCitationCount":7,"googleAuthor":"C Barone"},{"title":"How can molecular abnormalities influence our clinical approach","googleId":"8MbruARbqEgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346585","googleCitationCount":9,"googleAuthor":"W Wei","doi":"10.1093/annonc/mdx447","elsevierAuthor":"Wei W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"9"},{"title":"Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy","googleId":"HqdEDhcKhH8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350677","googleCitationCount":9,"googleAuthor":"P Boffetta","doi":"10.1093/annonc/mdx762","elsevierAuthor":"Boffetta P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2019-11-01","elsevierCoverDisplayDate":"November 2019","elsevierCitationCount":"0"},{"title":"Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib …","googleId":"_VChNlQP92gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34063-3/abstract","googleCitationCount":10,"googleAuthor":"P Galle"},{"title":"Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic …","googleId":"LE03kod8y4cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39110-9/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial","googleId":"zM44t18gR_sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49393-9/abstract","googleCitationCount":7,"googleAuthor":"IL Ray-Coquard"},{"title":"Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC)","googleId":"SkKTtPGi3QgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)65921-1/abstract","googleCitationCount":10,"googleAuthor":"J Kang"},{"title":"Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study","googleId":"7sVWQyyh4c0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43457-1/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"The landscape of NTRK fusions in Chinese patients with solid tumor","googleId":"sRlNzIBDgwoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48501-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant …","googleId":"mvXgIlqnYXQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934606X","googleCitationCount":11,"googleAuthor":"S Ladoire","doi":"10.1093/annonc/mdx487","elsevierAuthor":"Fizazi K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"9"},{"title":"Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies","googleId":"ESFT-2LgA_0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320538","googleCitationCount":15,"googleAuthor":"NA Wages","doi":"10.1093/annonc/mdw681","elsevierAuthor":"Hobbs B.P.","publicationName":"Journal of the National Cancer Institute","elsevierCoverDate":"2019-02-01","elsevierCoverDisplayDate":"1 February 2019","elsevierCitationCount":"12"},{"title":"Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine …","googleId":"nrznlVtFY6gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322616","googleCitationCount":12,"googleAuthor":"A Dasari","doi":"10.1093/annonc/mdx164","elsevierAuthor":"Peng F.","publicationName":"Colloids and Surfaces B: Biointerfaces","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0"},{"title":"Characterization of response to nivolumab plus ipilimumab (N+ I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc) …","googleId":"e7iXe_XL5M0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49264-8/abstract","googleCitationCount":10,"googleAuthor":"BI Rini"},{"title":"Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant …","googleId":"YlD0FRxHzlMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38411-8/abstract","googleCitationCount":14,"googleAuthor":"PA Konstantinopoulos"},{"title":"Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol","googleId":"FGZ0zLD2CboJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346071","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdx488","elsevierAuthor":"Bernichon E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"10"},{"title":"A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas","googleId":"L7sY3_utSc4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319167","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdw444","elsevierAuthor":"Agulnik M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-01-01","elsevierCoverDisplayDate":"1 January 2017","elsevierCitationCount":"11"},{"title":"Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies","googleId":"t75bdl-wglIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321507","googleCitationCount":19,"googleAuthor":"","doi":"10.1093/annonc/mdx207","elsevierAuthor":"Guo L.","publicationName":"Neoplasma","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"2018","elsevierCitationCount":"4"},{"title":"A Phase 1/2 trial of intratumoral (it) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L) 1-refractory melanoma","googleId":"BXclw3d9kUcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38454-4/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo …","googleId":"xaz0dx7r1Z8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324135","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdx043","elsevierAuthor":"Le-Rademacher J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"6"},{"title":"ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk'patients","googleId":"MiGZJQS89bAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341067","googleCitationCount":7,"googleAuthor":"M Hutchings","doi":"10.1093/annonc/mdy167","elsevierAuthor":"Hutchings M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"5"},{"title":"The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients—the …","googleId":"Y3lEWPcLi_YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353888","googleCitationCount":12,"googleAuthor":"S Chauvie","doi":"10.1093/annonc/mdx524","elsevierAuthor":"Carella A.M.","publicationName":"Annals of Hematology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"1 August 2018","elsevierCitationCount":"3"},{"title":"Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer","googleId":"XZfS_yDtzlYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48878-9/abstract","googleCitationCount":9,"googleAuthor":"M Voskoboynik"},{"title":"Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic …","googleId":"pBA4_G-SPE4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49507-0/abstract","googleCitationCount":8,"googleAuthor":"EEW Cohen"},{"title":"Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell …","googleId":"EkrCO7XiilQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319702","googleCitationCount":13,"googleAuthor":"BE Chen","doi":"10.1093/annonc/mdw653","elsevierAuthor":"Davison K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"9"},{"title":"Informatics for cancer immunotherapy","googleId":"_e7NI8pTSuYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419541503","googleCitationCount":10,"googleAuthor":"J Hammerbacher","doi":"10.1093/annonc/mdx682","elsevierAuthor":"Hammerbacher J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"8"},{"title":"Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99","googleId":"Ou-n1yx2_ywJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322288","googleCitationCount":14,"googleAuthor":"D Klingbiel","doi":"10.1093/annonc/mdw622","elsevierAuthor":"Pagani O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"9"},{"title":"Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer","googleId":"s_qbrsj3-BQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419355139","googleCitationCount":8,"googleAuthor":"F Khosrow-Khavar","doi":"10.1093/annonc/mdx822","elsevierAuthor":"Khosrow-Khavar F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-03-01","elsevierCoverDisplayDate":"1 March 2018","elsevierCitationCount":"5"},{"title":"The effects of nurses' empathy skills on attitudes towards patients with cancer","googleId":"UGG6AApT6TgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38827-X/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels","googleId":"97OmJZUbU38J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48557-8/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression","googleId":"oP_b8NJLFAQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31929-5/abstract","googleCitationCount":12,"googleAuthor":""},{"title":"A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS)","googleId":"Gg0zJkQzSaoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49288-0/abstract","googleCitationCount":8,"googleAuthor":"I Duran"},{"title":"ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)","googleId":"X_v2ca4mOu0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39134-1/abstract","googleCitationCount":12,"googleAuthor":"J Ledermann"},{"title":"Incidence of second tumors after treatment with or without radiation for rectal cancer","googleId":"6bFFfJLDlcQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319763","googleCitationCount":13,"googleAuthor":"","doi":"10.1093/annonc/mdw661","elsevierAuthor":"Rombouts A.J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"8"},{"title":"Revival of PI3K inhibitors in non-Hodgkin's lymphoma","googleId":"CEG4-ej9FiAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35270-6/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?","googleId":"et0Jlf86iSwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)31920-9/abstract","googleCitationCount":14,"googleAuthor":"R Danesi"},{"title":"Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment","googleId":"mSmu7NjsbngJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32077-0/abstract","googleCitationCount":14,"googleAuthor":"S Daneshmand"},{"title":"Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARv7 expression in circulating tumor cells","googleId":"sy8X2EDvFd8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32102-7/abstract","googleCitationCount":9,"googleAuthor":"C Reduzzi"},{"title":"A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer","googleId":"y984qFmMw-QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321684","googleCitationCount":11,"googleAuthor":"KL Mahon","doi":"10.1093/annonc/mdx247","elsevierAuthor":"Zhang A.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"8"},{"title":"Methylation in cell-free DNA for early cancer detection","googleId":"qTUhgCxAneQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34910-5/abstract","googleCitationCount":11,"googleAuthor":"FF de la Cruz"},{"title":"Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)","googleId":"wbzaTQ0J9fIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34064-5/abstract","googleCitationCount":10,"googleAuthor":"K Shitara"},{"title":"Cytoreductive surgery for ovarian cancer: quality assessment","googleId":"Si_wBuKzCKMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420346597","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdx448","elsevierAuthor":"Brand A.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"1 November 2017","elsevierCitationCount":"5"},{"title":"Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting …","googleId":"-dvwUuBFYzkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49104-7/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Cancer risk among 21st century blood transfusion recipients","googleId":"EFS7dJWUfUkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322033","googleCitationCount":11,"googleAuthor":"TO Yang","doi":"10.1093/annonc/mdw555","elsevierAuthor":"Yang T.O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"7"},{"title":"Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the …","googleId":"02T_Qe7j9K4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39117-1/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC","googleId":"reiw4tDd1lQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45491-4/abstract","googleCitationCount":8,"googleAuthor":"IV Bempt"},{"title":"Statistical controversies in cancer research: using standardized effect size graphs to enhance interpretability of cancer-related clinical trials with patient …","googleId":"VOQ_npCBWT8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321246","googleCitationCount":11,"googleAuthor":"ML Bell","doi":"10.1093/annonc/mdx064","elsevierAuthor":"Bell M.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"8"},{"title":"Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors","googleId":"_NHHrFpPaNcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50440-9/abstract","googleCitationCount":7,"googleAuthor":"IM Rodas"},{"title":"A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results","googleId":"WF8ShIPo8zgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37996-5/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)","googleId":"pkplFhe9OFUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49325-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study","googleId":"4rv899XNrSgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)56555-3/abstract","googleCitationCount":9,"googleAuthor":"S Peters"},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer …","googleId":"exBE5CKpzxsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43120-7/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach","googleId":"hByNxCw893MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43057-3/abstract","googleCitationCount":6,"googleAuthor":"DSW Tan"},{"title":"Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations","googleId":"FFHoMYpLHiQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49793-7/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (PTS) with …","googleId":"ILa2QrTyCNYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49701-9/abstract","googleCitationCount":7,"googleAuthor":"H Gogas"},{"title":"Improved survival in metastatic germ-cell cancer","googleId":"WoZ4C1ZU4N0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350574","googleCitationCount":8,"googleAuthor":"J Beyer","doi":"10.1093/annonc/mdx741","elsevierAuthor":"Fankhauser C.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"5"},{"title":"A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer","googleId":"n76Pxji-3_YJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322276","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdw621","elsevierAuthor":"Yoshioka H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"8"},{"title":"Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST)","googleId":"H8YSz_xX-ywJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38723-8/abstract","googleCitationCount":12,"googleAuthor":"ARA Razak"},{"title":"Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer","googleId":"_HHU9tNetO8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34581-8/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC …","googleId":"Axnebzzsj1oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49405-2/abstract","googleCitationCount":7,"googleAuthor":"RE O'Cearbhaill"},{"title":"Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project","googleId":"L1EumcapPtQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419349877","googleCitationCount":9,"googleAuthor":"U Dafni","doi":"10.1093/annonc/mdx629","elsevierAuthor":"Kerr K.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-01-01","elsevierCoverDisplayDate":"1 January 2018","elsevierCitationCount":"7"},{"title":"Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)","googleId":"yo2UfzeWQ9QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49164-3/abstract","googleCitationCount":7,"googleAuthor":"T Meyer"},{"title":"Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with …","googleId":"12CcdXNKCfcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49396-4/abstract","googleCitationCount":7,"googleAuthor":"V Moreno"},{"title":"High eosinophils lymphocyte ratio (ELR) related with subtype of breast cancer in Sanglah General Hospital, Bali","googleId":"oaHWuhNvDssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43014-7/abstract","googleCitationCount":6,"googleAuthor":"AAW Lestari"},{"title":"A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group","googleId":"FKmi36VbgvQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932023X","googleCitationCount":11,"googleAuthor":"","doi":"10.1093/annonc/mdx050","elsevierAuthor":"Kao C.Y.","publicationName":"European Journal of Cancer Care","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"1 September 2020","elsevierCitationCount":"0"},{"title":"Identification of a novel crizotinib-sensitive MET–ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing","googleId":"DGLcXY6_vVIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34242-5/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI) …","googleId":"TL0DYpF9zlkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38476-3/abstract","googleCitationCount":10,"googleAuthor":"J Larkin"},{"title":"Use of nivolumab in elderly patients with advanced non-squamous NSCLC: results from the Italian expanded access program (EAP)","googleId":"JeZvimCsZVcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38567-7/abstract","googleCitationCount":11,"googleAuthor":"MR Migliorino"},{"title":"Use of nivolumab in elderly patients with advanced non-squamous NSCLC: results from the Italian expanded access program (EAP)","googleId":"JeZvimCsZVcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38567-7/abstract","googleCitationCount":11,"googleAuthor":"MR Migliorino"},{"title":"A phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP sub-study SWOG S1400A","googleId":"bPE6Iia7I90J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33577-X/abstract","googleCitationCount":13,"googleAuthor":""},{"title":"Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary …","googleId":"kxdgsEGJ8vUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37820-0/abstract","googleCitationCount":9,"googleAuthor":"NH Segal"},{"title":"Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer","googleId":"PTCfGKQDUqQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352548","googleCitationCount":10,"googleAuthor":"","doi":"10.1093/annonc/mdx303","elsevierAuthor":"Blackwell K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"8"},{"title":"Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (PTS)","googleId":"mp9K3_U8oL0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49271-5/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer …","googleId":"x9yg4o0qsQ4J","googleLink":"https://www.researchgate.net/profile/Arun_Azad/publication/328455745_792OA_randomized_phase_II_study_of_cabazitaxel_CAB_vs_ABI_abiraterone_or_ENZ_enzalutamide_in_poor_prognosis_metastatic_castration-resistant_prostate_cancer_mCRPC/links/5bdad964299bf1124fb20b99/792OA-randomized-phase-II-study-of-cabazitaxel-CAB-vs-ABI-abiraterone-or-ENZ-enzalutamide-in-poor-prognosis-metastatic-castration-resistant-prostate-cancer-mCRPC.pdf","googleCitationCount":7,"googleAuthor":"KN Chi"},{"title":"A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk","googleId":"YmSRDRzXQkEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322641","googleCitationCount":10,"googleAuthor":"C Bosetti","doi":"10.1093/annonc/mdx167","elsevierAuthor":"Gomez-Rubio P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"10"},{"title":"Copy number alterations assessed at the single-cell level revealed mono-and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient","googleId":"O6kGfj98wNcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32274-4/abstract","googleCitationCount":10,"googleAuthor":"P Ferronika"},{"title":"Baseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) …","googleId":"pvhavE_UnJ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38569-0/abstract","googleCitationCount":10,"googleAuthor":"L Mezquita"},{"title":"Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation …","googleId":"2KintmRMi6cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50432-X/abstract","googleCitationCount":7,"googleAuthor":"N Colombo"},{"title":"Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)","googleId":"otu3FOFPhCsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50260-5/abstract","googleCitationCount":6,"googleAuthor":"B Keam"},{"title":"Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA","googleId":"-iQxm-QU-O0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38060-1/abstract","googleCitationCount":10,"googleAuthor":"MS Hofman"},{"title":"Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors","googleId":"N-DJLkVNhUMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35046-X/abstract","googleCitationCount":10,"googleAuthor":"JM Michot"},{"title":"Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the …","googleId":"o4xYEL7YA7sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38237-5/abstract","googleCitationCount":9,"googleAuthor":"J Ledermann"},{"title":"CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): A …","googleId":"hVhx1z_lOTcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50449-5/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors","googleId":"wZRwMlqwP8EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34141-9/abstract","googleCitationCount":7,"googleAuthor":"LM Sholl"},{"title":"Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) …","googleId":"k0CL5401In0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49258-2/abstract","googleCitationCount":6,"googleAuthor":"G Couchy"},{"title":"64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer","googleId":"TjLd3-Ugnq4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32158-1/abstract","googleCitationCount":11,"googleAuthor":""},{"title":"Phase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours","googleId":"uZZBBqJgbtUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43045-7/abstract","googleCitationCount":6,"googleAuthor":"V Subbiah"},{"title":"Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression","googleId":"zxDOEt4tFjwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49513-6/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect on outcomes","googleId":"P58Phs1avOkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66092-8/abstract","googleCitationCount":9,"googleAuthor":"S Salvatore"},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a …","googleId":"QFDL9MeZUX4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49218-1/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations","googleId":"iMyptmkb4qAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43458-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of …","googleId":"u088u6fvZ5EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341932054X","googleCitationCount":11,"googleAuthor":"AS Perlmutter","doi":"10.1093/annonc/mdw682","elsevierAuthor":"Perlmutter A.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"11"},{"title":"A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08)","googleId":"SBoGx6_4TE4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49219-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)","googleId":"202ljc2qi_UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49590-2/abstract","googleCitationCount":6,"googleAuthor":"M Hidalgo"},{"title":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort)(NCT02601950)","googleId":"uIQHn2fE7OcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50077-1/abstract","googleCitationCount":6,"googleAuthor":"RL Jones"},{"title":"Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8","googleId":"zsV_I6ViyJUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48486-X/abstract","googleCitationCount":9,"googleAuthor":"P Laurent-Puig"},{"title":"Short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): a planned interim analysis","googleId":"7HM5X7gZd8QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48961-8/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: pooled analysis of the OAK and POPLAR trials","googleId":"ypuHZ3N8lJoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32664-X/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival","googleId":"eh0G7pe7hdAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38730-5/abstract","googleCitationCount":10,"googleAuthor":"BA Van Tine"},{"title":"Modeling individual and relative accuracy of screening tools in geriatric oncology","googleId":"_W6gGBWE-VcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320290","googleCitationCount":10,"googleAuthor":"CA Bellera","doi":"10.1093/annonc/mdx068","elsevierAuthor":"Garcia M.V.","publicationName":"JAMA Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0"},{"title":"The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation","googleId":"AlKpG67mLt0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35517-6/abstract","googleCitationCount":8,"googleAuthor":"V Prasad"},{"title":"TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase …","googleId":"4W7dH3d3dywJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352524","googleCitationCount":10,"googleAuthor":"PM Specenier","doi":"10.1093/annonc/mdx300","elsevierAuthor":"Specenier P.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"12"},{"title":"Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse …","googleId":"AGT8yDUzRAwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454793","googleCitationCount":5,"googleAuthor":"E Ollier","doi":"10.1093/annonc/mdy035","elsevierAuthor":"Trone J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"4"},{"title":"An epidemiological insight into epithelioid sarcoma (ES): The open issue of distal-type (DES) versus proximal-type (PES)","googleId":"LGXnbdwGHyYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38736-6/abstract","googleCitationCount":9,"googleAuthor":"L Botta"},{"title":"Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis","googleId":"Djaa9aJh6-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34561-2/abstract","googleCitationCount":7,"googleAuthor":"H Uno"},{"title":"Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): efficacy and safety data","googleId":"tL0uk_KnP7IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33584-7/abstract","googleCitationCount":10,"googleAuthor":"RS Herbst"},{"title":"COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K–mutant melanoma","googleId":"d8QJxlVJtb4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39146-8/abstract","googleCitationCount":8,"googleAuthor":"GV Long"},{"title":"Updated results of M7824 (MSB0011359C): a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line (2L) NSCLC","googleId":"xtOf0Fm0HWIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49875-X/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study","googleId":"vlxBjswJCKQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39100-6/abstract","googleCitationCount":9,"googleAuthor":"P Cottu"},{"title":"Statistical controversies in clinical research: overlap and errors in the meta-analyses of microRNA genetic association studies in cancers","googleId":"l7iIRzX_KpsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419324111","googleCitationCount":9,"googleAuthor":"JI Shin","doi":"10.1093/annonc/mdx024","elsevierAuthor":"Park J.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-06-01","elsevierCoverDisplayDate":"1 June 2017","elsevierCitationCount":"6"},{"title":"CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence …","googleId":"zwg2g7sIzhkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49244-2/abstract","googleCitationCount":5,"googleAuthor":"M Akce"},{"title":"NCI-MATCH arms N & P: phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (Mut/del) or PTEN protein …","googleId":"WKJaqQzaQlwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48885-6/abstract","googleCitationCount":6,"googleAuthor":"O Jegede"},{"title":"Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies","googleId":"Faa6rKSZe2sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49122-9/abstract","googleCitationCount":7,"googleAuthor":"SJ Klempner"},{"title":"Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO …","googleId":"iF88J9IDxPYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38485-4/abstract","googleCitationCount":9,"googleAuthor":"D Schadendorf"},{"title":"Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small …","googleId":"gcriKNabDmsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419353967","googleCitationCount":7,"googleAuthor":"A Argiris","doi":"10.1093/annonc/mdx534","elsevierAuthor":"Argiris A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"5"},{"title":"TRIBE2: A phase III, randomized strategy study by GONO in the 1st-and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts)","googleId":"VStRIiT5upgJ","googleLink":"https://www.researchgate.net/profile/Gianluca_Masi/publication/328503649_LBA20TRIBE2_A_phase_III_randomized_strategy_study_by_GONO_in_the_1st-_and_2nd-line_treatment_of_unresectable_metastatic_colorectal_cancer_mCRC_patients_pts/links/5dd2cbc04585156b351e8234/LBA20TRIBE2-A-phase-III-randomized-strategy-study-by-GONO-in-the-1st-and-2nd-line-treatment-of-unresectable-metastatic-colorectal-cancer-mCRC-patients-pts.pdf","googleCitationCount":7,"googleAuthor":"S Lonardi"},{"title":"Population pharmacokinetic analyses for talazoparib (TALA) in cancer patients","googleId":"zdZdSBVbaGQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48898-4/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Not only tumor but also therapy heterogeneity","googleId":"yPEyYUtkJRMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34999-3/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials","googleId":"leJr73uXJtkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48725-5/abstract","googleCitationCount":6,"googleAuthor":"M Elmeliegy"},{"title":"Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor","googleId":"CsokYC2ZV6UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34197-3/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results","googleId":"HNYnz896378J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50392-1/abstract","googleCitationCount":6,"googleAuthor":"C Hulme"},{"title":"Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case–Control Consortium (PanC4)","googleId":"AnNwn_WmX-4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322264","googleCitationCount":10,"googleAuthor":"C Pelucchi","doi":"10.1093/annonc/mdw618","elsevierAuthor":"Pelucchi C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-02-01","elsevierCoverDisplayDate":"February 2017","elsevierCitationCount":"6"},{"title":"Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial","googleId":"y3l9KAw-KJYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38201-6/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients …","googleId":"Tfu1ODhXYEMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38405-2/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Chemotherapy-induced toxicity—a secondary effect caused by released DNA?","googleId":"eGkgK4xB5kEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35268-8/abstract","googleCitationCount":8,"googleAuthor":"T Helleday"},{"title":"30 months relapse-free survival, overall survival, and long-term toxicity update of (neo) adjuvant ipilimumab (ipi)+ nivolumab (nivo) in macroscopic stage III melanoma …","googleId":"uVN0BgNONXAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32759-0/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Pleural mesothelioma: is the surgeon still there?","googleId":"QHIGoicQKRUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934116X","googleCitationCount":6,"googleAuthor":"I Opitz","doi":"10.1093/annonc/mdy195","elsevierAuthor":"Opitz I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-08-01","elsevierCoverDisplayDate":"August 2018","elsevierCitationCount":"1"},{"title":"Comparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC)","googleId":"Yg6wxMr9-k0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38123-0/abstract","googleCitationCount":8,"googleAuthor":"SK Pal"},{"title":"Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability","googleId":"F9gE0H5vyFUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50279-4/abstract","googleCitationCount":5,"googleAuthor":"J Martin-Liberal"},{"title":"Phase II study of cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer: E-Rechallenge trial","googleId":"1b8-qnsI4g8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48947-3/abstract","googleCitationCount":6,"googleAuthor":"E Shinozaki"},{"title":"Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication","googleId":"Aiy0S5jwlmkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419341948","googleCitationCount":7,"googleAuthor":"L Xie"},{"title":"Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic …","googleId":"88iGymSPyOEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38964-X/abstract","googleCitationCount":9,"googleAuthor":"J Bennouna"},{"title":"Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial","googleId":"4cZ6OGX6KNIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354742","googleCitationCount":9,"googleAuthor":"","doi":"10.1093/annonc/mdx556","elsevierAuthor":"Glass B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-12-01","elsevierCoverDisplayDate":"1 December 2017","elsevierCitationCount":"4"},{"title":"Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell …","googleId":"79wZyRWvoQEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419454665","googleCitationCount":7,"googleAuthor":"MJ Awan","doi":"10.1093/annonc/mdy018","elsevierAuthor":"Awan M.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-04-01","elsevierCoverDisplayDate":"1 April 2018","elsevierCitationCount":"5"},{"title":"Combined pathologic‐genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay","googleId":"Z3qZ0vRJN_0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345430","googleCitationCount":6,"googleAuthor":"M Rosman","doi":"10.1093/annonc/mdy074","elsevierAuthor":"Gage M.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-05-01","elsevierCoverDisplayDate":"1 May 2018","elsevierCitationCount":"3"},{"title":"Pulmonary sarcomatoid carcinoma—a new hope","googleId":"sOj0Lcn0rQgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32288-4/abstract","googleCitationCount":9,"googleAuthor":"AS Mansfield"},{"title":"Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II","googleId":"z2E74tiDVPgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419350471","googleCitationCount":13,"googleAuthor":"I Sestak","doi":"10.1093/annonc/mdx713","elsevierAuthor":"Sestak I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2018-02-01","elsevierCoverDisplayDate":"1 February 2018","elsevierCitationCount":"7"},{"title":"A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial","googleId":"J8alWGTBcEQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49798-6/abstract","googleCitationCount":6,"googleAuthor":"S Peters"},{"title":"Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer","googleId":"rWHYVw3pLmIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35520-6/abstract","googleCitationCount":7,"googleAuthor":"C Abbosh"},{"title":"Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of …","googleId":"WxLMgpabXVYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38119-9/abstract","googleCitationCount":8,"googleAuthor":"MO Grimm"},{"title":"Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced …","googleId":"CcVG-7Wo73wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49819-0/abstract","googleCitationCount":5,"googleAuthor":"L Mezquita"},{"title":"Real-world data on nivolumab treatment in Asian patients with advanced hepatocellular carcinoma","googleId":"4QZ2XKqg88EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49160-6/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation …","googleId":"0u6uKKBChdQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37577-3/abstract","googleCitationCount":8,"googleAuthor":"R Gelber"},{"title":"Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: Results of the CirCe T-DM1 trial","googleId":"UPpXznuLn40J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37611-0/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors","googleId":"EbajW8uk2jAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37792-9/abstract","googleCitationCount":8,"googleAuthor":"K Shitara"},{"title":"A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients …","googleId":"TMnIfTVDadYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37897-2/abstract","googleCitationCount":9,"googleAuthor":"M Hidalgo"},{"title":"Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950)","googleId":"LbLRR1QH8ssJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50329-5/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Cancer stigma related to beliefs of patients and care providers","googleId":"qEQMHjtaC9IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49997-3/abstract","googleCitationCount":5,"googleAuthor":"H Malhotra"},{"title":"Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and …","googleId":"wX-gArpm9VwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321714","googleCitationCount":9,"googleAuthor":"U De Giorgi","doi":"10.1093/annonc/mdx259","elsevierAuthor":"De Giorgi U.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-08-01","elsevierCoverDisplayDate":"1 August 2017","elsevierCitationCount":"8"},{"title":"Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)","googleId":"IixMObcX2doJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49159-X/abstract","googleCitationCount":5,"googleAuthor":"C Barone"},{"title":"Efficacy of afatinib in the clinical practice: First results of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany","googleId":"7MAhmurffwgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49861-X/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Immune checkpoint inhibitors-related orchitis","googleId":"k8ITcS84Td0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32066-6/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line …","googleId":"3Etu5EQPAWAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)66217-4/abstract","googleCitationCount":10,"googleAuthor":""},{"title":"Association of plasma concentrations of branched-chain amino acids with risk of colorectal adenoma in a large Japanese population","googleId":"tQ2aO8U2j2MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320526","googleCitationCount":9,"googleAuthor":"S Budhathoki","doi":"10.1093/annonc/mdw680","elsevierAuthor":"Budhathoki S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-04-01","elsevierCoverDisplayDate":"1 April 2017","elsevierCitationCount":"9"},{"title":"Health-related quality of life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib …","googleId":"4SACoEJs7JwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37892-3/abstract","googleCitationCount":9,"googleAuthor":"S Hudgens"},{"title":"Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM)","googleId":"JVQ3nljZeOoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38269-7/abstract","googleCitationCount":8,"googleAuthor":"SZ Usmani"},{"title":"Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study …","googleId":"27Fs3gJtFJsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48911-4/abstract","googleCitationCount":6,"googleAuthor":"A Krämer"},{"title":"Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma …","googleId":"0h-UvuzlqlwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50448-3/abstract","googleCitationCount":6,"googleAuthor":"N Meyer"},{"title":"The effect of loneliness on cancer mortality","googleId":"R_iMZKC-MjsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)34918-8/abstract","googleCitationCount":9,"googleAuthor":"E Ambrosini"},{"title":"Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?","googleId":"zVN3XqkU3XgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34553-3/abstract","googleCitationCount":6,"googleAuthor":"LA Diaz"},{"title":"No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?","googleId":"MdtGXOMXBTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32162-3/abstract","googleCitationCount":9,"googleAuthor":"Y Sunakawa"},{"title":"Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape","googleId":"m_HGMp3PJVoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419320149","googleCitationCount":9,"googleAuthor":"DJ Vis","doi":"10.1093/annonc/mdx037","elsevierAuthor":"Stevens I.","publicationName":"PLoS Computational Biology","elsevierCoverDate":"2020-10-05","elsevierCoverDisplayDate":"5 October 2020","elsevierCitationCount":"0"},{"title":"Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+ I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma …","googleId":"dB6_QWc55DAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49263-6/abstract","googleCitationCount":6,"googleAuthor":"BI Rini"},{"title":"Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma","googleId":"7b7f52cXm1IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34554-5/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced …","googleId":"2S3PhaN0jG4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49165-5/abstract","googleCitationCount":5,"googleAuthor":"T Yau"},{"title":"Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced …","googleId":"2S3PhaN0jG4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49165-5/abstract","googleCitationCount":5,"googleAuthor":"T Yau"},{"title":"Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer","googleId":"upXe_EbA6AwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49862-1/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Oncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018)","googleId":"ey79iY0JZMUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37787-5/abstract","googleCitationCount":8,"googleAuthor":"S Danson"},{"title":"Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of …","googleId":"SnMi6rDf79wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49192-8/abstract","googleCitationCount":5,"googleAuthor":"S Nomura"},{"title":"Genomic medicine France 2025","googleId":"RDbuA1CJBJoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)45473-2/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Analytic validation of tumor mutational burden as a companion diagnostic for combination immunotherapy in non-small cell lung cancer","googleId":"8_GW3SVfrIMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48482-2/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Prognostic utility of HPV specific testing in addition to p16 immunohistochemistry in oropharyngeal squamous cell carcinoma","googleId":"ys_QIPbDK_YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34198-5/abstract","googleCitationCount":6,"googleAuthor":"A Santambrogio"},{"title":"Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective","googleId":"P-Ks0EaXmAYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419345843","googleCitationCount":8,"googleAuthor":"C Thieblemont","doi":"10.1093/annonc/mdx358","elsevierAuthor":"Reddy N.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"3"},{"title":"Chemotherapy in end-of-life care","googleId":"0ijitt8KcDoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)32081-2/abstract","googleCitationCount":9,"googleAuthor":""},{"title":"Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): preliminary results from the phase IIIb, international, open-label …","googleId":"86URG_FAnVgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)33699-3/abstract","googleCitationCount":6,"googleAuthor":"A Falcone"},{"title":"Navigating the highlights of phase III trials: a watchful eye on evidence-based radiotherapy","googleId":"zrZ_uQm9JgQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341934582X","googleCitationCount":7,"googleAuthor":"","doi":"10.1093/annonc/mdx347","elsevierAuthor":"Trone J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"5"},{"title":"Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) …","googleId":"5mMsK0b0gc8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39121-3/abstract","googleCitationCount":7,"googleAuthor":"J Edeline"},{"title":"Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the circulating cell-free genome atlas (CCGA) study","googleId":"7eINOEgSKLwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48476-7/abstract","googleCitationCount":5,"googleAuthor":"MC Liu"},{"title":"RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients","googleId":"ZanpkEJT3NcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35523-1/abstract","googleCitationCount":5,"googleAuthor":"P Carmeliet"},{"title":"The future of UK healthcare: problems and potential solutions to a system in crisis","googleId":"-IzjfJM0DHkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419321295","googleCitationCount":9,"googleAuthor":"A Haines","doi":"10.1093/annonc/mdx136","elsevierAuthor":"Dineen-Griffin S.","publicationName":"PLoS ONE","elsevierCoverDate":"2019-08-01","elsevierCoverDisplayDate":"1 August 2019","elsevierCitationCount":"17"},{"title":"An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab …","googleId":"0oHUCn9zIS8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419346083","googleCitationCount":7,"googleAuthor":"JC Soria","doi":"10.1093/annonc/mdx489","elsevierAuthor":"Temam S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-11-01","elsevierCoverDisplayDate":"November 2017","elsevierCitationCount":"6"},{"title":"Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC) …","googleId":"1Aijnu-5Ks0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49409-X/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Atezolizumab+ bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150","googleId":"MDhk9wDWOy4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49243-0/abstract","googleCitationCount":7,"googleAuthor":"MP Ducreux"},{"title":"Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study","googleId":"PMETrGgHENgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419319659","googleCitationCount":8,"googleAuthor":"C Oing","doi":"10.1093/annonc/mdw648","elsevierAuthor":"Oing C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-03-01","elsevierCoverDisplayDate":"March 2017","elsevierCitationCount":"8"},{"title":"Analysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs)","googleId":"FcE-ZlFJ3xsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38437-4/abstract","googleCitationCount":7,"googleAuthor":"AB Schrock"},{"title":"PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors","googleId":"FRGL0rbIaSYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)37839-X/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors","googleId":"xYQDpFz2FJQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)34602-2/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"A phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL","googleId":"RQphHGK1WZoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38623-3/abstract","googleCitationCount":7,"googleAuthor":"S Clarke"},{"title":"Detection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): circulating tumour (ct) DNA …","googleId":"sJinVWgMwIkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)38577-X/abstract","googleCitationCount":7,"googleAuthor":""},{"title":"Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) …","googleId":"medh-4M0SdEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419352627","googleCitationCount":8,"googleAuthor":"A Psyrri","doi":"10.1093/annonc/mdx320","elsevierAuthor":"Psyrri A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-09-01","elsevierCoverDisplayDate":"September 2017","elsevierCitationCount":"6"},{"title":"Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB …","googleId":"ZRds5-27lJUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50273-3/abstract","googleCitationCount":6,"googleAuthor":"A Puccini"},{"title":"M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with post-platinum esophageal adenocarcinoma (EAC): Preliminary …","googleId":"CILzF8eBg4QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49105-9/abstract","googleCitationCount":5,"googleAuthor":"A Khattak"},{"title":"TRIUMPH Study: A multicenter phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive …","googleId":"5TuNu7z-q38J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39097-9/abstract","googleCitationCount":8,"googleAuthor":""},{"title":"Kinase fusions in colorectal cancers: a unique biologic subset","googleId":"WUq5GpjCnUkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)48923-0/abstract","googleCitationCount":6,"googleAuthor":"F Pietrantonio"},{"title":"Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)","googleId":"CqE-zjVeDAMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50464-1/abstract","googleCitationCount":6,"googleAuthor":"DS Tan"},{"title":"Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet","googleId":"GNc_h7abBzgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35001-X/abstract","googleCitationCount":6,"googleAuthor":"AJ Armstrong"},{"title":"A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability","googleId":"jM8f4rr55NQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39019-0/abstract","googleCitationCount":7,"googleAuthor":"D Tougeron"},{"title":"Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen+/-gonadotropin …","googleId":"PB265SW4nzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50398-2/abstract","googleCitationCount":4,"googleAuthor":"M Reinisch"},{"title":"Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility","googleId":"ldcm9ADMJfcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419322586","googleCitationCount":7,"googleAuthor":"Y Zhang","doi":"10.1093/annonc/mdx161","elsevierAuthor":"Zhang Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2017-07-01","elsevierCoverDisplayDate":"July 2017","elsevierCitationCount":"6"},{"title":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950)","googleId":"JXEhguGzaDsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)50080-1/abstract","googleCitationCount":5,"googleAuthor":""},{"title":"Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L) 1 inhibitors (IO …","googleId":"miDYMwHljw8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49828-1/abstract","googleCitationCount":6,"googleAuthor":""},{"title":"Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444","googleId":"95qOOxbOaIAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)49594-X/abstract","googleCitationCount":5,"googleAuthor":""}]